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Abstract
Prostate cancer (PCa) is the most frequent cancer in men above the age
of 50 years. Despite radical prostatectomy or radiation therapy as primary
treatment, 15-30% of patients will develop an advanced or metastatic cancer
requiring systemic therapies. Reference treatment of advanced PCa relies on
pharmacological or surgical androgen deprivation therapy. However, despite
initial efficacy of androgen deprivation (AD), the tumor inevitably adapts to
low testosterone environment and becomes hormone refractory (HRPCa).
A better understanding of the mechanisms of androgen independence is
necessary to improve the management of HRPCa. Although autophagy confers
chemoresistance in some cancers, its role in the development of HRPCa
remained unknown. We found that AD or treatment with the anti-androgen
bicalutamide promoted autophagy in HRPCa-derived LNCaP cells. This effect
was associated with an inhibition of the PI3K/Akt/mTOR pathway and with a
disruption of the complex formed by androgen re...
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ADP : adenosine diphosphate 
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AND : other androgenic steroidal precursor 
ANT : adenine nucleotide transporter 
APAF-1 : apoptotic peptidase activating factor 1 
AR : androgen receptor 
ARE : androgen response element 
ATP : adenosine triphosphate 
ATF4 : activating transcription factor 4 
ATF6 : activating transcription factor 6 
Atg : autophagy-related gene 
ATP : adenosine triphosphate 
Bad : Bcl-2-associated death promoter 
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Bcl-xL : B-cell lymphoma-extra large 
BH : Bcl-2 homology domain 
BI-1 : Bax inhibitor-1 
Bid : BH3 interacting-domain death agonist 
Bif-1 : Bax-interacting factor-1 
Bik : Bcl-2 interacting killer 
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ITPR : inositol trisphosphate receptor gene 
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MCU : mitochondrial Ca
2+
 uniporter 
MED1 : mediator complex subunit 1 
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NCoR : nuclear receptor corepressor 
NCX : Na+/Ca
2+
 exchanger 
Nix : Bcl2/adenovirus E18 interacting protein 3-like 
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p16
INK4a
 : cyclin-dependent kinase inhibitor 2A (inhibitor of cyclin-dependent kinase 4) 
p21
Cip1 
: cyclin-dependent kinase inhibitor 1A (CDK-interacting protein 1) 
p27
Kip1
 : cyclin-dependent kinase inhibitor 1B 
PAS : pre-autophagosomal structure 
PARP1 : poly(ADP-ribose) polymerase-1 
PCa : prostate cancer 
PDK1 : phosphoinositide-dependent kinase-1 
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Raptor : regulatory-associated protein of mTOR 
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ROC : receptor-operated channel 
ROS : reactive oxygen species 
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RyR : ryanodine receptor 
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SRC : steroid receptor coactivator 
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Introduction 
1 - The prostate cancer 
The prostate is an exocrine gland of the male reproductive system located in the pelvis just 
below the bladder and traversed by the urethra and the ejaculatory ducts (Fig. 1). It has the 
dimension of a chestnut and weighs approximately 20 grams in adulthood. Its main function is 
to secrete a part of the seminal fluid, a constituent of the sperm. It also contributes to the 
proper functioning of ejaculation. The prostate is composed of tubulo-alveolar glands and 
smooth muscle cells surrounded by a fibro-elastic capsule. The integrity of this prostatic 
capsule is a crucial element to consider in prostate cancer (PCa) diagnosis. Cancers that are 
fully enclosed by this capsule are called localized, and those whose cancer cells go beyond the 
capsule are at least locally advanced (classified as T3 in the TNM staging system). The vast 
majority of cases of PCa develop from the glandular epithelium and therefore are 
adenocarcinomas [1]. 
PCa is the most frequent cancer of men above the age of 50 years in the European Union (Fig. 
2). More than 340,000 cases and 70,000 deaths have been reported in 2012 in Europe [2]. PCa 
development can be monitored by the measurement of serum prostate specific antigen (PSA) 
levels, a peptidase whose expression is regulated by the androgen receptor (AR). Despite 
radical prostatectomy or radiation therapy as primary treatment, rising PSA values are still 
observed in approximately 15-30% of patients and are related to an advanced or metastatic 
cancer requiring systemic therapies [3]. Like normal prostate cells, PCa cells depend on 
androgens for their survival and growth. Charles Huggins was awarded the 1966 Nobel Prize 
for discovering that removal of androgens triggers their death [4]. Thus, reference treatment 
of advanced PCa relies on pharmacological or surgical androgen deprivation (AD) therapy 
[5]. 
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Fig. 1: The prostate gland and its different zones. From [6] 
Under the bladder, the prostate is traversed by the urethra and the ejaculatory ducts. It 
comprises four different zones: the transition zone, the central zone, the peripheral zone and 
the anterior fibromuscular stroma. The transition zone, in contact with the urethra, is the place 
where benign prostatic hyperplasia (BPH) develops. BPH is encountered in the majority of 
men after 50 years and may result into an increase in volume of a portion of prostate but does 
not always require treatment. The peripheral zone, easily palpable on rectal examination, is 
the place where cancer frequently (but not exclusively) develops [1]. 
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Fig. 2: Number of new cases and age specific incidence rates of PCa in the United 
Kingdom in 2006. From [7] 
PCa is the most common cancer among men in developed countries. PCa risk is strongly 
related to age.  
 
2 - The androgen receptor 
In prostatic cells, testosterone is converted by the 5α-reductase to dihydrotestosterone (DHT) 
that has a greater affinity for the AR [8]. DHT binds to AR which functions as an intracellular 
transcriptional factor. It comprises an N-terminal modulatory domain, a DNA-binding domain 
and a ligand-binding domain. In its unbound conformation, AR, mainly located in the 
cytoplasm, is associated with a complex of heat shock proteins. The androgen binding 
releases AR from the complex and leads to its homodimerization and its translocation to the 
nucleus. Translocated AR binds to androgen response element (ARE) sequences on the 
promoter/enhancer regions of AR target genes. It recruits coregulators (including coactivators 
and corepressors) and the transcriptional machinery to allow the expression of androgen-
responsive genes [9]. In PCa cells, AR regulates the expression of numerous genes involved 
in transcription, splicing, ribosomal biogenesis, cell growth and bioenergetics processes [10]. 
Besides, steroid hormones can activate multiple signaling cascades within minutes (Fig. 3). 
These rapid androgen effects do not require the nuclear translocation of AR but rather depend 
on non-genomic activities of AR located in the cytoplasm and/or tethered to the plasma 
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membrane [11, 12]. They have especially been observed in PCa cells, in which AR splice 
variants without DNA-binding domain and primarily associated to the membrane were also 
identified [13]. In these cells, androgens stimulate the phosphoinositide 3-kinase (PI3K), the 
kinase Raf-1 and the protein kinase C (PKC), which results in activation of Erk-1 and -2 
(extracellular signal-regulated kinases-1 and -2 also called mitogen-activated protein kinases 
or MAPKs) [14]. The activation of the MAPK pathway also depends on an association of AR 
with oestradiol receptor β and Src kinase and promotes cell proliferation [15]. Furthermore, 
androgens have been shown to activate the prosurvival PI3K/Akt pathway by enhancing an 
AR binding to p85, the regulatory subunit of class Ia PI3K, in the PCa-derived LNCaP cell 
model [16] and in vas deferens epithelial cells [17]. An interaction of Akt with AR located 
into lipid rafts microdomains is also stimulated by androgens and prevented by the AR 
antagonist bicalutamide in LNCaP cells [18]. Besides, androgens can induce a rapid Ca
2+
 
influx via L-type calcium channels in the same cell line. The intracellular Ca
2+
 increase does 
not appear to be mediated by classical AR, but rather through a G protein-coupled receptor 
(GPCR) or a receptor associated with a GPCR [19]. Indeed, the androgen non-genomic 
activities seem also related to unconventional receptors localized on the plasma membrane 
and which cannot be blocked by AR antagonists. The stimulation of these membrane-bound 
receptors seems to result in anti-tumor responses. Non-internalizable testosterone-BSA 
conjugates activate signaling cascades leading to a reorganisation of the actin cytoskeleton, 
the cell growth suppression and the apoptotic regression of PCa cells [20, 21]. The exact 
molecular identity of these unconventional receptors had long been remained elusive. 
Recently, such a membrane receptor was discovered in the ZIP9 zinc transporter subfamily. 
Its activation by testosterone induces zinc influx and triggers apoptosis in prostate and breast 
cancer cells [22]. 
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Fig. 3: Genomic and non-genomic AR activities in PCa. 
Androgens (And) can cross the plasma membrane and interact with cytoplasmic androgen 
receptor (AR). This leads to the dimerization of AR and its translocation to the nucleus. 
Translocated AR recognizes androgen response element (ARE) sequences on the 
promoter/enhancer regions of AR target genes and promotes their expression. Besides, 
androgens can have rapid non-genomics effects. Activated AR in the cytoplasm and/or at the 
plasma membrane can interact with several signaling molecules and trigger multiple signaling 
cascades including the PI3K and MAPK/Erk pathways, thereby stimulating the cell growth. 
Oppositely, activation of membrane-bound unconventional ARs (uARs) can elevate [Ca
2+
]c 
and modulate the activity of several signaling pathways, which results in the PCa regression. 
The stimulation by androgens of ZIP9 protein, one of these uARs, leads to Zn
2+
 entry and cell 
death. 
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The genomic and non-genomic activities of AR are therefore multiple in PCa cells, regulating 
cell survival as well as cell growth. Despite the anti-tumoral effects of the activation of some 
types of membrane AR, the suppression of androgenic stimulation seems the best strategy to 
counter the development of advanced PCa. 
 
3 - The androgen deprivation therapy 
Strategies of AD therapy are diverse and can be combined. They include orchiectomy (which 
irreversibly reduces the level of androgen in the blood), the use of AR antagonists such as 
flutamide, bicalutamide and enzalutamide (which compete with androgens for binding to the 
AR) and the use of GnRH antagonists as well as GnRH agonists. 
GnRH antagonists compete with GnRH for binding to its receptor in the pituitary gland, 
which limits the secretion of luteinizing hormone and consequently of androgen. GnRH 
agonists have a longer biological half-life than normal GnRH and their continued presence at 
high levels initially results in an excessive production of luteinizing hormone by the pituitary 
gland and in turn of testosterone by the testicles. However, chronic exposure to GnRH 
agonists eventually leads to a downregulation of GnRH receptors with subsequent suppression 
of luteinizing hormone secretion and testosterone production. A castrate testosterone level is 
usually achieved within 2 to 4 weeks after injection of GnRH agonists [23]. 
 
4 - Mechanisms of hormone resistance in PCa 
The blockade of AR activities results in tumor regression. However, despite this initial 
efficacy of AD, most PCa will adapt to low testosterone environment becoming hormone-
refractory (HRPCa) [24]. Until recently, HRPCa progression was considered as a necessarily 
lethal event, mainly characterised by the development of bone metastases and their 
complications. Since 2004, two drugs have been improving the care of patients: docetaxel, an 
anti-microtubule agent, resulting in prolonged survival by about three months, and zoledronic 
acid, a bone-protecting bisphophonate, which delays the onset of skeletal-related events [25]. 
However, benefits of this additional treatment remain modest. A better understanding of the 
phenomenon of androgen independence is necessary to ameliorate the management of 
HRPCa. Some mechanisms explaining the progression to HRPCa have already been identified 
(Fig. 4). 
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AR keeps playing a major role in the cancer growth despite androgen depletion. Mutations or 
amplifications of the AR have been observed, thereby increasing its sensitivity to androgen or 
permitting its activation by other ligands including estrogens, corticosteroids and 
progesterone. Moreover, members of the family of steroid receptor coactivators (SRC) are 
often overexpressed. The activities of numerous AR coactivators such as MED1, FoxA1 and 
GATA2 are stimulated whereas those of the nuclear receptor corepressor (NCoR) are reduced 
[26]. Besides, growth factors, via their binding with receptor tyrosine kinases, can activate 
PI3K/Akt or MAPK/Erk signaling pathways leading to AR activation independently of steroid 
interaction. Interleukins and neuropeptides have also been noticed to produce the same effect 
[27]. Thereby, transcriptional activities of the AR can be stimulated by its phosphorylation 
despite the absence of ligand [28]. 
Even in the absence of constitutive activation of AR-dependent pathways, PCa cells can 
acquire the ability to synthesize androgen from cholesterol which limits the benefits of 
androgen level reduction in cancerous tissues despite castration. This makes necessary the use 
of steroids synthesis inhibitors, which prevent PCa cells as well as testicles and adrenal glands 
from producing androgens by inhibiting the family of cytochrome P450 enzymes [29]. 
However, the AR pathway is sometimes bypassed, other signaling pathways being 
deregulated. Stimulation of the insulin-like growth factor pathway and overexpression of 
prosurvival chaperone proteins in response to androgen ablation are involved in androgen 
independence [30, 31]. The loss of phosphatase PTEN (phosphatase and tensin homolog) 
often occurs during the progression of PCa, thereby stimulating pro-survival PI3K/Akt 
pathway [32]. Upregulation of anti-apoptotic molecules such as Bcl-2 and Bcl-xL has also 
been reported to participate to androgen resistance of PCa [33, 34]. Besides, mutations of p53 
tumor suppressor often observed in HRPCa cells contribute to their growth in the absence of 
androgen [35]. 
Moreover, a neuroendocrine differentiation is favored. Indeed, neuroendocrine cells become 
more prevalent after long-term AD. They present dense core granules in their cytoplasm 
together with extensions of neuron-like processes, are nonmitotic and do not express the AR. 
However, they produce various neuropeptides such as chromogranin A and neurotensin, 
which have been shown to stimulate proliferation of the surrounding androgen-independent 
cancer cells [36]. 
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Fig. 4: Mechanisms of hormone resistance and AR deregulation in PCa. From [37] 
Ligand-dependent and ligand-independent mechanisms involved in HRPCa progression can 
be distinguished : (1) acquisition by the PCa cells of the ability to synthesize androgen from 
steroidal precursors ; (2) mutations of the AR increasing its sensitivity to androgen or 
allowing its activation by alternate ligands ; (3) amplification of the AR, enhancing its activity 
; (4) ligand-independent activation of AR through cross-talk with other signaling pathways ; 
(5) stimulation of the AR coactivators and inhibition of the AR corepressors enhancing its 
transcriptional activity ; (6) deregulation of other signaling pathways and overexpression of 
anti-apoptotic molecules, such as Bcl-2. (Abbreviations: AKT, akt serine/threonine kinase; 
AND, other androgenic steroidal precursors; AR, androgen receptor; DHEA, 
dehydroepiandrosterone; DHT, dihydrotestosterone; ERK, extracellular signal-regulated 
kinase; P, phosphorylated residues; PI3K, phosphoinositide 3-kinase; PTEN, phosphatase and 
tensin homolog; Bcl-2, B-cell lymphoma 2.) 
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5 - Cell growth and AD therapy 
Tumor regression induced after AD is dependent on apoptosis in a subset of PCa cells but also 
on cell cycle arrest in others [38]. 
Progression within the cell cycle is allowed by the ordered activation of cyclin-dependent 
kinases (CDKs) combined to their associated cyclins, the latter controlling the catalytic 
activity of kinases [39]. AD leads to the reduced activity of CDK2 and 4 and the 
hypophosphorylation of their downstream substrate, the retinoblastoma tumor suppressor 
protein (Rb), resulting in G0-G1 cell cycle arrest. The inhibition of CDK2 and 4 is related to a 
decrease of cyclins A and D levels, to an overexpression of p27
Kip1
, a CDK2 inhibitor, and to 
a downexpression of p21
Cip1
 [40, 41]. Originally identified as CDK inhibitor, p21
Cip1
, an 
androgen-responsive gene product [42], also participates to the formation of CDK4-cyclin D 
complexes [43, 44]. 
AR therefore governs the G1-S transition (Fig. 5). Androgens indirectly control cyclins D 
levels by promoting the expression of numerous genes favoring nutrient availability that 
activates the energy sensor mTOR (mammalian target of rapamycin) and stimulates the 
translation of cyclins D proteins [45]. Activation of AMPK (5’ adenosine monophosphate-
activated protein kinase) by androgens and subsequent enhancement of mitochondrial 
function seem also participate in the stimulation of cell growth [46]. 
It can be noted that while AD activates Rb by suppressing its phosphorylation, thereby 
enabling it to repress the expression of genes required for S-phase entry [47], Rb expression is 
often altered in advanced PCa [48]. Rb inhibition induces cell proliferation in the absence of 
androgenic stimulation [49], suggesting that Rb deficiency may participate to the 
development of hormone resistance phenotype. 
Unfortunately, long-term AD results in the outgrowth of AD-resistant clones from the initially 
growth arrested population [50]. Surprisingly, androgens induce G1 cell cycle arrest in such 
castration-resistant PCa cells through the accumulation of p27
Kip1
, the inhibition of CDK2 
activity and the lowered expression of cyclin A and S-phase kinase-associated protein 2 
(Skp2) required for p27
Kip1
 degradation [51, 52]. Interestingly, an intermittent AD (a 
succession of AD periods and off-therapy intervals) may delay the definitive acquisition of an 
androgen-independent growth [53, 54]. 
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Fig. 5: The regulation of cell cycle by AR. Adapted from [41] 
Activated AR induces the accumulation of cyclins D through mTOR stimulation, which 
results in CDK4 activation. Besides, androgen-induced p21
Cip1
 expression and p27
Kip1
 
degradation improve the activity of cyclin D/CDK4 and cyclin E/CDK2 complexes, 
phosphorylating the retinoblastoma tumor suppressor protein Rb. Phosphorylated Rb is 
inactivated and cannot impede the expression of genes required for G1-S transition including 
cyclin A, which allows the progression within the cell cycle.  
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Furthermore, high concentrations of testosterone or DHT (low nanomolar) also repress cell 
proliferation of androgen-sensitive PCa cells [55, 56]. In fact, androgen-stimulated response 
appears to be biphasic. At low levels, increasing androgen concentration promotes a dose-
dependent cell growth whereas at higher concentrations, proliferation is inhibited. The 
optimal androgen level varies depending on the cellular model. These data, the anti-tumoral 
effects of membrane AR activation (see above) and the fact that high serum testosterone 
levels do not seem to increase the risk of PCa as well as the tumor aggressivity [57] have 
changed minds on the role of androgens in PCa development. Without questioning the interest 
of AD to block the PCa progression, testosterone therapies are now considered. Clinical trials 
have even been conducted [58-60]. 
 
6 - Cellular senescence and AD therapy 
Cell cycle arrest encountered after AD was recently investigated in more detail and 
senescence characteristics were identified [61-63]. Cellular senescence is an irreversible arrest 
of cell growth triggered in response to diverse stimuli including genomic and epigenomic 
damages, oncogenic stimulation and telomere shortening (reviewed in [64]). Senescence 
restricts the replicative life span of cells and impedes uncontrolled cell division. In addition of 
its definitive growth arrest, a senescent cell is characterised by an increase in volume and, if 
adherent, a flattened morphology. Moreover, several markers allow its detection such as the 
senescence-associated β-galactosidase (SA-βgal), the p16
INK4a
 tumor suppressor protein and a 
persistent DNA damage response signaling. Besides, a senescent cell, which remains 
metabolically active, secretes various molecules including cytokines, growth factors and 
proteases to modulate the proliferation of the surrounding cells, to promote inflammation and 
to prepare the tissue for repair. 
A subset of PCa cells submitted to AD presents in vitro and in vivo senescence-associated 
changes, among which a stable cell cycle arrest, a modification of their phenotype, the 
expression of molecular markers of senescence and the secretion of cytokines and proteases 
[61, 62]. A senescent arrest is seen as a mechanism of tumor suppression. However, AD-
induced senescence in PCa cells seems to contribute to their survival and to promote the 
clonal expansion of a senescence-resistant androgen-refractory subpopulation through the 
secretion of paracrine factors [65]. 
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It can be noticed that the cell cycle arrest triggered by high concentrations of androgen is also 
a form of cellular senescence [66]. The latter is rapidly induced through the stimulation of the 
PI3K/Akt/mTOR pathway by the high levels of AR agonists. 
 
Cellular senescence therefore participates to the failure of AD therapy. However, it seems that 
other mechanisms, in addition to those previously described, could be provided to explain the 
development of hormone resistance phenotype. Indeed, numerous studies established a 
participation of autophagy in apoptosis resistance in many cancers [67] but its role in HRPCa 
progression remains unrecognized. 
 
7 - Autophagy 
7.1 - Three distinct autophagic processes 
The word “autophagy”, derived from the Greek meaning “eating of self”, was first introduced 
in 1963 by the Nobel Prize laureate Christian de Duve who described lysosomal degradation 
of intracellular components in rat liver perfused with glucagon [68]. The concept of 
autophagy has been rediscovered in the mid-1990s and now refers to three different processes 
(Fig. 6): macro-autophagy, micro-autophagy and chaperone-mediated autophagy, all of which 
converge to a common degradation phase mediated by lysosomes [69]. Macro-autophagy 
involves the formation of double- or multiple-membrane vesicles, named autophagosomes, 
which sequester cytosolic components such as proteins, mitochondria, endoplasmic reticulum 
(ER) or Golgi membranes. These autophagosomes fuse with lysosomes to form 
autolysosomes, which degrade their contents by hydrolysis. In micro-autophagy, portions of 
the cytoplasm are directly engulfed by the lysosomes through invaginations of the lysosomal 
membrane. By contrast, in chaperone-mediated autophagy, proteins are translocated one-by-
one across the lysosomal membrane thanks to their association with chaperone proteins that 
are recognized by the lysosomal membrane receptor Lamp-2 (lysosomal-associated 
membrane protein 2) [70]. 
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Fig. 6: Proteolytic systems in mammalian cells. From [71] 
Proteins or organelles are brought to lysosomes from the extracellular environment 
(heterophagy) or from inside the cell (autophagy). A well-known heterophagy form is 
endocytosis. Three different types of autophagic mechanisms are distinguished in mammalian 
cells: macroautophagy, microautophagy, and chaperone-mediated autophagy (CMA). Besides, 
an alternative, lysosomal-independent, pathway for degradation of intracellular proteins is 
well described: the ubiquitin-proteasome system (UPS). 
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7.2 - The autophagy machinery 
Molecular mechanisms underlying autophagy have been extensively reviewed in [72-74]. The 
physiological importance of macro-autophagy being well established as its role in many 
diseases, autophagy is often reduced to the concept of macro-autophagy. Indeed, macro-
autophagy (henceforth simply referred to as “autophagy”) is more often observed and most 
characterized. Autophagy was initially identified as a mechanism triggered by the deficiency 
in nutrients or “starvation”. The major player in energy-sensing is the complex mTORC1 
(mammalian target of rapamycin complex 1), which is activated downstream of Akt, PI3-
kinase and growth factor receptors (Fig. 7) and inhibits autophagy when nutrients are 
available [75]. In response to amino acid sufficiency, mTORC1 is associated to the lysosome 
surface that contains the GTPase Rheb (Ras homolog enriched in brain), required for its 
activation [76]. Under starvation, mTORC1 is detached from the lysosome and its kinase 
activity is rapidly shut down allowing autophagy induction to supply cells with metabolic 
substrates. Thereby, mTORC1 is considered as the major negative regulator of autophagy. Its 
artificial inhibition by rapamycin promotes autophagy [77]. Nevertheless, autophagy is a 
finely regulated process involving numerous other signaling pathways like p53 or MAPK 
pathways. Today, autophagy is recognized as a cellular function answering diverse stimuli 
including hypoxia, reactive oxygen species (ROS), absence of growth factor, DNA damage 
and viral or bacterial infection. However, autophagy is also known to be active at basal levels 
in most cell types where it plays a housekeeping role eliminating unfolded proteins and 
supernumerary or damaged organelles [74]. 
Identification of more than 30 AuTophaGy-related (Atg) genes has been made in yeast 
Saccharomyces cerevisiae. Many of them are conserved in other eukaryotes as mammals, thus 
emphasizing the significance of autophagy through evolution [78]. Among these Atg genes, a 
subset is required for the formation of an isolation membrane. The latter, also named 
phagophore or preautophagosome, is generated at the ER-mitochondria contact site in 
mammalian cells [79]. Membrane extensions of the ER from which these nascent organelles 
are formed have been described [80, 81]. Nevertheless, the lipid bilayer of phagophores could 
have other origins including the Golgi apparatus [82], the outer mitochondrial membrane [83], 
the plasma membrane [84] and possibly the nuclear envelope [85]. Besides, one cannot 
completely rule out de novo membrane formation from cytosolic lipids. 
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Fig. 7: The PI3K/Akt/mTOR pathway. 
The PI3K/Akt/mTOR pathway regulates various cellular functions including proliferation, 
survival, metabolism, autophagy and protein synthesis. Growth factors, cytokines and 
hormones, by binding receptor tyrosine kinases (RTKs), cytokine receptors, or G protein–
coupled receptors (GPCRs), activate class I PI-3 kinase, which generates 
phosphatidylinositol-3,4,5-trisphosphate (PIP3) at the plasma membrane. PIP3 recruits Akt to 
the membrane where it can be phosphorylated and stimulated by the phosphoinositide-
dependent kinase-1 (PDK1). The phosphatase, PTEN, can negatively regulate the activation 
of Akt by catalysing the dephosphorylation of PIP3. Activated Akt, also known as protein 
kinase B (PKB), can phosphorylate a large number of substrates including tuberous sclerosis 
protein 2 (TSC2). Phosphorylation of TSC2 within the TSC1-TSC2 complex blocks its ability 
to inactivate Rheb (Ras homolog enriched in brain), thereby allowing Rheb to stimulate 
mTOR complex 1 (mTORC1) at the lysosome surface where they are both recruited in 
response to amino acid sufficiency. The full activation of mTORC1 therefore depends on the 
presence of both growth factors and amino acids. Besides, Akt promotes mTORC1 activation 
by phosphorylating PRAS40 (proline-rich Akt substrate of 40 kDa), an mTORC1 inhibitor 
protein. Activated mTORC1 can in turn phosphorylate various proteins including the Ulk-1 
complex (Unc-51-like kinase 1), the eukaryotic translation initiation factor 4E binding protein 
1 (4EBP-1) and the p70 ribosomal protein S6 kinase (p70S6K). The phosphorylation of 
4EBP-1 releases the translation initiation factor eIF4E while p70S6K phosphorylates and 
activates the S6 protein of the 40S ribosomal subunit, therefore allowing the protein synthesis. 
In contrast, the phosphorylation of Ulk-1 complex represses the catabolic process of 
autophagy [86]. 
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The mammalian homologue of Atg1, Unc-51-like kinase 1 (Ulk-1), in a complex with other 
Atg proteins including Atg13, regulates the phagophore formation. Ulk-1 activity is itself 
negatively regulated by mTORC1 that phosphorylates Ulk-1 and Atg13 under nutrient-rich 
conditions. After starvation or rapamycin inhibition, mTORC1 is inactivated and 
dephosphorylated Ulk-1 becomes enzymatically active [87]. In contrast, AMPK stimulates the 
Ulk-1 complex by phosphorylating distinct sites in response to decreases in intracellular ATP 
(Fig. 8) [88]. Ulk-1 plays a pivotal role in regulating the localization and the activity of Atg 
proteins such as Atg9 essential for the initiation of autophagy [89]. Besides, Ulk-1 can 
maintain the autophagy activation by inhibiting mTORC1 in a positive-feedback loop [90, 
91]. Surprisingly, Ulk-1 also exerts a negative-feedback by phosphorylating AMPK and 
inhibiting its activity, highlighting the acute regulation of the catabolic process [92]. 
The class III PI-3 kinase is involved in several vesicular trafficking pathways and participates 
in the autophagosome formation when complexed to Beclin-1, the mammalian homologue of 
Atg6, and other regulatory proteins such as Atg14 [93]. Class III PI3K/Beclin-1 produces 
phosphatidylinositol-3-phosphate (PIP), therefore recruiting PIP-binding proteins to the site of 
phagophore formation [80, 94] and stabilizing Ulk-1 nearby [95]. The presence of the 
complex near the site is itself controlled by the Ulk-1-mediated phosphorylation of one of its 
associated regulatory proteins, Ambra1 [96]. Besides, Ulk-1 and AMPK stimulate the kinase 
activity of pro-autophagic class III PI3K/Beclin-1 complex by phosphorylating Beclin-1 [97, 
98] whereas mTORC1 represses it by phosphorylating Atg14 [99]. Another regulatory protein 
of the complex is Bcl-2, which disrupts the interaction of Beclin-1 with class III PI3K. 
Thereby, the interaction between Beclin-1 and Bcl-2 (and Bcl-xL) at the ER inhibits 
autophagy [100, 101]. This dual role of Bcl-2, anti-apoptotic as anti-autophagic, emphasizes 
the close relationship between these two cellular functions (see below). 
The concerted actions of Atg proteins eventually lead to the expansion and conversion of the 
phagophore into an autophagosome. Two ubiquitin-like conjugation systems have been 
reported (Fig. 9). The first one allows the binding of the ubiquitin-like protein, Atg12, with 
Atg5. Conjugated Atg5-Atg12 further associate with Atg16 and interact with the phagophore 
membrane, where they participate to the insertion of another conjugated Atg protein, the LC3- 
II [102]. Indeed, the second ubiquitin-like conjugation system refers to the processing of 
microtubule-associated protein, light chain 3 (LC3), a mammalian homologue of Atg8. Upon 
induction of autophagy, cytosolic pro-LC3 is cleaved by the protease Atg4 to generate LC3-I.  
The carboxyterminal glycine exposed by the cleavage then becomes covalently linked to 
phosphatidylethanolamine, so as to produce processed LC3-II. The latter is integrated on both 
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Fig. 8: The AMPK signaling pathway. Adapted from [103] 
AMPK (5’ adenosine monophosphate-activated protein kinase) is a central regulator of 
cellular metabolism which is stimulated when adenosine triphosphate (ATP) production is 
insufficient and adenosine monophosphate (AMP) and adenosine diphosphate (ADP) levels 
are increased. AMPK is composed of a catalytic subunit (α) and two regulatory subunits (β 
and γ). Its phosphorylation on Thr172 by LKB1 (liver kinase B1) and conformational changes 
induced by its binding to ADP leads to its activation. Besides, an intracellular Ca
2+
 elevation 
can also stimulate AMPK through CaMKKβ (Ca
2+
/calmodulin-dependent kinase kinase β). 
AMPK controls cell growth, autophagy, metabolism and cell polarity by phosphorylating 
various substrates such as TSC2 (tuberous sclerosis protein), Raptor (regulatory-associated 
protein of mTOR), Ulk-1 (Unc-51-like kinase 1) and transcriptional regulators. The 
phosphorylation of TSC2 and Raptor by AMPK results in mTOR complex 1 inhibition and 
participates, in addition to the phosphorylation of Ulk-1 and class III PI3K/Beclin 1 
complexes, in the stimulation of autophagy by AMPK. 
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internal and external membranes of the crescent phagophore. The other Atg8 homologues 
which have been described (GABARAP, GATE-16) are also modified by the same 
mechanism [104]. LC3-II is involved in the autophagosomes closure [105] and can link 
“adaptors” molecules to target defined structures such as protein aggregates or organelles to 
the autophagic machinery. Among the adaptor molecules, the best-characterized ones are p62 
(also named sequestosome1, SQTM1) and NBR1 (neighbour of BRCA1 gene 1), both 
recognizing ubiquitinated proteins, thus complementing the proteasome in the degradation of 
oligomeric and aggregated proteins [106]. The binding affinity of p62 to ubiquitinated 
proteins can be upregulated by ULK1 in response to an accumulation of protein aggregates 
[107]. Furthermore, LC3-II can specifically recognize the mitochondrial protein Nix, a 
member of the Bcl-2 family of apoptotic regulators, to allow the degradation of damaged 
mitochondria, thereby demonstrating that autophagy is more than a nonspecific self-
degradation process [108]. 
Detection of LC3-I to LC3-II conversion by immunoblotting, LC3 punctate relocalization by 
fluorescence, together with electron microscopy for autophagosome observation, are the main 
methods for monitoring autophagy. Conversion of cytosolic LC3-I to autophagosomal LC3-II 
can be readily followed in immunoblotting, LC3-II migrating faster than LC3-I in sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). LC3-II/actin and LC3-
II/LC3-I ratios can be measured and are correlated with the number of autophagosomes. 
However, LC3-II life-time is relatively short, since autophagosomes get rapidly degraded. 
This interferes with autophagy monitoring by LC3-II/LC3-I measurement. To circumvent this 
inconvenience, lysosomal degradation can be prevented by protease inhibitors, such as E64d 
and pepstatin A, or inhibitors of the vacuolar H
+
-ATPase, such as bafilomycin A1. This 
procedure allows to determine total influx of processed LC3-II and thereby the cumulative 
autophagic activity. It has long been advised to exclusively normalize the levels of LC3-II to 
β-actin or other reference proteins, but not to that of LC3-I. However, this choice can be 
discussed in some cases [109]. For instance, when actin as well as other cytoplasmic proteins 
is degraded by autophagy, determination of the LC3-II/LC3-I ratio becomes more appropriate. 
Besides, by putting aside the turnover of the unconjugated form of LC3, we may miss part of 
the overall picture of the autophagic process. 
Alternatively, chimeric constructs of LC3 fused with fluorescent proteins have been generated 
to follow by fluorescence microscopy the recruitment of LC3 into autophagosome membranes 
upon autophagy induction. Expression and degradation of p62 and NBR1 can also be 
measured to monitor autophagic activity [109]. 
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Fig. 9: The molecular mechanisms of the autophagosome formation. Adapted from [74] 
Autophagy induction is dependent on the recruitment of different AuTophaGy-related (Atg) 
proteins. One of them is Ulk-1 (Unc-51-like kinase 1), the mammalian homologue of Atg1, 
which regulates the formation of the phagophore at the ER, in a complex with other Atg 
proteins including Atg13. The energy sensor AMPK (5’ adenosine monophosphate-activated 
protein kinase) stimulates the Ulk-1 complex whereas mTOR complex 1 (mTORC1) represses 
it under nutrient-rich conditions. Activated Ulk-1 controls the activity of Atg9 protein and 
recruits the class III PI3K/Beclin-1 complex to the ER by phosphorylating Ambra1, one of its 
associated regulatory proteins. In turn, the class III PI3K/Beclin-1 complex recruits other 
proteins required for the phagophore formation by producing phosphatidylinositol-3-
phosphate (PIP). Ulk-1 and AMPK stimulates the complex activity by phosphorylating 
Beclin-1 whereas mTORC1 and Bcl-2 represses it by respectively phosphorylating Atg14 and 
disrupting the interaction between Beclin-1 and class III PI3K. 
Two ubiquitin-like conjugation systems are required for the phagophore expansion: the Atg5-
Atg12 conjugation and the processing of LC3 (microtubule-associated protein, light chain 3). 
Atg12 covalently binds to Atg5 and associates with Atg16 on the autophagosomal membrane. 
Cytosolic pro-LC3 is cleaved by the protease Atg4 to produce LC3-I. The latter can be 
covalently linked to PE (phosphatidylethanolamine), so as to generate LC3-II which is 
integrated on both internal and external autophagosomal membranes. LC3-II can bind 
“adaptors” molecules including p62 and NBR1 (neighbour of BRCA1 gene 1) to target 
defined intracellular structures and to allow their selective degradation. 
By its closure, the autophagosome sequesters various cytoplasmic components. Its fusion with 
a lysosome, thereby forming an autolysosome, results in their degradation by hydrolysis. 
 
 30 
The maturation of autophagosomes seems to occur through several fusion events with vesicles 
originating from the endosomal compartment. Thus, autophagosomes have been reported to 
fuse with early endosomes and then with multivesicular endosomes, forming amphisomes. 
Finally, the outer membrane of amphisomes fuses with the lysosomal membrane, resulting in 
“fused organelles” called autolysosomes. Initially, autophagosome lumen has the same pH as 
the surrounding cytoplasm, but during this maturation process, autophagic vacuoles become 
acidic. This pH decrease activates lysosomal proteases such as cathepsins B, L and D, and 
results in the final degradation of the autophagic vacuoles content [110]. A main regulator of 
autophagosomes maturation is Rab7, a member of small GTPases, which is essential in the 
trafficking of vacuoles along microtubules and participates in the fusion with endo/lysosomal 
membranes [111]. The lysosomal membrane protein Lamp-2 is also critical for functional 
autophagy, due to its involvement in the fusion process. This is emphasized in Danon disease 
in which a mutation in the LAMP-2 gene causes hypertrophic cardiomyopathy, skeletal 
muscle myopathy and variable mental retardation [112]. 
 
7.3 - Autophagy functions 
A strong increase of autophagy was observed to promote cell death. Thus, autophagy has long 
been perceived as a form of programmed cell death which has been called “type II” 
programmed cell death, in opposition to apoptosis, the classical “type I” programmed cell 
death. However, it is now well accepted that cell death is often associated with, but rarely due 
to, autophagy. Moreover, autophagy inhibition has more often been reported to enhance it 
rather than prevent cell death (see below). Thus, autophagy is instead regarded as a stress 
adaptation pathway that allows cell survival [113]. 
Besides this narrow and complex relationship with cell death, autophagy maintains a 
particular link with cellular growth control where mTORC1 still plays a central role. 
Autophagy is known to induce cell cycle arrest and to promote senescence while it is inhibited 
in mitosis [114]. Moreover, autophagic function is essential during embryogenesis and 
postnatal development [115]. Besides, its ability to remove damaged organelles such as 
stressed mitochondria provides its significance in aging. Furthermore, misregulation of 
autophagy can lead to the pathogenesis of a number of human diseases including 
neurodegenerative, muscle or heart diseases, and cancer [113]. 
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7.4 - Dual-faced role of autophagy in cancer 
A clear link is observed between autophagy defects and cancer. Autophagy can be perceived 
as a protective mechanism against cancerogenesis. However, autophagy can also promote 
survival of tumor cells in a stressful environment and thereby constitutes a significant 
contribution to tumor maintenance. A multitude of studies have investigated the role of 
autophagy in tumorigenesis, cancer progression and anticancer treatments. Although 
conflicting conclusions have emerged from this intense research effort, it now seems clear 
that autophagy involvement in cancer must be considered at two levels: (i) cancerogenesis and 
cancer development and (ii) treatment resistance (Fig. 10). 
 
 
7.4.1 - Anti-tumor role of autophagy during cancerogenesis 
Autophagy regulation closely overlaps with signaling pathways involved in tumorigenesis 
including mTOR pathway. As previously described, mTORC1 is the major negative regulator 
of autophagy. However, the mTOR protein regulates several other functions including cell 
survival, protein synthesis or cell growth. In tumor cells, constitutively active RTKs (receptor 
tyrosine kinases) and/or persistent production of autocrine growth factors are often observed 
and lead to activation of the mTOR pathway [116]. Besides, oncoproteins connecting RTKs to 
mTOR such as class I PI-3 kinase, Akt or the small GTPase Ras, are considered to inhibit 
autophagy. Conversely, several tumor suppressor genes involved in the upstream inhibition of 
mTOR such as TSC1/TSC2 and phosphatase PTEN activate autophagy [113]. The death-
associated protein kinase 1 (DAPK1), a calcium-dependent serine/threonine kinase which 
promotes both apoptosis and autophagy, has also tumor suppressor properties and is 
frequently silenced in human cancers by epigenetic mechanisms [117]. 
Tumorigenesis seems to be favored by autophagy inhibition. Reduced expression of proteins 
required for autophagy has been noticed in cancer cells. For example, the essential autophagy 
gene, Beclin-1, is monoallelically deleted in many cases of human breast, ovarian and prostate 
cancer [118]. Likewise, numerous brain tumors have reduced levels of Beclin-1, which 
inversely correlate with clinical malignancy [119]. Thus, Beclin-1 can be considered as a 
tumor suppressor. Its gene transfer inhibits tumor cells growth while mutant mice with 
monoallelic deletion of Beclin-1 show increased frequency of spontaneous malignancies [118, 
120]. Other components of the class III PI3K/Beclin-1 complex seem to share the same 
properties like UVRAG (UV radiation resistance-associated gene) which is often 
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monoallelically deleted in human colon cancers and the overexpression of which suppresses 
the proliferation and tumorigenicity of human colon cancer cells [121]. In mice, the loss of 
Bif-1, another regulatory protein of the complex, inhibits autophagosome formation and 
results in the development of spontaneous tumors [122]. Atg genes other than Beclin-1 also 
have tumor suppressor effects, such as Atg5 and Atg7 whose deletion in
 
mice leads to the 
development of liver adenomas [123], or Atg4, whose absence in a mouse model favors the 
occurrence of chemically-induced fibrosarcomas [124]. Moreover, rearrangements in different 
types of leukemia are frequently met in a region of chromosome 3 where Rab7 gene is 
localized [125]. Besides, Beclin-1 interacts with Bcl-2 family proteins, which are well-known 
to be involved in tumorigenesis while regulating autophagic activity. Indeed, anti-apoptotic 
Bcl-2 family members (Bcl-2 proper, Bcl-xL, Bcl-w and Mcl-1) are prominent oncoproteins 
whereas pro-apoptotic members (Bax, Bak and BH3-only proteins) are considered as tumor 
suppressors [116]. By their regulation of the activity of class III PI3K/Beclin-1 complex, the 
anti-apoptotic factors inhibit autophagy and could therefore favor cancer development. 
Inversely, by freeing Beclin-1 from inhibitory interactions with Bcl-2 and its anti-apoptotic 
homologues, the BH3-only proteins such as Bad, Bik, Noxa or Puma promote autophagy 
[126].  
In human cancers, the most commonly mutated tumor suppressor gene is p53. p53 is 
inactivated in more than 50% of human tumors [127]. p53 is crucial in eukaryotic cells where 
it controls numerous functions including cell cycle, senescence, DNA repair and apoptosis. 
Furthermore, p53 plays a role in the regulation of autophagy. It can induce the expression of 
damage-regulated autophagy modulator (DRAM), a lysosomal protein which activates 
autophagy and is also essential for p53-mediated apoptosis [128]. Moreover, DNA damage 
induces a p53-dependent autophagy via AMPK activation and inhibition of the mTOR 
pathway [129]. Otherwise, re-expression of p53 in p53-deficient cancer cells results in 
autophagosome formation [130]. The expression of p14
ARF
, an alternate reading frame 
product of the CDKN2A locus which inhibits the ubiquitination-dependent degradation of 
p53, is frequently abolished in many cases of human cancers including PCa [131]. p14
ARF
 is 
known to promote both p53-dependent and p53-independent autophagy [132]. Moreover, 
p14
ARF
 mRNA produces a shorter isoform, short mitochondrial form of ARF (smARF), which 
also induces massive p53-independent autophagy [133]. However, it should be noted that 
while transcriptional activities of p53 promote autophagy, cytosolic p53 has been shown to 
inhibit it [134]. 
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Except conflicting data about p53, numerous observations thus reinforce the idea that 
autophagy exerts a tumor suppressing role. Several explanations can be proposed. First, a cell 
can be eliminated by both apoptosis and autophagy that surpasses the safe threshold. And of 
course, the presence of an alternative pro-death mechanism is essential if one pathway is 
inactivated. Suppression of these two functions would further sustain tumor development. 
Moreover, autophagy defects are noted to increase necrotic cell death within tumors, 
associated with inflammation which facilitates angiogenesis and tumor growth [135]. It can 
also be highlighted that functional autophagy is necessary in the induction of an anticancer 
immune response by its role in the presentation of antigens [136, 137]. Furthermore, 
autophagy inactivation increases genomic instability that facilitates cancer progression. 
Indeed, autophagy limits metabolic stress and associated oxidative damage, thus protecting 
the genome [138]. The degradation of altered mitochondria as source of reactive oxygen 
species (ROS) is essential to prevent DNA damage [139]. Besides, autophagy inhibition has 
been shown to result in deficient repair of DNA damage although the role that autophagy 
plays in this function is still unclear [140, 141]. Finally, cell growth limitation by autophagy 
may also participate to preserve genome integrity [114]. The autophagic process therefore 
appears as an important mechanism by which cancer initiation and progression are prevented. 
 
 
7.4.2 - Pro-tumor role of therapy-induced autophagy 
In some cancers (especially when essential apoptotic modulator, like Bax and Bak or 
caspases, are defective), autophagy induction in response to chemotherapy has been reported 
to promote cell death [142, 143]. However, autophagy has most frequently been demonstrated 
to favor survival of tumor cells exposed to changes in their microenvironment or to various 
treatments. Indeed, when a solid tumor is growing, it quickly depletes its blood supply, 
leaving portions of the tumor undergoing hypoxia and imbalances in nutrient supply. 
Inhibition of autophagy induced by these conditions can promote cell death [144]. Moreover, 
in addition to conventional cytotoxic drugs, numerous pharmacological agents such as anti-
angiogenic molecules, kinase inhibitors, proteasome inhibitors or HDAC inhibitors are known 
to induce autophagy [145]. Pharmacological inhibitors of autophagy (e.g., chloroquine and 
hydroxychloroquine, 3-methyladenine, bafilomycin A1, monensin, NH4Cl) and siRNA 
targeting Atg genes (e.g., Atg5, Beclin-1, Atg7, Atg10) have been used to sensitize tumor 
cells to various stress inducers such as glucose and amino acid deprivation, growth factor 
withdrawal, radiation therapy or above mentioned pharmacological agents [116]. Several 
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ongoing phase I/II trials targeting autophagy in cancer have even been conducted with the use 
of chloroquine or its derivatives, safe antimalarial drugs which inhibit lysosome acidification 
[145]. 
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Fig. 10: Dual-faced role of autophagy in cancer. 
Pathways involved in autophagy control are often deregulated during malignant 
transformation. Autophagic process is thus considered to have tumor suppressor properties. 
However, autophagy also represents a mechanism of cell survival providing resistance to 
various anti-tumoral treatments. 
 
 
 
8 - Cell death and autophagy 
Classically, two types of mechanisms leading to cell elimination are described: the 
programmed cell death, which is physiological and tolerogenic, and the necrosis, an 
accidental, pathological and immunogenic cell death. The programmed cell death is mainly 
related to apoptosis, a form of cell death which exhibits particular morphological features 
such as chromatin condensation, nuclear fragmentation or plasma membrane blebbing. 
Besides, for a long time, the terms apoptosis and programmed cell death had the same 
meaning, until autophagic cell death and programmed necrosis were described [146]. 
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8.1 - Apoptosis 
Two pathways regulating apoptosis have been described, the extrinsic pathway and the 
intrinsic or mitochondrial pathway [147, 148]. The extrinsic pathway is triggered by binding 
of lethal ligands, such as FAS ligand (FAS-L) but also TNFα or TRAIL to specific receptors 
(FAS, TNFα receptor 1 and TRAIL receptor 1-2 respectively). Combination of ligand with its 
death receptor results in the recruitment of different proteins including death domain-
containing protein (FADD) and pro-caspase-8. This assembly forms the death-inducing 
signaling complex (DISC) where pro-caspase-8 is cleaved to give active caspase-8 (cysteinyl 
aspartate-specific protease-8). Activation of caspase-8 catalyses the proteolytic maturation of 
caspase-3 and triggers the execution phase of apoptosis.  
The intrinsic pathway is dependent on various non-receptor-mediated stimuli that can consist 
in the absence of certain growth factors or cytokines, toxins, viral infections, hypoxia, 
oxidative stress, DNA damage, cytosolic calcium overload or radiation. These stimuli induce 
changes in mitochondrial membranes that result in mitochondrial outer membrane 
permeabilization (MOMP), loss of the mitochondrial transmembrane potential (∆Ψm) (due to 
permeabilization of the mitochondrial inner membrane) and arrest of ATP synthesis and ∆Ψm-
dependent transport activities. Besides, the respiratory chains get uncoupled, producing 
important amount of ROS which amplifies the apoptotic signal [149]. 
MOMP has been related to two mechanisms [147]. In the first, pores are generated through 
the formation of permeability transition pore complexes (PTPC) which raise the permeability 
of the inner mitochondrial membrane and induce, due to osmotic forces, a swelling of the 
matrix as water enters, which results in the outer membrane break. The molecular nature of 
the PTPCs has long been debated. However, convincing evidence in favor of formation of 
these complexes from the F0F1 ATP synthase was recently provided [150, 151]. The second 
mechanism involved in MOMP is mediated by proteins of the Bcl-2 family (Fig. 11). Indeed, 
in response to apoptotic stimuli, pro-apoptotic members Bax and Bak undergo conformational 
changes leading to their oligomerization on the mitochondrial outer membrane and the 
formation of pores. Conversely, anti-apoptotic members (e.g., Bcl-2, Bcl-xL, Bcl-w) can 
inhibit this process by interacting with Bax and Bak [152]. 
With MOMP, the release into the cytosol of proteins normally confined within the 
mitochondrial intermembrane space occurs. Among these, two groups can be described. The 
first group gathers cytochrome c, SMAC (second mitochondria-derived activator of caspases, 
also known as DIABLO) and HTRA2 (high temperature requirement protein A2). Released 
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cytochrome c binds and activates Apaf-1 (apoptotic peptidase activating factor 1) as well as 
pro-caspase-9, forming the “apoptosome”. Activated caspase-9 can in turn cleave and activate 
pro-caspase-3, thus engaging the caspase-dependent proteolytic cascade. SMAC/DIABLO 
and HTRA2 inhibit the anti-apoptotic activities of members of the IAP family (inhibitors of 
apoptosis proteins). 
A second group of mitochondrial proteins is released after the cell has committed to die. They 
include AIF (apoptosis-inducing factor), endonuclease G and CAD (caspase-activated 
DNase). They are translocated to the nucleus where they induce chromatin condensation and 
oligonucleosomal DNA fragmentation (Fig. 12). 
The extrinsic and intrinsic pathways are connected by Bid (BH3-interacting domain death 
agonist), another pro-apoptotic Bcl-2 family protein. It is cleaved by active caspase-8, 
producing a mitochondrion-permeabilizing fragment known as truncated Bid (tBid). 
Accumulation of tBid at the mitochondria causes MOMP, ∆Ψm dissipation and cytochrome c 
release [149]. 
 
 
Fig. 11: The Bcl-2 protein family. Adapted from [153]. 
Bcl-2 (B-cell lymphoma-2) proto-oncogene was identified from the discovery of a 
chromosomal translocation involving chromosomes 14 and 18 in B-cell follicular lymphoma. 
This translocation places Bcl-2 under the control of an immunoglobulin gene enhancer 
thereby increasing its expression. Bcl-2 is the first of a family of genes that can be either anti-
apoptotic or pro-apoptotic. Each Bcl-2 family protein contains at least one of the four 
characteristic Bcl-2 homology (BH) domains (named BH1, BH2, BH3 and BH4) which 
correspond to α-helical segments. Anti-apoptotic members (Bcl-2, Bcl-xL, Mcl-1) have the 
four BH domains and a hydrophobic transmembrane (TM) domain allowing their integration 
into lipid bilayer. For their part, pro-apoptotic members are distinguished into two groups, 
those that only have the BH3 domain (e.g. Bid, Bim and Bad) and those with several BH 
domains and a TM domain (e.g. Bax and Bak). Such pro-apoptotic proteins were long 
described as having three BH domains (BH1, BH2 and BH3), whereas anti-apoptotic proteins 
contain a supplementary BH4 domain conferring anti-apoptotic activity. However, the BH4 
domain was recently redefined as a structural motif also present in Bax and Bak [152, 154].  
 
 
Extrinsic and intrinsic pathways lead to the execution phase of apoptosis. Initiator caspases 
(caspase-8 and caspase-9) activate caspase-3 and effector caspases cascade. These caspases in 
turn activate cytoplasmic endonucleases and proteases, and cleave various cellular 
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components that cause the morphological changes seen in apoptotic cells. Indeed, apoptotic 
cells exhibit specific microscopic features. First, cell shrinkage and rounding are observed 
because of cytoskeleton disruption. The cytoplasm appears dense and the organelles more 
tightly packed. Chromatin undergoes condensation (pyknosis) until nuclear envelope becomes 
discontinuous and fragmented DNA escapes. Formation of irregular buds on cell membrane 
(blebbing) occurs followed by separation of cell fragments into several vesicles known as 
apoptotic bodies [155]. The latter are rapidly phagocytosed by macrophages due to the 
recognition of phosphatidylserine externalized during the apoptotic process and thereby 
displayed at their surface [156]. Therefore, apoptotic cells do not release their immunogenic 
constituents into the surrounding environment [155]. 
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Fig. 12: Pathways regulating apoptosis. Adapted from [157] 
Two distinct pathways have been reported to conduct to apoptosis: the extrinsic and intrinsic 
pathways. The extrinsic pathway is triggered via the stimulation of death receptors such as 
FAS, TNFα receptor and TRAIL receptor. Activated receptors recruit different proteins 
including death domain-containing protein (FADD) and pro-caspase-8 which form the death-
inducing signaling complex (DISC) where pro-caspase-8 is cleaved to give active caspase-8. 
Caspase-8 in turn activates caspase-3 to trigger the execution phase of apoptosis.  
The intrinsic pathway is induced in response to various intracellular stresses and involves the 
mitochondrial outer membrane permeabilization (MOMP) which results in the release of 
cytochrome c. The latter can bind and activate Apaf-1 (apoptotic peptidase activating factor 1) 
and pro-caspase-9, thereby forming the “apoptosome”. Activated caspase-9 can in turn cleave 
pro-caspase-3, engaging the caspase-dependent proteolytic cascade which leads to the cell 
death. These two pathways are not independent, extrinsic pathway being able to activate 
intrinsic pathway through Bid (BH3-interacting domain death agonist) cleavage. 
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8.2 - A debatable autophagic cell death 
An autophagic cell death has been described during the development of lower eukaryotes 
[158, 159] and in vitro in some cancer cells where apoptosis is disrupted (e.g. Bax/Bak 
double-knockout) [142, 143]. Besides, a nonphysiological over-activation of autophagy which 
exceeds a safe threshold has been reported to cause cell death [67]. Morphological features 
characteristic of autophagy and apoptosis have often been observed concomitantly. For 
instance, MG132 proteasome inhibitor has been noticed to induce apoptosis and autophagy-
mediated cell death in PC3 prostate cancer cells [160]. In this model and in some others, 
inhibition of autophagy partially suppresses cell death. However, if it is well accepted that 
cells can undergo autophagy before or during their elimination, it seems rarely to be the 
process by which cells actually die [161]. Autophagy could rather play a role of partner of 
apoptosis [67]. By the interaction between p62 and caspase-8, the autophagy stimulated by the 
proteasome inhibition and the subsequent accumulation of p62 and LC3 have been noticed to 
favor caspase-8 aggregation and activation, thereby inducing apoptosis [162, 163]. Moreover, 
in Bax/Bak double-knockout or in Bcl-xL-overexpressing cells that are defective in apoptosis, 
prolonged ER stress and associated autophagy have been demonstrated to promote a necrosis-
like cell death [164]. Some authors even speak of cell death impostor [165]. In fact, today, 
autophagy is further considered as a cytoprotective mechanism activated in response to 
various stress. It can serve to supply energy and nutrients when they are limited and to 
maintain genomic integrity by eliminating depolarized mitochondria that are a source of 
genotoxic ROS. Moreover, specific degradation of mitochondria by autophagic process 
(mitophagy) may circumscribe apoptosis by preventing MOMP and subsequent release of 
cytochrome c [166]. Besides, as explained above, the resistance to many anticancer drugs is 
related to the triggering of a prosurvival autophagy [145]. Several clinical research studies 
have been conducted to define optimal strategies to repress autophagy in tumor cells [167, 
168]. 
 
8.3 - Cross-talk between autophagy and apoptosis 
Although autophagy most frequently constitutes a prosurvival pathway, numerous conflicting 
data show that autophagy and apoptosis are closely related. It can be noted that several 
autophagy-related genes are involved in apoptosis regulation and their knockdown may not be 
without effect on apoptotic cell death. For instance, Atg3 and Atg12 have been reported to be 
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conjugated and localized to the mitochondrial outer membrane where they regulate 
mitochondrial fusion. Disruption of the formation of this complex inhibits mitochondrial 
pathway-mediated apoptosis [169]. Moreover, Atg12 knockdown is noticed to suppress 
intrinsic apoptosis. Indeed, free form of Atg12 promotes apoptosis by binding and 
inactivating prosurvival Bcl-2 family members, such as Bcl-2 and Mcl-1 [170]. For its part, 
Atg4 can be cleaved by caspase-3 during apoptosis generating fragments which enhance 
delipidation of the Atg8 homologue GABARAP and sensitizes cells to apoptosis [171]. 
Besides, calpain-mediated Atg5 cleavage is observed during apoptosis. Truncated Atg5 is 
translocated to the mitochondria and interacts with Bcl-xL to enhance cytochrome c release 
and caspases activation [172]. Beclin-1 can also be cleaved by caspase-3, losing its ability to 
promote autophagy. Moreover, one of its truncated fragments localizes to mitochondria and 
increases cell sensitivity to apoptosis [173]. Various proteins other than Atg family members 
but evenly participating in the regulation of autophagy also interfere with apoptosis 
mechanisms [174]. For instance, apoptosis induction leads to caspases and calpains-mediated 
cleavage of Ambra1, a member of class III PI3K/Beclin-1 complex, which inhibits pro-
survival autophagy [175]. Moreover, UVRAG, another protein of the class III PI3K/Beclin-1 
complex, is known to interact with Bax, thus inhibiting its translocation to mitochondria and 
the induction of apoptosis [176]. Otherwise, Bcl-2 family proteins are involved in the 
regulation of the two functions. As we have previously seen, anti-apoptotic members of Bcl-2 
family (including Bcl-2 itself, but also Bcl-xL or Mcl-1) can interact with Beclin-1 to inhibit 
the formation of class III PI3K/Beclin-1 complex and the autophagy induction. Through their 
competitive interaction with Bcl-2, Bcl-xL or Mcl-1, BH3-only proteins suppress this 
inhibition and promote autophagy [126, 177]. Jnk1 (c-Jun N-terminal kinase) by 
phosphorylating Bcl-2 at multiple sites, thus decreasing its ability to bind Bax as Beclin-1, is 
reported to induce apoptosis and autophagy [178]. Besides, through its substrate c-Jun, Jnk1 
increases the transcription of Beclin-1 gene [179]. Calpains, a family of Ca
2+
-dependent 
cysteine proteases activated during execution phase of apoptosis, are also involved in 
autophagy process. Indeed, in calpain-deficient cells, an impaired autophagy has been 
observed [180]. Apoptosis and autophagy are also interconnected by several signaling 
pathways which share the control of these two functions. Indeed, as we have explained above, 
mTOR and p53 pathways regulate cell survival by playing on apoptosis and autophagy 
induction. Moreover, DAPK1, known to induce apoptosis in response to various stimuli, can 
also regulate autophagy in different ways. DAPK1 is noticed to interact with and to 
phosphorylate Beclin-1, which suppresses the inhibitory Beclin-1/Bcl-2 interaction. It also 
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interacts with MAP1B (microtubule-associated protein 1B), which facilitates autophagosomes 
trafficking along microtubules. Finally, it has been demonstrated to activate p53 and increase 
p14
ARF
 mRNA splicing producing pro-autophagic smARF [181]. 
 
8.4 - Regulated necrosis 
Although necrosis had been considered for a long time to be only an uncontrolled mechanism, 
a regulated necrosis was recently highlighted. This regulated necrosis (or necroptosis) is under 
the control of various proteins including RIPK (Receptor interacting protein kinases) or 
PARP1 (poly(ADP-ribose) polymerase-1) and responds to several stimuli such as DNA 
damage and activation of death receptors [182]. 
 
9 - Calcium signaling 
In rat prostatic cells, the role of intracellular calcium in the programmed cell death triggered 
by androgen removal has been known for 25 years [183, 184]. The involvement of Ca
2+
 in the 
resistance to apoptosis in PCa cells is clearly established [185]. We have tried to understand 
more precisely how Ca
2+
 signaling participates to the mechanisms of hormone resistance. 
Calcium is a versatile intracellular messenger, which regulates many different cellular 
functions such as gene transcription, muscular contraction, cell differentiation, cell cycle, 
migration, secretion and apoptosis. Ca
2+
 exerts its effects as a signal by binding to various 
proteins including calmodulin, a Ca
2+
-binding messenger protein which plays the role of 
sensor of cytosolic [Ca
2+
] and transduces calcium signals to target proteins. Ca
2+
 signaling is 
dependent on extensive cellular machinery allowing a precise spatiotemporal control of 
[Ca
2+
]. While extracellular environment contains more than 1 mM Ca
2+
, cytosolic [Ca
2+
] 
remains very low (~100 nM), due to the active extrusion of Ca
2+
 through the plasma 
membrane by the plasma-membrane Ca
2+
-ATPase (PMCA) and the Na+/Ca
2+
 exchanger 
(NCX) or through the membranes of intracellular organelles such as the ER by the 
sarco/endoplasmic reticulum Ca
2+
 ATPase (SERCA) pump. The presence of numerous Ca
2+
-
binding proteins in its lumen (calreticulin, calnexin, etc.) in addition to the SERCA activity 
makes ER the main intracellular Ca
2+
 store. A strong gradient is thus generated, ER 
accumulating Ca
2+
 in more than thousandfold excess in comparison to the cytosol [186] (Fig. 
13). 
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Almost all Ca
2+
 signals correspond to brief pulses of Ca
2+
, released in all the cytoplasmic 
compartments or limited to only sub-domains or specific organelles. [Ca
2+
] perturbations can 
take a few milliseconds to several hours. These Ca
2+
 transients can have two origins : (i) the 
internal stores, due to the presence of two channels at their surface, the inositol trisphosphate 
receptor (IP3R) and its close relative, the ryanodine receptor (RyR), and (ii) the extracellular 
medium [187]. 
In the latter case, they are dependent on the opening of various plasma membrane channels in 
response to stimuli such as membrane depolarization, agonists, stretch or the depletion of 
internal stores. These channels are thus classified according to their mechanisms of activation: 
voltage-operated channels (VOC) present in excitable cells and essential for muscle 
contraction, for action potential generation and for exocytosis of neurotransmitters in synaptic 
cleft, receptor-operated channels (ROC), which bind external ligand that activates them, 
second-messenger-operated channels (SMOC) which respond to internal messengers, store-
operated channels (SOC) opened by the depletion of intracellular Ca
2+
 store (particularly the 
ER), thermosensors and stretch-activated channels [187]. Some of them belong to the 
transient receptor potential (TRP) channel family, on which we focused our attention 
specifically on TRPM8 largely expressed in PCa cells [188]. 
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Fig. 13: The Ca
2+
 homeostasis. Adapted from [189] 
Cellular Ca
2+
 homeostasis is finely regulated via a set of pumps, exchangers and channels. 
Ca
2+
 signals are the result of influx from the extracellular space mediated via diverse plasma 
membrane channels or originate from releases from internal stores through inositol 
trisphosphate receptors (IP3R) and ryanodine receptors (RyR). (Abbreviations: ADP, 
adenosine diphosphate; ATP, adenosine triphosphate; CRT, calreticulin; DAG, 
diacylglycerol; ER, endoplasmic reticulum; GPCR, G protein-coupled receptor; InsP3, inositol 
trisphosphate; InsP3R, inositol trisphosphate receptor; NCX, Na
+
/Ca
2+
 exchanger; PIP2, 
phosphatidylinositol-4,5-bisphosphate; PLC, phospholipase C; PMCA, plasma-membrane 
Ca
2+
-ATPase; ROC, receptor-operated channel; RTK, receptor tyrosine kinase; RyR, 
ryanodine receptor; SERCA, sarco/endoplasmic reticulum Ca
2+
 ATPase; SMOC, second-
messenger-operated channel; SOC, store-operated channel; VDAC, voltage-dependent anion 
channel; VOC, voltage-operated channel.) 
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9.1 - The TRPM8 channel 
The family of TRP channels is so designated because they were originally described in 
Drosophilia whose photoreceptors with mutations in the trp locus responded to a continuous 
light with a transient receptor potential. The mammalian TRP channels mediate a variety of 
sensations like the sensations of pain, warmth or coldness, different kinds of tastes, olfaction, 
hearing, touch and vision [190, 191]. Furthermore, they are reported to respond to various 
agonists, modifications of pH or pressure, and oxidative stress. Nevertheless, the activation 
and regulation mechanisms of TRP channels are not well known. Structurally, TRP channels 
comprise four subunits, themselves composed of six transmembrane domains (Fig. 14). The 
mammalian TRPs are encoded by at least 28 genes. These are divided into two broad groups: 
group 1 including TRPC ("C" for canonical), TRPV ("V" for vanilloid), TRPM ("M" for 
melastatin) and TRPA ("A" for ankyrin) and group 2 including TRPP ("P" for polycystic) and 
TRPML ("ML" for mucolipin). 
 
Extracellular
Intracellular
N
C
 
Fig. 14: The TRP architecture. Adapted from [192] 
TRP channels present six membrane-spanning domains: S1 to S6 transmembrane domains. 
They assemble into homo- or heterotetramers to form non-selective cationic channels. 
 
TRPM8 is a non-selective cation channel assembled in homotetramer and activated by 
temperatures below 26°C. While acid pH inhibits TRPM8, many chemicals compounds such 
as menthol, icilin or eucalyptol shift activation threshold to higher temperatures explaining the 
cold sensation produced by these molecules when they are in contact with nerve endings of 
the oral cavity. Temperature sensitivity of TRPM8 is also dependent on the transmembrane 
voltage. Moreover, cellular microenvironment finely regulates channel activity. Indeed, 
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presence of phosphatidylinositol 4,5-bisphosphate seems essential. Its depletion is involved in 
the desensitization of TRPM8 as well as PKC and calmodulin. Furthermore, GPCRs, in 
particular activated by inflammatory mediators and growth factors, have also been noticed to 
control TRPM8 opening [193]. Originally, TRPM8 is known to be expressed in 
thermosensitive neurons (trigeminal ganglia, dorsal root ganglia) but also in prostate and liver 
[190]. 
It is now well established that TRP channels are involved in PCa initiation and progression. 
TRPV6 expression is increased in advanced PCa and significantly correlated with the degree 
of aggressiveness of the cancer, measured by the Gleason score (which determines the 
histological grading of PCa and indicates the long-term prognosis of the disease [194]), 
making it a strong predictor of the clinical outcome [195]. For its part, TRPM8 is presented as 
a promising PCa biomarker and a putative therapeutic target in PCa treatment. Its expression 
in PCa increases more than any other prostate specific gene compared to non-malignant 
tissues. The channel is also overexpressed in other cancers such as breast, lung and colon 
cancers [193]. Dendritic cells loaded with a cocktail of peptides derived from different PCa-
associated antigens including TRPM8 have been used for vaccination in a phase I clinical trial 
to treat patients reached by HRPCa [196]. 
In prostate, TRPM8 localization depends on the differentiation status of prostate epithelial 
cells. Whereas secretory mature prostate epithelial luminal cells expressed functional plasma 
membrane TRPM8, the channel activity is reported to be lost in the plasma membrane in 
dedifferentiated prostate epithelial cells but conserved on the ER membrane, due to a 
truncated splice variant of TRPM8 [188]. Cells obtained from PCa biopsies present a stronger 
TRPM8-mediated current density than normal prostate or benign prostate hyperplasia cells. 
But if TRPM8 expression has been noticed to be upregulated in PCa epithelia, it is mostly lost 
in dedifferentiated and androgen-independent cells [197, 198]. Indeed, TRPM8 expression in 
prostate cells is abolished after anti-androgen therapy [199]. Actually, one androgen response 
element (ARE) is present in the promoter of trpm8 gene and eleven AREs in its introns, 
making TRPM8 expression directly under control of AR activity [200]. 
Two studies have presented TRPM8 as an ER Ca
2+
 release channel in the PCa cell line 
LNCaP [200, 201]. Zhang and Barritt detected TRPM8 by immunofluorescence both in the 
plasma membrane and the ER of LNCaP cells and showed that, in the absence of extracellular 
Ca
2+
, cooling and high concentrations of menthol were able to induce a small increase in 
intracellular Ca
2+
. Nevertheless, the increase was much higher in presence of extracellular 
Ca
2+
, suggesting an inward current from extracellular medium. Otherwise, they found that 
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both activation by menthol and inhibition by antagonist capsazepine or siRNA-mediated 
silencing of TRPM8 reduced LNCaP cells survival. Therefore, although TRPM8-mediated 
Ca
2+
 influx seems beneficial, a prolonged overstimulation and a subsequent Ca
2+
-overload can 
become toxic [200]. In turn, Prevarskaya and her team also observed TRPM8 on intracellular 
structures in LNCaP cells. They also measured the menthol-induced Ca
2+
 release from the ER 
and an inward current carried not by TRPM8 but rather by SOCs activated by menthol-
induced store depletion [201]. However, the localization of TRPM8 in LNCaP cells continues 
to be debated [202]. The specificity of antibodies directed against TRP channels is frequently 
questioned. Moreover, chemical compounds used at high concentrations to induce these 
currents could not be very specific of TRPM8. Thus, Voets and his collaborators showed that 
menthol could induce a Ca
2+
 release from the ER independently of TRPM8 channels. Besides, 
in LNCaP cells, they detected TRPM8 only in the plasma membrane [203]. 
In the prostate, cellular microenvironment is important in the regulation of TRPM8 opening. 
Indeed, TRPM8 activation in PCa cells has already been reported to depend on PSA-activated 
bradykinin 2 receptor pathway [204], phosphatidylinositol 4,5-bisphosphate [205], and 
lysophospholipid generated by the Ca
2+
-independent phospholipase A2 [206]. 
In PCa, TRPM8 seems to be involved in the regulation of cell proliferation and migration. 
Thus, in androgen-independent PCa PC-3 cells, exogenous TRPM8 overexpression has been 
shown to inhibit cell cycle and migration while facilitating apoptosis induced by starvation 
[207]. Besides, PSA has been noted to activate and increase the number of functional TRPM8 
channels thus reducing PC-3 cells motility [204]. Moreover, in the other androgen-
independent DU145 cell line which endogenously expresses TRPM8, cell growth and 
migration have also been reported to be inhibited by menthol [208]. Migration control of PCa 
cells by TRPM8 seems to depend on their association with two recently discovered proteins 
named TAF1 and TAF2 (TRP channel-associated factors) [209]. 
9.2 - Inositol trisphosphate receptors 
Among the elements of Ca
2+
 signaling machinery, IP3R channel also appears to be involved 
in the mechanisms of cancerogenesis [210].  
The primary structure of IP3R presents different domains: an N-terminal IP3-binding domain, 
a regulatory/coupling domain in the middle of the molecule, a Ca
2+
 channel-forming region 
localized to the C-terminus, with six transmembrane domains, and a short cytoplasmic C-
terminal tail, the gating domain. Three IP3R isoforms (IP3R1, 2 and 3), generated from 
ITPR1, ITPR2 and ITPR3 genes, form homo- and heterotetramers of molecular weight of 
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about 1.2 MDa (Fig. 15). Their opening is triggered by IP3, which is mainly produced at the 
cell membrane in response of GPCRs or RTKs activation by ligands such as hormones and 
growth factors. Activated membrane receptors stimulate phospholipase C (PLC) which carry 
out the hydrolysis of phosphatidylinositol-4,5-bisphosphate (PIP2) to release IP3 and 
diacylglycerol (DAG). Due to its hydrophilic composition, IP3 can diffuse away from its 
production site and binds IP3Rs on the ER surface. This binding increases the sensitivity of 
the receptor to cytosolic Ca
2+
, which activates it at low concentrations and inhibits it at the 
higher concentrations that occur after Ca
2+
 release [211, 212]. For its part, luminal Ca
2+
 can 
also modulate IP3R activity, the depletion of ER Ca
2+
 store being known to decrease the 
channel sensitivity to IP3 [213, 214]. IP3R contains multiple phosphorylation sites and is 
associated with several regulatory proteins such as IRBIT (IP3R-binding protein released by 
IP3) and Bcl-2, themselves regulated by various kinases and phosphatases and making 
difficult the perfect understanding of IP3R regulation [212]. However, several mechanisms of 
control have been established. It has been demonstrated that PKA (cyclic AMP-dependent 
protein kinase) phosphorylates IP3R1 on two sites, S1589 and S1716, both located in the 
regulatory domain, leading to an increase of its sensitivity towards IP3 [215, 216]. Other 
kinases such as CaMKII (Ca
2+
/Calmodulin dependent kinase II), PKG (cyclic GMP-
dependent protein kinase), PKC and Akt modulate IP3R opening [212]. Besides, several Bcl-2 
family members are involved in the control of IP3R activity. Indeed, beside their roles in the 
permeability of the mitochondrial outer membrane and in the regulation of class III 
PI3K/Beclin-1 complex, Bcl-2 family proteins have repeatedly been reported to modulate the 
ER Ca
2+
 content and its release. Although the involved mechanisms are still not fully 
understood (see the following chapter), a regulation of IP3R opening by the Bcl-2 family 
members has been highlighted [217]. 
IP3R channel seems involved in cancer progression. Indeed, IP3R expression profile is 
reported to be altered in several cancers such as glioblastoma [218] and gastric cancers [219]. 
The aggressiveness of colorectal carcinomas is also correlated to the expression of IP3R3 
[220]. Moreover, modulation of IP3R expression seems involved in the growth of breast 
cancer cells [221]. We can also notice these conflicting data about IP3R involvement in the 
resistance to anti-tumor treatment : the overexpression of IP3R constitutes a mechanism of 
resistance to cisplatin in non-small-cell and small-cell lung cancer cells [222] while a reduced 
expression of IP3R1 decreases sensitivity to the same drug in bladder cancer cells [223]. 
Besides, numerous proto-oncogenes such as Akt [224], Bcl-2 or Bcl-xL [217] as explained 
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above, but also tumor suppressors such as the promyelocytic leukemia protein (PML) [225], 
BRCA1 [226] and Beclin-1 [227] regulate IP3R function and ER Ca
2+
 store content. 
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Fig. 15: The IP3R structure. Adapted from [228]. 
Three of the four IP3R subunits are represented on the figure. Each of them is composed of an 
N-terminal IP3-binding domain, a central regulatory domain, a Ca
2+
 channel-forming region 
with 6 transmembrane domains and a C-terminal gating domain. 
 
As we have previously seen, several signaling pathways regulate both apoptosis and 
autophagy. Ca
2+
 signaling has also been demonstrated to be involved in the control of these 
two functions, which again supports the notion of a close link between them. 
 
10 - Calcium and apoptosis 
The high toxicity of a cellular Ca
2+
 overload has been known since the late 1960s. Indeed, one 
of the first effects described for Ca
2+
 ionophores was their toxicity [229]. Originally, the toxic 
role of Ca
2+
 was related to necrosis as in the case of excitotoxicity, in which necrotic death 
occurs in neurons after glutamate-dependent hyperstimulation and subsequent massive Ca
2+
 
influx [230]. However, in recent years, numerous reports have indicated an involvement of 
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Ca
2+
 in apoptosis regulation. In particular, the ER Ca
2+
 store has been reported to modulate 
the sensitivity to apoptosis [231]. 
 
10.1 - Role of the ER Ca
2+
 store 
The ER represents the main intracellular store of Ca
2+
 and serves many functions among 
which the folding, the post-translational modification and the trafficking of proteins. As ER 
chaperones require a high Ca
2+
 concentration for their activity, an [Ca
2+
]ER reduction can 
promote the accumulation of unfolded proteins, a condition referred to as ER stress. To 
overcome this stress, a particular pathway called the unfolded protein response (UPR) is 
triggered (Fig. 16). It precludes the accumulation of unfolded proteins by the release of three 
proteins, PERK (PKR-like eIF2α kinase), IRE1 (inositol requiring enzyme 1) and ATF6 
(activating transcription factor 6), normally bound to and inactivated by the luminal 
chaperone GRP78 (glucose regulation protein 78 also called BiP for Binding immunoglobulin 
protein). By their transcriptional and translational activities, these proteins inhibit general 
protein synthesis, while selected synthesis of chaperones and protein folding enzymes is 
favored. Moreover, they promote, through ERAD (ER-associated degradation) system, the 
retrograde translocation of ER proteins to the cytoplasm to allow their degradation by the 
proteasome [232, 233]. In the case of excess ER stress that UPR’s mechanisms fail to reduce, 
the UPR activates apoptosis by upregulation of the proapoptotic factor CHOP (CCAAT/-
enhancer-binding protein homologous protein) and Jnk-dependent inactivation of Bcl-2 [234, 
235]. 
The concept wherein ER Ca
2+
 is closely related to apoptosis control also comes from the 
recognition that Bcl-2 proteins are localized on the membranes of organelles deeply involved 
in Ca
2+
 storage (the ER and the mitochondria). Indeed, in addition to their direct role in 
apoptosis and more precisely in the control of the permeability of the mitochondrial outer 
membrane, Bcl-2 family proteins have been reported to govern the ER Ca
2+
 content and its 
release (reviewed in [236]). The first observation suggesting a role of Bcl-2 on ER Ca
2+
 dates 
back to 1993, when Bcl-2 overexpression was shown to protect hematopoietic cells from 
apoptosis induced by interleukin-3 withdrawal by precluding Ca
2+
 transfer from the ER to the 
mitochondria [237]. Similar data were obtained in other studies. For example, Bcl-2 
overexpression was demonstrated to abolish cytosolic Ca
2+
 increase provoked by serum 
withdrawal in murine fibroblasts [238]. 
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Fig. 16: The UPR signaling pathway. Adapted from [239] 
An ER stress is known to trigger the unfolded protein response (UPR). Such a pathway 
depends on the release of PERK (PKR-like eIF2α kinase), IRE1 (inositol requiring enzyme 1) 
and ATF6 (activating transcription factor 6) from GRP78 (glucose regulation protein 78), 
which leads to their activation. Released and oligomerized IRE1 achieves the splicing of 
XBP1 mRNA, which generates the transcription factor XBP1. IRE1 also mediates the 
inactivation of Bcl-2 by stimulating Jnk (c-Jun N-terminal kinase). Released ATF6 
translocates to the Golgi apparatus where it is cleaved to produce an active transcription 
factor. PERK undergoes oligomerization and phosphorylates the translation initiating factor 
eIF2α, thereby repressing the general protein synthesis while promoting the translation of the 
transcription factor ATF4 (activating transcription factor 4). ATF4, ATF6 and XBP1 promote 
the expression of various genes required for ERAD (ER-associated degradation) and for the 
restoration of ER homeostasis. However, upon severe ER stress, the UPR triggers apoptosis 
by increasing the expression of the pro-apoptotic transcription factor CHOP (CCAAT/-
enhancer-binding protein homologous protein). 
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Moreover, Bcl-2 inhibits the induction of apoptosis by thapsigargin, a specific inhibitor of the 
SERCA pump, by reducing Ca
2+
 efflux through the ER membrane [240]. 
Actually, various stimuli among which oxidative stress [241], ozone [242], palmitate [243] or 
paclitaxel [244] induce Ca
2+
 release from the ER in order to trigger apoptosis. Bcl-2 
overexpression counteracts this process in numerous models [245, 246]. However, one point 
remains controversial. Several reports emphasize if it decreases the Ca
2+
 release from the ER, 
Bcl-2 preserves rather than depletes ER Ca
2+
 store [236]. Nonetheless, more recent data, 
including direct measurements of luminal Ca
2+
 with ER-targeted Ca
2+
-sensitive fluorescent 
probes, seem to demonstrate the opposite. Pinton et al. showed an increased ER Ca
2+
 leak, 
hence reducing the [Ca
2+
]ER after Bcl-2 overexpression. Ca
2+
 release caused by IP3-generating 
agonists was subsequently decreased in both the cytosol and the mitochondria. Moreover, 
they observed a decrease of the amplitude of store-operated Ca
2+
 entry (SOCE), the Ca
2+
 
influx through the plasma membrane activated in response to the depletion of intracellular 
Ca
2+
 store [247]. These reduced [Ca
2+
]ER and increased permeability of the ER membrane 
have been confirmed in other models [248, 249]. Indeed, it has been demonstrated that Bcl-2 
overexpression in the PCa-derived LNCaP cell line decreases [Ca
2+
]ER through the reduction 
of calreticulin and SERCA2b expressions and restricts SOCE by decreasing the number of 
functional plasma membrane channels [250]. 
The mechanism by which Bcl-2 regulates Ca
2+
 store content is still a matter of debate. In 
addition to the possibility of a pore formation by Bcl-2 itself, it could reduce the activity of 
SERCA pumps. Interestingly, SERCA overexpression, by increasing ER Ca
2+
 store content, 
has been observed to improve the sensitivity to apoptosis [251]. Besides, an interaction 
between Bcl-2 and SERCA, which destabilizes SERCA pump, has been reported [252]. 
Furthermore, calreticulin overexpression has a similar effect on cell survival and Ca
2+
 
homeostasis. Meanwhile, calreticulin depletion increases resistance to apoptosis [253]. Bcl-2 
has also been reported to interact with IP3R, thus reducing its open probability and IP3-
induced Ca
2+
 release (IICR) [254, 255]. This interaction involves the BH4 domain of Bcl-2 
that binds to the regulatory domain in the middle of IP3R [256]. In addition, Bcl-2 but also 
Bcl-xL and Mcl-1 are demonstrated to bind another site in the C-terminal domain of IP3R, 
which in this case would enhance its gating. These last interactions lower [Ca
2+
]ER and 
increase IICR at low [IP3] to likely stimulate bioenergetics but decrease it at high [IP3], 
thereby avoiding a lethal Ca
2+
 overload in the cytosol [217]. However, although Bcl-xL is 
also able to modulate Ca
2+
 release through IP3R, its anti-apoptotic activity seems less potent 
than Bcl-2 due to a single amino-acid difference [257]. Besides, the anti-apoptotic functions 
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of Bcl-2 through its regulation of ER Ca
2+
 store could depend on its phosphorylation status 
and interactions with pro-apoptotic family members [235]. Indeed, Bax and Bak also localize 
at the ER where they induce ER Ca
2+
 emptying leading to an accumulation of Ca
2+
 in the 
mitochondria and a subsequent release of cytochrome c [258]. Furthermore, Korsmeyer and 
his team observed that in Bax/Bak double-knockout cells, IP3R1 was hyperphosphorylated, in 
particular at Ser1756 (human Ser1716), a PKA and PKG phosphorylation site. This increases 
ER Ca
2+
 leak and thereby reducing [Ca
2+
] in the ER. They also demonstrated that Bcl-2 
knockdown is able to decrease IP3R1 phosphorylation and restore [Ca
2+
]ER [259]. This last 
observation shows us how IP3R regulation by Bcl-2 can be complex and not just related to 
direct interactions. 
The Ca
2+
 release from the ER is known to range from confined spikes produced by a single or 
a few channels through propagating repetitive waves to massive influx generated by the 
opening of the entirety of the IP3R and RyR channels throughout the ER. Whereas oscillatory 
and moderate Ca
2+
 pulses are recognized to be beneficial for the cell, a bulk release is 
deleterious. The effects of Ca
2+
 release from the ER on cell survival seem mainly dependent 
on the Ca
2+
 entry into the mitochondria [260]. 
 
10.2 - The mitochondrial Ca
2+
 
The ER is tightly associated to mitochondria, 20% of the mitochondrial surface being in direct 
contact with ER membranes [261]. The ER communicates with mitochondria through 
contiguous membranes, which have been reported to be expanded in some situations such as 
under ER stress and/or apoptotic conditions [262, 263]. These contact sites are called 
mitochondria-associated membranes (MAM) and support direct transfer of lipids, ATP and 
proteins between the two organelles [264]. Moreover, MAM are enriched in Ca
2+
 channels 
and Ca
2+
-sensing ER chaperones allowing an easy exchange of cations [231]. Indeed, IP3R is 
incorporated in a protein complex with GRP75 and the outer mitochondrial membrane VDAC 
channel to promote a Ca
2+
 flux between the two organelles [265]. The close apposition of ER 
and mitochondria creates a confined space wherein Ca
2+
 released from the ER can reach 
concentrations in the millimolar range. Thus, despite the low affinity of mitochondrial 
transporters, large Ca
2+
 fluxes can cross the mitochondrial membranes (Fig. 17). The outer 
mitochondrial membrane is penetrated through VDAC while Ca
2+
 is taken up into the matrix 
through MCU, the mitochondrial Ca
2+
 uniporter whose molecular identity was discovered 
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only recently [266, 267]. This transport is primarily driven by the ∆Ψm generated by the 
electron transport in normally respiring mitochondria [260]. 
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Fig. 17: The mitochondrial calcium uptake. Adapted from [268]. 
The close apposition of ER and mitochondrion allows a rapid Ca
2+
 transfer between these two 
organelles. Ca
2+
 is released in the intermembrane space through the complex formed by IP3R 
(inositol trisphosphate receptor), GRP75 (75 kDa glucose regulation protein) and VDAC 
channel (voltage-dependent anion channel), and passes through the inner mitochondrial 
membrane by the mitochondrial Ca
2+
 uniporter (MCU). 
 
 
The capacity of mitochondria to accumulate Ca
2+
 seems, as for the ER, under the control of 
Bcl-2 family members. Thus, Bcl-2 has repeatedly been reported to enhance Ca
2+
 storage 
while protecting mitochondria from Ca
2+
 overload [269-271]. 
Mitochondrial Ca
2+
 uptake has a crucial physiological function. It contributes to the 
mitochondrial metabolism and ATP production. Actually, the activity of pyruvate 
dehydrogenase as those of two enzymes of the Krebs cycle (isocritrate and α-ketoglutarate 
dehydrogenases) is dependent on Ca
2+
. Moreover, some metabolite transporters are regulated 
by Ca
2+
 [272]. Nevertheless, a direct effect of [Ca
2+
]m increase on mitochondrial permeability 
transition has been known for almost 40 years [273]. Indeed, a bulk Ca
2+
 arrival is detrimental 
(Fig. 18). It impairs respiration chain, increasing ∆Ψm. At high ∆Ψm, harmful reactive oxygen 
species (ROS) production rises [274]. Moreover, high ∆Ψm promotes the mitochondrial 
sponging of Ca
2+
, increasing [Ca
2+
]m which may reach the activation threshold of the 
permeability transition pore, leading to ∆Ψm dissipation, mitochondria swelling and triggering 
of the intrinsic apoptosis pathway [271, 275]. 
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Fig. 18: The mitochondrial Ca
2+
 handling: checkpoint of apoptosis. Adapted from [276] 
Whereas moderate Ca
2+
 transfer from the ER to the mitochondria is beneficial, contributing to 
the mitochondrial metabolism, massive Ca
2+
 accumulation in the organelle triggers cell death. 
Bcl-2, by reducing [Ca
2+
]ER, restricts any mitochondrial Ca
2+
 overload and thereby protects 
from apoptosis. 
 
 
10.3 - The cytosolic Ca
2+
  
Several agents such as TGFβ1, doxorubicin or radiation have been shown to induce apoptosis 
by elevating [Ca
2+
]c in prostate and bladder cancer cells [277]. Indeed, the Ca
2+
 released from 
the ER into the cytosol paired with store-operated Ca
2+
 entry also contributes to the induction 
of apoptosis. Cytosolic Ca
2+
 increase allows activation of the cysteine proteases known as 
calpains by an autocatalytic cleavage. They are reported to cleave Bcl-2 and Bcl-xL thereby 
reducing their anti-apoptotic activities and leading to Bcl-2 conversion into a pro-apoptotic 
protein [278]. Moreover, calpains cleave pro-apoptotic Bid into its active form, inducing 
cytochrome c release [279]. These Ca
2+
-dependent proteases can also cleave and activate 
caspase-12, localized on the cytoplasmic side of the ER, to trigger apoptosis in response to 
Ca
2+
 store depletion [280]. Besides, [Ca
2+
]c rise directly or indirectly activates numerous 
kinases and phosphatases. Among them, the Ca
2+
-dependent serine-threonine phosphatase 
calcineurin that is able, once activated, to dephosphorylate Bad, another BH3-only protein, 
thereby enhancing its heterodimerization with Bcl-xL and initiating the intrinsic 
mitochondrial pathway [281]. However, a modest increase of [Ca
2+
]c, on the contrary, can 
 55 
lead to Bad phosphorylation and sequestration to protein 14-3-3 through activation of 
CaMKK, highlighting the versatility of Ca
2+
 signaling in cell survival [282]. Furthermore, 
caspases can cleave different components of the Ca
2+
 signaling machinery: IP3R1 has been 
reported to be cleaved by caspase-3 [283, 284] which would generate a constitutively open 
channel and would enhance Ca
2+
 release [285]; plasma membrane Na
+
/Ca
2+
 exchanger and 
PMCA pumps, essential for the return of [Ca
2+
]c to basal levels, can also be cleaved by 
caspases and calpains thereby increasing Ca
2+
 overload [286, 287]. 
 
11 - Calcium and autophagy 
Ca
2+
 was first reported to be involved in autophagy control in 1993 when Gordon et al. 
discovered that chelation of either intra- and extracellular Ca
2+
 as well as overload of 
cytosolic Ca
2+
 inhibit autophagy [288]. Since then, several reports have confirmed the dual 
role that plays Ca
2+
 homeostasis in this catabolic process. Indeed, Ca
2+
 and some elements of 
Ca
2+
 signaling machinery have repeatedly been presented as negative regulators of autophagy 
whereas an increased Ca
2+
 influx has also been noticed to stimulate this function [289]. 
 
11.1 - Suppression of autophagy by Ca
2+
 signaling 
The inhibitory function of Ca
2+
 signaling on autophagy is mainly related to IP3R. Indeed, the 
Ca
2+
 channel has been established to play an important role in autophagy. Its inhibition by 
xestospongin B (as the reduction of IP3 levels by lithium) and its knockdown lead to 
autophagy [290, 291]. Besides, basal autophagic flux is higher in IP3R triple knock out 
(TKO) chicken DT40 B lymphocytes than in their wild-type counterparts [292, 293]. 
Heterologous expression of IP3R1 or IP3R3, but not RyR, decreases autophagy levels in these 
TKO cells, thereby confirming an IP3R-mediated negative regulation of autophagy. Kroemer 
and his team, by demonstrating an interaction between Beclin-1 and the IP3-binding domain 
of the receptor, have proposed that the involvement of IP3R in autophagy would be explained 
by its role of scaffold protein facilitating Beclin-1 interaction with Bcl-2. Thus, xestospongin 
B would induce autophagy by dissociating Beclin-1 from IP3R/Bcl-2 complex. Besides, they 
have suggested that the Ca
2+
 channel function of IP3R would not be involved, Beclin-1 
knockdown leaving unchanged the [Ca
2+
]ER [294]. However, the Ca
2+
-independent nature of 
the mechanism of autophagy control by IP3R is not unanimously accepted. Indeed, expression 
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of functionally inactive IP3R mutants in TKO cells has been observed as not suppressing 
autophagy in the same manner as wild-type IP3Rs, suggesting that the channel function of the 
molecule would be important in its properties of autophagy regulator [292, 293]. 
Foskett and his collaborators have demonstrated that a mitochondrial uptake of IP3R-released 
Ca
2+
 is required to provide optimal bioenergetics. In the absence of this Ca
2+
 transfer, as it is 
the case in TKO cells, metabolic enzymes such as pyruvate dehydrogenase are inactivated, 
ATP production decreased and AMPK activated, which induces a prosurvival autophagy 
[293]. In addition of these data, Bax inhibitor-1 (BI-1) overexpression has been noticed to 
promote autophagy by decreasing [Ca
2+
]ER, thereby reducing IP3R-mediated Ca
2+
 transfer to 
the mitochondria, which affects mitochondrial respiration and ATP production, and leads to 
AMPK activation and autophagy induction [295]. 
The induction of autophagy by inhibitors of high voltage-activated (L-type) Ca
2+
 channels 
also highlights the anti-autophagic properties of Ca
2+
 [296, 297]. Interestingly, these 
inhibitors, by influencing [Ca
2+
]c, impact the activity of calpains, which indirectly control the 
PLC activation and IP3 production [298, 299]. Therefore, blocking L-type Ca
2+
 channels may 
also lead to a reduced Ca
2+
 transfer to the mitochondria. 
Besides, the late-phase of autophagy can also be inhibited by Ca
2+
 signaling. In obesity in 
particular, a chronic [Ca
2+
]c increase in hepatocytes preventing autophagosome-lysosome 
fusion and deregulating autophagy has recently been described [300]. 
 
11.2 - Promotion of autophagy by Ca
2+
 signaling 
If some modulations of Ca
2+
 homeostasis seem able to repress autophagy, a release of Ca
2+
 in 
the cytosol has repeatedly been reported to stimulate autophagy. Indeed, various drugs which 
elevate [Ca
2+
]c such as SERCA inhibitor thapsigargin, Ca
2+
 ionophore ionomycin, ATP or 
vitamin D3 compounds have been demonstrated to inhibit mTOR activity and induce 
autophagy. This process seems to be dependent on CaMKKβ and AMPK activation and can 
be inhibited by the localization of  Bcl-2 to the ER membrane, where it lowers [Ca
2+
]ER and 
reduces IP3-induced Ca
2+
 release into the cytosol [301]. The ability of Bcl-2 to decrease Ca
2+
 
store content thereby appears as another anti-autophagic mechanism of the protein beyond its 
inhibitory interaction with Beclin-1. The signaling pathways involved in this autophagy 
triggering have been discussed, some studies showing that thapsigargin can induce autophagy 
without AMPK stimulation [302] and even apart from mTOR inhibition but through PKCθ 
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[303]. Besides, cadmium-induced [Ca
2+
]c rise has been noted to lead to autophagy via the 
activation of Erk [304]. 
Although the buffering of cytosolic Ca
2+
 by BAPTA-AM prevents such autophagy, thereby 
proving the significance of Ca
2+
 in this function, prolonged treatment with these molecules 
could also result in ER Ca
2+
 store emptying and subsequent unfolded protein response, which 
itself can trigger autophagy through different pathways [232]. However, thapsigargin-induced 
autophagy is still present in UPR-deficient cells, therefore supporting the direct role of Ca
2+
 in 
autophagy induction [303]. 
The Ca
2+
 release from other compartments than ER can also promote autophagy. Indeed, the 
lysosomal two pore channels opening by nicotinic acid adenine dinucleotide phosphate 
(NAADP) has been reported to induce autophagy [305]. 
Actually, Ca
2+
 signaling modulation could even be a mechanism allowing the triggering of 
autophagy in response to numerous stimuli. Indeed, nutrient deprivation-induced autophagy is 
suppressed by the Ca
2+
 chelator BAPTA-AM [306]. A remodeling of the Ca
2+
 signalosome 
has even been observed during starvation-induced autophagy. At the beginning of the 
autophagic response, Bultynck and his collaborators have reported an overexpression of Ca
2+
-
binding chaperones calreticulin and GRP78 which increase the ER Ca
2+
 content. Furthermore, 
starvation leads to an increased Beclin-1 binding to the IP3R resulting in a higher sensitivity 
of the receptor towards IP3. The authors have suggested that by promoting the release of Ca
2+
 
into the cytosol, Beclin-1/IP3R interaction would have a pro-autophagic function in starved 
cells, whereas it would inhibit autophagy in non-starved cells by facilitating Beclin-1 
tethering to Bcl-2 and beneficial IP3R-mediated Ca
2+
 transfer to the mitochondria. They have 
shown that xestospongin B suppresses starvation-induced autophagy although it enhances 
basal levels of autophagy [227]. Moreover, they have recently highlighted that the mTOR 
inhibitor and autophagy inducer rapamycin also remodels Ca
2+
 homeostasis. They have found 
that rapamycin elevates the ER Ca
2+
 content by reducing Ca
2+
 leakage from the compartment 
and increases IP3-induced Ca
2+
 release, while buffering intracellular Ca
2+
 with BAPTA-AM 
precludes autophagy, indicating that cytosolic Ca
2+
 is essential for the induction of autophagy 
by rapamycin [307]. 
Besides, diverse autophagy regulators seem influenced by Ca
2+
. Thus, the class III PI3K has 
been noticed to be under the control of Ca
2+
 and calmodulin [308], as well as DAPK [309], 
members of the S100 Ca
2+
-binding protein family [310] and the kinase of the eukaryotic 
elongation factor (eEF-2 kinase) [311]. Although Ca
2+
-dependent calpains are known to 
cleave Atg5, producing a pro-apoptotic residue [172], they seem also required for autophagy. 
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Indeed, as we have previously seen, in calpain-deficient cells, autophagy is impaired [180]. 
Furthermore, the Ca
2+
 channel TRPML3 is recruited to autophagosomes upon induction of 
autophagy [312]. Its overexpression promotes autophagy whereas its knockdown or the 
expression of a channel-dead dominant negative reduces it. Therefore, Ca
2+
 participates in the 
induction of autophagy but may also be required for the maturation of autophagosomes. 
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Aims and objectives 
As explained in the introduction, a better understanding of the mechanisms of androgen 
independence is necessary to improve the management of HRPCa. More precisely, we have to 
determine why apoptosis is not significantly engaged after the pro-death AD in HRPCa. We 
made several assumptions. While autophagy protects many cancer cells from apoptosis, its 
possible involvement in HRPCa progression remained unexplored. Hence, we sought to 
clarify its activity in HRPCa cells and to understand its function. To this end, we used LNCaP 
cells, isolated in 1977 from a needle aspiration biopsy of a lymph node of a 50 year old man 
with confirmed diagnosis of metastatic prostate carcinoma [313]. We can reproduce AD 
therapy in vitro by culturing these cells in medium supplemented with charcoal stripped fetal 
calf serum, in which steroid hormones have been removed, or by treating them with AR 
antagonists such as bicalutamide. LNCaP cells can survive in culture after androgen 
withdrawal and therefore constitute a valid model of HRPCa. However, they are also 
considered as androgen-sensitive PCa cells since their growth is still dependent on the 
androgen concentration. Thus, they appear as a valid model for studying the transition to 
hormone independence. 
In these cells, we have also observed various modifications of Ca
2+
 homeostasis after AD. 
These led us to explore the role of the Ca
2+
 signaling machinery in the apoptosis resistance of 
LNCaP cells to androgen deprivation. Indeed, as we have explained above, Ca
2+
 is known to 
participate in the regulation of both apoptosis and autophagy. We therefore wanted to study its 
involvement in these two processes in our model. 
Thus, the aim of this work was to answer several issues allowing us to give new elements to 
the understanding of the cell survival mechanisms engaged in HRPCa in response to AD: 
a) Does androgen control autophagy in HRPCa cells? And if so, by what mechanisms? 
b) Is autophagy responsible in resistance to AD in HRPCa? 
c) What are the mechanisms behind these Ca
2+
 homeostasis alterations? 
d) Is Ca
2+
 signaling involved in androgen independence and apoptosis resistance? 
e) Is there a crosstalk between these modifications in Ca
2+
 homeostasis and the 
autophagic process? 
Two research papers and additional data answering these diverse items are presented in the 
following sections. 
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Results 
 
Research paper 1 / Androgen deprivation and androgen receptor competition by 
bicalutamide induce autophagy of hormone-resistant prostate cancer cells and confer 
resistance to apoptosis. 
 
Research paper 2 / Endoplasmic reticulum Ca
2+
 content decrease by PKA-dependent 
hyperphosphorylation of type 1 IP3 receptor contributes to prostate cancer cell resistance to 
androgen deprivation. 
 
Supplementary data 
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BACKGROUND. Treatment of advanced prostate cancer (PCa) relies on pharmacological or
surgical androgen deprivation. However, it is only temporarily efficient. After a few months
or years, the tumor relapses despite the absence of androgenic stimulation: a state referred to
as hormone-refractory prostate cancer (HRPCa). Although autophagy confers chemoresist-
ance in some cancers, its role in the development of HRPCa remains unknown.
METHODS. Autophagic flux was assayed by GFP-LC3 clustering, by LC3-I to LC3-II con-
version and transmission electron microscopy. Cell death was detected by sub-G1 quantifica-
tion and concomitant measurement of transmembrane mitochondrial potential and plasma
membrane permeabilization. Inhibition of autophagy was achieved by siRNAs and pharma-
cological inhibitors.
RESULTS. Androgen deprivation or treatment with the anti-androgen bicalutamide pro-
moted autophagy in HRPCa-derived LNCaP cells. This effect was dramatically reduced after
depletion of Atg5 and Beclin-1, two canonical autophagy genes, and was associated with an
inhibition of the androgen-induced mTOR pathway. The depletion of Atg5 and Beclin-1 sig-
nificantly increased the level of cell death induced by androgen deprivation or bicalutamide.
Finally, the safe anti-malarial drug chloroquine, an inhibitor of autophagy, dramatically
increased cell death after androgen deprivation or bicalutamide treatment.
CONCLUSION. Taken together, our data suggest that autophagy is a protective mechanism
against androgen deprivation in HRPCa cells and that chloroquine could restore hormone
dependence. This set of data could lead to the development of new therapeutic strategy
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INTRODUCTION
Prostate cancer (PCa) is the most frequent cancer in
men above the age of 55 years. Only low-grade and
locally advanced PCa are curable and, despite signifi-
cant progresses in early detection and curative treat-
ments, 30% of patients will develop an advanced or
metastatic cancer requiring systemic therapies [1].
Reference treatment of advanced PCa relies on phar-
macological or surgical androgen deprivation thera-
py. However, despite initial efficacy of androgen
deprivation, the tumor inevitably relapses becoming
hormone-refractory (HRPCa) and progresses to meta-
static disease. Effective treatment at this stage is
largely limited to docetaxel-based chemotherapies
conferring a median survival of only 17–19 months
[2,3]. Moreover, despite numerous clinical trials, con-
sensus about the management of non-metastatic
HRPCa has not emerged. All these observations lead
the scientific community to decipher the mechanisms
involved in androgen-independent phenotype devel-
opment in PCa, and to develop novel strategies to
circumvent hormone independence of advanced pros-
tate cancers [4]. Deregulations of multiple pathways
have been involved in the progression of PCa to
HRPCa, including aberrant activation of the androgen
receptor or abnormalities in the PI3K/AKT signaling
and PTEN function [5–7]. However, the role of
autophagy, which seems to be involved in apoptosis
resistance in some cancers, remains unknown in the
development of HRPCa.
The general concept of ‘‘autophagy,’’ introduced
in 1963 by the Nobel Prize laureate Christian de
Duve, has now been dismembered into a variety of
intracellular processes, including chaperone-mediat-
ed autophagy, micro- and macro-autophagy, all of
which eventually converge to a common degradation
phase mediated by lysosomes [8,9]. Macroautophagy
(hereafter referred to as autophagy) has recently been
involved in the pathogenesis of diverse diseases in-
cluding cancer [10]. During autophagy, bulk portions
of the cytoplasm, including organelles and long-lived
proteins, are sequestered in double- or multiple-mem-
branes vacuoles (autophagosomes) that fuse with
lysosomes that degrade their contents. Upon autoph-
agy induction, the LC3-I protein is modified into the
PE-conjugated form, LC3-II. This latter is associated
with autophagosomes and its detection is routinely
used to monitor autophagy [11]. Basal levels of auto-
phagy contribute to cellular homeostasis by ensuring
the turnover of supernumerary, aged, and damaged
components. Atg genes encode proteins required in
the various phases of autophagic pathways [12].
Dramatic increase of autophagy level has long
been considered as a particular form of cell death
(termed type II cell death), characterized by massive
accumulation of autophagosomes and dependence on
Atg genes [13–15]. In contrast, under stress conditions
such as starvation or growth factor withdrawal, auto-
phagic pathways operate to supply cells with meta-
bolic substrates and hence represent an important
pro-survival mechanism. Under carbon and nitrogen
starvation, for instance, the activity of mammalian
target of rapamycin (mTOR; the major negative regu-
lator of autophagy) is rapidly shut down, and the en-
suing up-regulation of autophagic pathway supplies
cells with metabolic substrates to meet their energetic
demands [12]. These observations prompted some
investigators to consider that cell death is often asso-
ciated with autophagy but is rarely due to autophagy
[16].
Here, we investigated these processes in PCa cells
derived from a lymph node metastasis of a hormone-
refractory patient (LNCaP cells). In these cells, a mu-
tation in the androgen receptor gene creates a promis-
cuous receptor able to bind to other steroids [17]. It
turns out that LNCaP cells are able to grow in culture
despite the absence of androgen and therefore consti-
tute a valid cellular model of HRPCa. We show that
either androgen deprivation or the specific antiandro-
gen agent bicalutamide induce mTOR-associated
autophagy. Moreover, specific inhibition of autoph-
agy by siRNAs targeting Atg genes restores sensitivity
of LNCaP cells to androgen deprivation or bicaluta-
mide treatment. Pharmacological inhibition of auto-
phagy by the safe anti-malarial drug chloroquine was
also able to increase susceptibility of LNCaP to andro-
gen ablation and bicalutamide treatment. We hope
that those finding will pave the way to clinical trials
using chloroquine in combination with anti-androgen
therapy in HRPCa.
MATERIALSANDMETHODS
CellCulture andReagents
LNCaP and DU145 cells (American Type Culture
Collection, CRL-1740, and HTB-81) were grown at
378C in an humidified atmosphere of 5% CO2–95%
air in RPMI 1640 (Gibco, 52400) supplemented with
10% fetal calf serum, 100 IU/ml penicillin (Gibco,
10270), and 100 mg/ml streptomycin (Gibco, 15140).
Cells were cultured up to passage 30. Analysis of the
effect of androgen deprivation was performed by cul-
turing cells for 2 days in RPMI 1640 medium supple-
mented with charcoal-stripped FCS (Gibco, 12676) for
serum steroid hormone removal (ÿR1881 condition).
As control condition, the synthetic agonist of the an-
drogen receptor (AR) methyltrienolone (R1881), was
added to the medium at 0.2 nM (þR1881 condition).
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The effects of the non-steroidal anti-androgen bicalu-
tamide (Bic; Sigma–Aldrich, Saint Louis, MO, B9061)
were tested by culturing LNCaP cells for 2 days
in RPMI1640 supplemented with FCS, R1881 and
at 50 mM Bic (þBic condition) or without Bic (ÿBic
condition). Chloroquine (Sigma–Aldrich, C6628) was
used at 100 mM, concanamycin A (Sigma–Aldrich,
27689) at 1 mM, rapamycin (Sigma–Aldrich, R8781) at
100 nM, E-64d (Sigma–Aldrich, E8640) at 10 mg/ml
and pepstatin A (Sigma–Aldrich, P5318) at 10 mg/ml.
Nuclei were stained with 10 mg/ml Hoechst 33342
(Molecular Probes-Invitrogen, H3570).
GFP-LC3Transfectionand Imaging
LNCaP cells were seeded in six-well culture plates
until to reach 80% confluence. Cells were then trans-
fected with a plasmid coding for GFP-LC3 using Lip-
ofectamine reagent (Invitrogen, 11668-019) according
to manufacturer’s instructions. After 24 hr, cells were
plated on glass coverslips and 48 hr later, were
subjected to various treatments during 2 days. GFP
fluorescence was analyzed on an inverted Axiovert
200 microscope (Zeiss, Oberkochen, Germany) using
FITC excitation and emission wavelengths (100, NA
1.4, oil immersion). Images were acquired with a
Zeiss Axiocam and analyzed by the Zeiss Axiovision
software.
ElectronMicroscopy
After three washes with ice-cold PBS, samples
were fixed in 1% glutaraldehyde, postfixed in osmi-
um tetroxide and embedded in Epon. Ultrathin sec-
tions (80 nm) were contrasted with uranyl acetate and
lead citrate, and were examined through a Philips
CM12 (Philips) electron microscope operated at
80 kV.
Immunoblotting
Cells were harvested by scraping in PBS and
re-suspended in lysis buffer containing (mM) 20 Tris–
HCl (pH 7.5), 150 NaCl, 1 Na2EDTA, 1 EGTA, 1%
Triton, 2.5 sodium pyrophosphate, 1 b-glycerophos-
phate, 1 Na3VO4, 1 mg/ml leupeptin and 1 mM phe-
nylmethanesulfonylfluoride. Extracts were diluted in
a mix of LDS Sample Buffer and Sample Reducing
Agent (NuPAGE1, Invitrogen, NP0007 and NP0009)
and heated at 958C for 3 min. Samples were electro-
phoresed on 10% or 12% SDS–polyacrylamide gels
(Invitrogen, NP0301BOX and NP0341BOX) and trans-
ferred onto nitrocellulose membranes (Biorad, 162-
0097). The blots were saturated in TBS-T buffer
(20 mM Tris, 137 mM NaCl, 0.05% Tween 20, pH 7.6),
containing 5% skimmed milk for 1 hr at room temper-
ature, incubated overnight at 48C with primary
antibodies: anti-AR (Millipore Corporation 06-680)
was used at a dilution of 1:250, anti-BECN1 (Santa
Cruz Biotechnology, sc-1142) at a dilution of 1:500,
anti-LC3 (Cell Signaling Technology, 3868), anti-p62
(Cell Signaling Technology, 8025), anti-Atg5 (Cell Sig-
naling Technology, 2630), anti-AktS473 (Cell Signaling
Technology, 9271), anti-4EBP-1 (Cell Signaling Tech-
nology, 9452), anti-phospho-p70S6kT389 (Santa Cruz
Biotechnology, sc-11759) and anti-p70S6k (Santa Cruz
Biotechnology, sc-230) at a dilution of 1:1,000, and
anti-PI3 Kinase p85 (Millipore Corporation, 06-195)
at a dilution of 1:3,000. Immunodetection of b-actin
with monoclonal anti-actin antibody (Sigma–Aldrich,
A5441) was used as loading control (dilution
1:10,000). After incubation with appropriate second-
ary antibodies coupled to peroxidase, peroxidase
activity was detected with ECLþ (Amersham,
RPN2132) on ECL hyperfilm. Immunoblots were
quantified using ImageMaster densitometry program
(GE Healthcare).
Co-Immunoprecipitation
Cells were harvested by scraping in PBS and re-
suspended in lysis buffer. Cell lysates were centri-
fuged and 500 mg of total protein was subjected to
immunoprecipitation using GammaBind G Sepharose
(GE Healthcare, 17-0895-01) and anti-p85 or anti-
Androgen Receptor antibodies overnight at 48C. After
four washes with PBS, immunocomplexes were elut-
ed in a mix of LDS Sample Buffer and Sample Reduc-
ing Agent, heated at 958C for 3 min and analyzed by
immunoblotting as described above.
siRNATransfection
The siRNAs targeting Atg5 and BECN1 as well
as the non-silencing control siRNA (siUNR) were
purchased from Thermo Fisher Scientific. LNCaP
cells were transfected using DharmaFECT reagent
(Thermo Fisher Scientific, T-2002-03) according to the
manufacturer’s instructions. Twenty-four hours later,
cells were plated on six-well plates and after 48 addi-
tional hours, subjected to various treatments. Five
days after transfection, efficiency of siRNA-mediated
depletion of the genes of interest was assessed in
Western blot.
FlowCytometry
Cyto-IDTM Green autophagy assay (Enzo, ENZ-
51031-K200) was performed as recommended by
the manufacturers’ instructions. Briefly, LNCaP cells
were seeded into six-well plates and treated 48 hr in
the different conditions in the presence of E64d/pep-
statin A. Then, cells were trypsinized, washed, and
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resuspended in Cyto-IDTM Green autophagy detec-
tion reagent and incubated at room temperature for
30 min. Cyto-ID Green autophagy reagent was mea-
sured in the FL-1 channel (530/30 nm bandpass filters
with excitation at 488 nm).
Simultaneous detection of mitochondrial mem-
brane potential (DCm) dissipation and plasma mem-
brane permeabilization was determined by staining
with 40 nM DCm-sensitive fluorochrome DiOC6(3)
(Molecular Probes-Invitrogen, D273) and 1 mg/ml
vital dye propidium iodide (PI; Sigma–Aldrich,
P1304MP). All PIþ events have been considered as
DiOC low. Cell cycle analysis was performed by per-
meabilizing cells with 0.01% triton X-100 and subse-
quent staining by 50 mg/ml PI. Cytofluorometric
analyses were performed on a FACSCalibur equipped
with CellQuest Pro software (Becton Dickinson).
StatisticalAnalysis
Data are presented as means  SD. Student’s
t-test, two-way ANOVA, and two-sample Wilcoxon
rank-sum (Mann–Whitney) analysis were used to
determine statistical significance when appropriate.
RESULTS
AndrogenDeprivationAsWellAsBicalutamide
EnhancesAutophagic FluxinLNCaPCells
Autophagy was first monitored by detection of
GFP-LC3 accumulation into vacuoles. After 2 days of
androgen deprivation or bicalutamide treatment, an
increased number of LNCaP cells exhibited a relocali-
zation of GFP-LC3 (Fig. 1A,B). The number of cells
containing more that 10 cytoplasmic puncta increased
approximately twofold after androgen removal and
threefold after bicalutamide addition in comparison
with control conditions. Transmission electron mi-
croscopy showed double- or multiple-membranes
structures, considered as hallmarks of autophagy
(Fig. 1C). Those observations were corroborated by
LC3-I/LC3-II immunodetection. In response to andro-
gen deprivation or bicalutamide, LC3-I significantly
decreased suggesting its conversion into LC3-II. How-
ever, since LC3-II also tends to be degraded, the ratio
LC3-II/LC3-I typically used to quantify autophagy
did not increase significantly (Fig. 1D,E) [11]. To
avoid this degradation, we used a combination of
E64d and pepstatin A in order to inhibit lysosomal
function [18]. In the presence of inhibitors, LC3-II/
LC3-I ratio was significantly increased in control con-
ditions showing the existence of a detectable basal
autophagic flux in LNCaP cells. In those conditions,
treatment with bicalutamide or androgen deprivation
greatly enhanced LC3-II accumulation and therefore
the LC3-II/LC3-I ratio (Fig. 1D,E). Similar results
were observed after treatment with flutamide, anoth-
er AR antagonist (Fig. S1).
Expression of the adaptor protein p62 mediating
the interaction between ubiquitinated proteins and
LC3 was also assessed in response to androgen depri-
vation and bicalutamide. In those conditions, the
amount of p62 was significantly decreased (P < 0.05,
three independent experiments). This effect was abol-
ished by pretreating cells with E64d/pepstatin A
inhibitors (Fig. 2A). Finally, a new flow cytometry-
based strategy was used to monitor autophagy in cells
stained with a fluorescent cationic amphiphilic tracer
dye that rapidly partitions into the hydrophobic envi-
ronment of multi-lamellar vesicles (Cyto-ID autoph-
agy detection kit). As expected, fluorescent signal was
significantly increased after androgen deprivation
and bicalutamide treatment (Fig. 2B,C).
AndrogenDeprivationandBicalutamide-Induced
AutophagyAreMediatedbytheAndrogen
ReceptorSignalingPathway
To rule out that the increased level of autophagy
after androgen deprivation or bicalutamide treatment
could be an off-target effect, experiments were ex-
tended to the DU-145 cell line devoid of AR. Neither
biochemical signs (LC3-I ! LC3-II conversion) nor
morphological manifestations (GFP-LC3 relocaliza-
tion) of autophagy were observed in DU-145 after an-
drogen deprivation or bicalutamide, confirming that
autophagy induced by both treatments in LNCaP
cells was mediated by the AR (Fig. 3A,B). The positive
control rapamycin was able to increase LC3-I ! LC3-
II conversion demonstrating that autophagic path-
ways are functional in DU-145 cells (Fig. 3C).
AndrogenDeprivationandBicalutamide Induce
mTOR-AssociatedAutophagy
To look for an implication of the mTOR signaling
pathway in autophagy induced by disruption of the
AR pathway, we checked by immunoblotting the
phosphorylation of AktS473, the upstream kinase of
mTOR, and of the substrates of this latter, p70S6kT389
and 4EBP-1 (Fig. 4A). Androgen deprivation reduced
phosphorylation of AktS473 by 21  18% (P < 0.05,
N ¼ 6) and phosphorylation of p70S6kT389 by
44  23% (P < 0.01, N ¼ 4). Similarly, bicalutamide
treatment reduced phosphorylation of AktS473 by
27  28% (P < 0.05, N ¼ 6) and phosphorylation of
p70S6kT389 by 45  21% (P < 0.01, N ¼ 4). 4EBP-1
can be phosphorylated on various sites. Immunoblot-
ting with the antibody against the total form of 4EBP-
1 reveals a shift to a lower molecular weight when
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Fig. 1. Effects of androgen deprivation and bicalutamide treatment on the autophagic flux in LNCaP cells.A,B: Fluorescence monitoring
of autophagy based on GFP-LC3 relocalization. A: Representative images of GFP-LC3-labeled punctae in LNCaP cells in control condition
versus bicalutamide exposure.B:Histogram showing the number of cells exhibitingmore than10 fluorescentdots in the indicated conditions
(P < 0.01, n ¼ 3).C:Transmissionelectronmicroscopyof LNCaPcells culturedin thepresence of Bic.Representative images of three inde-
pendentexperiments.D,E: Immunoblot analysis (D)anddensitometry (E)of LC3-I ! LC3-II conversioninLNCaPcells eitherdeprivedin an-
drogen (ÿR1881), or treatedwith50 mMbicalutamide (þBic) for48 hr, in the absence or in thepresence of thelysosomalproteases inhibitors
10 mg/ml E64d and10 mg/mlpepstatin A.b-actin immunodetection is used as a loading control.Bar histogram shows the LC3-II/LC3-I ratios
in the indicated conditions.Data are presented as means  SD of 7^19 independent experiments. , : Significantly different than control
conditionsin thepresenceofE64d/pepstatinAinhibitors (P < 0.05;P < 0.01).
‰
: Significantlydifferentthansimilarconditionsin theabsence
ofinhibitors (
‰
P < 0.05).
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the protein is dephosphorylated. On this basis, we
concluded that the non-phosphorylated form was
predominant after androgen ablation. Previous stud-
ies showed that AR interacts with the regulatory sub-
unit of class Ia PI3-K, p85a, and therefore stimulates
the PI3K/Akt/mTOR pathway [19]. We thus moni-
tored AR/p85 interaction in response to androgen
deprivation and bicalutamide. Our results confirmed
that p85 and AR cross-co-immunoprecipitate
(Fig. 4B). However, AR expression was significantly
decreased in LNCaP cells in which AR signaling was
inhibited (Fig. 4C). Indeed, we observed a reduction
of AR expression by 70  21% after androgen deple-
tion (P < 0.05, n ¼ 6) and by 45  22% after bicaluta-
mide treatment (P < 0.05, n ¼ 8).
siRNA-Mediated InhibitionofAutophagySensitizes
LNCaPCellstoBicalutamide-InducedApoptosis
To test whether autophagy induced by androgen
deprivation or bicalutamide was mediated by the ca-
nonical pathway, we transfected LNCaP cells with
siRNAs targeted against Atg5 and Atg6/Beclin-1
(BECN1) genes, two autophagy-related genes. As
shown in Figure 5A, pools of four siRNAs targeted
against different regions of the Atg5 and BECN1
mRNAs dramatically reduced their protein levels and
increased LC3-I content (Fig. 5A). In the presence of
E64d/pepstatin A, Atg5 and BECN1 depletion signifi-
cantly decreased basal LC3-I ! LC3-II conversion
(Fig. 5B,C) and GFP-LC3 recruitment to punctae
Fig. 2. Assessmentof pro-autophagic effects of androgen deprivation andbicalutamidebydetection of p62 degradation and accumulation
of autophagic vacuoles.A: Immunoblot analysis ofp62expressioninLNCaPcells eitherdeprivedinandrogen (ÿR1881),or treatedwith50 mM
bicalutamide (þBic) for 48 hr, in the absence or in thepresence of the lysosomalproteases inhibitors10 mg/mlE64dand10 mg/mlpepstatinA
(representative of three independentexperiments).B: Flowcytometry-basedprofiling and (C) quantification of Cyto-IDTM probe accumula-
tion in same conditions as in (A). Data are expressed mean of fluorescence  SD of three independent experiments (P < 0.05;
P < 0.001).
Fig. 3. Lackof effectof androgen deprivation or bicalutamide on the autophagic fluxofAR-deficientDU-145 cells.A: Immunoblot analysis
of LC3-I ! LC3-II conversion in DU-145 either deprived in androgen (ÿR1881), or treated with 50 mM bicalutamide (þBic) for 48 hr.
B: Autophagy monitoring by GFP-LC3 relocalization in the same conditions. Bar histogram shows the number of cells with more of
10 fluorescentdots after culture in the indicatedconditions.Data arepresented asmeans  SD of three independentexperiments.C: Immu-
noblotanalysis ofLC3-I ! LC3-IIconversioninDU-145treatedwith100 nMrapamycin for24 hr.
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(Fig. 5D). Depletion of Atg5 completely inhibited bica-
lutamide-induced autophagy whereas the effect of
BECN1 depletion was only partial.
To distinguish whether autophagy induced by
bicalutamide represents a mechanism of cell survival
or cell death, we measured the consequences of Atg5
and BECN1 depletion on bicalutamide-induced apo-
ptosis. Measurements of DNA content by PI staining
on permeabilized cells showed that neither treatment
induced significant cytotoxicity. However, Atg5 or
BECN1 repression markedly increased sub-G1 cell
population after bicalutamide treatment (Fig. 5E).
Mitochondrial membrane potential (DCm) dissipation
and plasma membrane permeabilization, determined
by simultaneous assessment of DCm (with the DCm-
sensitive fluorochrome DiOC6(3)) and cell viability
(with the vital dye PI) similarly showed an increase in
apoptosis after Atg5 repression after bicalutamide
treatment (Fig. 5F). This assay failed to reveal a sta-
tistically significant effect of BECN1 depletion in re-
storing sensitivity to apoptosis. Interestingly, Atg5
depletion was more efficient than BECN1 to both
block autophagy (Fig. 5C,D) and restore cytotoxicity
(Fig. 5F).
ChloroquineStrongly IncreasesApoptosis
InducedbyAndrogenDisruption
Considering that autophagy induced by androgen
disruption could be a therapeutic target in the man-
agement of HRPCa, we tested the effect of the safe
anti-malarial drug chloroquine on androgen depriva-
tion and bicalutamide-induced autophagy. Chloro-
quine dramatically reduced LC3-II degradation, in
line with the fact that chloroquine is a well known
inhibitor of lysosomal activity (Fig. 6A). This reinfor-
ces the fact that autophagic basal flux is important in
LNCaP cells (see also Fig. 1D). To validate the inhibi-
tory effect of chloroquine on autophagy, we therefore
measured the level of GFP released from autophagic
cleavage of the GFP-LC3 fusion protein in LNCaP
cells. A recent study has indeed demonstrated that ac-
cumulation of GFP in the presence of lysosomal inhib-
itors is a marker of autophagy [20]. We confirmed
that GFP accumulated upon chloroquine treatment
and found that this was exacerbated by bicalutamide
treatment. Similar results were obtained in the pres-
ence of cathepsin inhibitors E64d and pepstatin A
(Fig. 6B). Chloroquine also dramatically increased the
level of apoptosis induced by androgen deprivation
and bicalutamide, as assessed by sub-G1 detection
(Fig. 6C) and simultaneous measurement of DCm
dissipation and plasma membrane permeabilization
(Fig. 6D). Indeed, the proportion of cells exhibiting
DNA degradation was increased about tenfold upon
combined bicalutamide and chloroquine treatment
compared to the situation where bicalutamide is
added alone. Similar observations were obtained by
associating androgen deprivation and chloroquine.
Importantly, the inhibitor of the vacuolar Hþ-ATPase,
concanamycin A, a well-known inhibitor of autoph-
agy also enhanced toxicity of androgen and bicaluta-
mide treatment (Fig. 6E).
DISCUSSION
Previous studies have investigated the inhibitory
role of androgen on autophagy in PCa cells. In
Fig. 4. Both androgen deprivation and bicalutamide induce
mTOR-associated autophagyby regulating AR/PI3-K interaction in
LNCaP cells. A: Immunoblot analysis of phosphorylation of
p70S6kT389, AktS473 and 4EBP-1 in LNCaP cells either deprived in
androgen (ÿR1881), or treatedwith 50 mMbicalutamide (þBic) for
48 hr.B: Cross co-immunoprecipitation of AR and p85 of LNCaP
cells treated as in (A).Total protein extracts were immunoprecipi-
tated (IP) for p85 (upper panel) or AR (lower panel), followed
bySDS^PAGEseparationandimmunoblotting forARandp85.Rep-
resentative of three independent experiments (C) Abundance of
total AR and p85 in the total proteins extracted from LNCaP
treated as in (A). Representative of six to eight independent
experiments.
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Fig. 5. Effectsof siRNA-mediatedinhibitionof autophagyoncelldeathinducedbybicalutamide.A: Immunoblotanalysis showing thedeple-
tion of Atg5 and BECN15 days after transfection of LNCaP cells with the indicated siRNAs pools and the LC3-I ! LC3-II conversion after
48 hr treatmentwithorwithout50 mMBic for48 hr after transfectionwith theindicatedsiRNAspool.Representative of threeindependent
experiments.B:LC3-I ! LC3-IIconversioninLNCaPtreatedasin (A) in thepresenceofE64d/pepstatinA.Representative of six independent
experiments.C: Quantification of experiments showed in B.Bars presentmeans  SD of LC3-II/LC3-I ratios from six independent experi-
ments. Two-way ANOVA revealed a significant difference (P < 0.05, P < 0.01) between the transfections with the indicated siRNAs.
D:Bar histogram showing thenumberof cells exhibitingmore than10 fluorescentdots in LNCaPco-transfectedby the indicated siRNAs and
the GFP-LC3 construct, and cultured with or without 50 mM Bic for 48 hr (means  SD of three independent experiments, P < 0.01,
P < 0.001).E: Bar histogram showing theproportion of sub-G1cells detectedbyDNAcontent analysis after PI staining in permeabilized
LNCaPcellspreviously transfectedwith the indicated siRNAs andculturedin the absence or in thepresence of 50 mMBic for 48 hr.Data are
presented asmeans  SD of three independent experiments. P < 0.01, P < 0.001.F: Bar histogram showing cytofluorimetric analysis
of the effects of siRNA-mediated autophagy inhibition on apoptosis-associatedmitochondrial transmembrane potential (DCm) dissipation
andplasmamembranepermeabilization.Transfected cells were labeledwith theDCm-sensitive probeDiOC6(3) andwith PI.White andgray
columns represent percentages of cells exhibiting DCm loss alone (DiOC6(3)
low) or in associationwith plasmamembrane breakdown (PIþ),
respectively.Data arepresentedasmeans  SDof threeindependentexperiments,P < 0.001.
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particular, androgen supplementation was shown to
inhibit autophagy induced by serum starvation in
LNCaP cells [21,22]. Moreover, association of hypoxia
and androgen deprivation induced an AMPK-mediat-
ed autophagy in PCa cells but, in this study, androgen
deprivation alone was not sufficient to promote the
same effect [23]. In the present study, we clearly show
that androgen deprivation by itself and, importantly,
AR blockade by the clinically used bicalutamide
increase the autophagic flux in LNCaP cells. In this
cellular model, we observed an important amount of
LC3-II. This could be due to a high basal flux of
autophagy in LNCaP cells. However, this has to be
interpreted in light of the fact that antibodies against
LC3 better recognized LC3-II form. This rendered de-
tection of LC3-I ! LC3-II conversion by immunoblot-
ting not optimal. Indeed, androgen deprivation or
bicalutamide induced only a minor decrease of LC3-I
Fig. 6. Effects of the association of bicalutamide or androgen deprivation and chloroquine on cell death induced by androgen deprivation
or bicalutamide treatment.A: Immunoblot showing LC3-II level in the absence (ÿCQ) or in thepresence (þCQ) of100 mMchloroquine and
with or without 50 mMbicalutamide for 72 hr.B: Immunoblot showing GFP level in LNCaP cells treated in the presence of100 mMCQ or
E64d/pepstatinAwith orwithout 50 mMbicalutamide for 48 hr.Representative of two independentexperiments.C:Bar histogram showing
theproportionof sub-G1cells detectedbyDNAcontent analysis after PI staininginpermeabilizedLNCaPcellspreviouslyculturedin the indi-
catedconditions.Data arepresentedasmeans  SD of threeindependentexperiments. P < 0.001.D:Bar histogram showingcytofluori-
metric analysis of apoptosis-associatedmitochondrial transmembrane potential (DCm) dissipation and plasma membrane permeabilization
on LNCaP cells cultured in an androgen-depletedmedium (ÿR1881) or with 50 mMBic in the absence or in the presence of100 mMCQ for
72 hr.Whiteandgraycolumnsrepresentpercentagesofcells exhibitingDCm loss alone (DiOC6(3)
low)or inassociationwithplasmamembrane
breakdown (PIþ), respectively. Data are presented as means  SD of three independent experiments, P < 0.05, P < 0.001. E: Same
experiments as in (D) except that chloroquine treatmentwas replacedby1 mMconcanamycin A (Conca) treatment and that the duration of
treatmentwas48 hr.Data arepresentedasmeans  SDof four independentexperiments,P < 0.001.
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but no obvious increase of LC3-II. However, addition
of E64d/pepstatin A clearly revealed the increase
of LC3-II suggesting that androgen deprivation or
bicalutamide do stimulate autophagy. In contrast to
assessment of LC3-I ! LC3-II conversion by immu-
noblotting, detection of GFP-LC3 clustering showed a
dramatic increase in autophagy after both treatments.
Transmission electron microscopy showed typical
multiple-membrane structures compatible with mac-
ro-autophagy. All these results were confirmed by
p62 degradation and by a new flow cytometry assay
based on the fluorimetric detection of autophagic
vacuoles. This was associated with a reduction of
phosphorylated forms of Akt and p70S6k, suggesting
that autophagy induced by AR signaling disruption is
associated to the inhibition of the PI3-K/Akt/mTOR
pathway, a master regulator of multiple forms of
autophagy. Several reports indicated that androgens
trigger the PI3-K/Akt/mTOR pathway by increasing
the interaction between the activated AR and p85, the
regulatory subunit of class Ia PI3-K [19,21,24,25]. Con-
sistently, we observed that AR interacted with p85.
However, our data also showed that AR expression
was decreased after androgen deprivation or bicaluta-
mide treatment. We therefore suggest that androgen
ablation, by decreasing AR expression, increased the
cytosolic amount of free p85 that in turn inhibits the
PI3-K activity. This observation gives a novel insight
to explain the inhibition of mTOR after androgen sig-
naling pathway disruption.
The impact of autophagy in neoplastic transforma-
tion and cancer therapy remains speculative and
cross-talk between apoptosis and autophagy is a cru-
cial question to address to develop optimal treatments
for cancer patients [26]. On the one hand, several tu-
mor suppressors involved in the inhibition of mTOR,
including PTEN or TSC1 and TSC2, stimulate autoph-
agy and, conversely, mTOR-activating oncogene
products such as class I PI3-K and Akt inhibit auto-
phagy. The p53 tumor suppressor gene promotes
autophagy in DNA-damaged cells whereas apoptosis
inhibitors Bcl-2 and Bcl-XL overexpressed in a series
of cancers also inhibit autophagy. Moreover, deficien-
cies in the autophagic machinery are associated with
an increase in tumor susceptibility and several anti-
cancer therapies induce accumulation of autophago-
somes in cancer cell lines in vitro (for a review see
ref. 10). On the other hand, the prosurvival properties
of autophagy can be exploited by cancer cells to resist
to metabolic stress or cytotoxic therapies. Indeed,
autophagy has recently been pointed out as an im-
portant mechanism of resistance to chemotherapy,
radiation therapy or immunotherapy since pharmaco-
logical or siRNAs-mediated inhibition of autophagy
usually accelerates, rather than prevents, cell death in
these settings [27,28].
Our study provides novel insights in the role of
autophagy in PCa by demonstrating the possibility to
restore sensitivity of HRPCa cells to hormone therapy
by inactivating autophagic degradation, suggesting
that autophagy is a prosurvival mechanism in LNCaP
cells. Chloroquine and concanamycin A, two well-
known inhibitors of autophagy, dramatically in-
creased cell death after androgen depletion or bicalu-
tamide treatment. Inhibition of autophagy by Atg5 or
BECN1 depletion had significant but smaller effects
on bicalutamide-induced cell death than pharmaco-
logical inhibitors. This might be due to the fact that
siRNA-mediated depletion of Atg5 and BECN1 was
not complete and that therefore autophagy was not
entirely blocked. Chloroquine is already being tested
to restore sensitivity to cytostatic drugs in lung can-
cer, breast cancer and metastatic HRPCa. Because of
the lack of effective therapy in the management of
non-metastatic HRPCa, the combination of chloro-
quine and hormone therapy could constitute a useful
strategy at this stage of the disease.
In conclusion, our study clearly suggests that clini-
cal trials investigating the association between hor-
mone therapy and chloroquine should be considered
to improve the management of HRPCa patients and
delay the apparition of metastasis and the recourse to
chemotherapy.
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a  b s  t  r a  c  t
Reference  treatment  of advanced  prostate  cancer (PCa) relies  on pharmacological  or  surgical  andro-
gen deprivation  therapy.  However, it is only temporarily  efficient as  tumor  cells inevitably  adapt  to
the low testosterone  environment  and become  hormone-refractory  (HRPCa).  We  observed  that  andro-
gen removal  in  HRPCa-derived LNCaP  cells causes different alterations  in  their Ca2+ homeostasis  among
which  a reduction  of ER  Ca2+ content.  We  show  that the  decrease in  [Ca2+]ER is  due to  a modest  overex-
pression of type 1  IP3R and  a threefold increased  phosphorylation  of IP3R1  on Ser-1716, a protein kinase
A  (PKA)  consensus  site, both implicated  in  ER  Ca2+ leak. Accordingly, ER  Ca2+ content was restored  by
siRNA-mediated  down-regulation  of IP3R1  or  by inhibition of its  phosphorylation  by  competition with
a permeant  TAT-peptide containing  the Ser-1716 consensus phosphorylation sequence  or by treatment
with the  PKA inhibitor  H89.  Moreover,  inhibition of the IP3R1  phosphorylation  by both  methods  sensi-
tized the  LNCaP cells  to androgen deprivation-induced  apoptosis. In  addition,  SERCA2b  overexpression
precluded  the  effect  of androgen deprivation on ER  Ca2+ store content  and reduced  resistance to  androgen
deprivation. Taken together, these  results indicate  that  lowering the  ER  Ca2+-store content  by increasing
IP3R1  levels  and  IP3R1  phosphorylation  by PKA is a protective mechanism by which  HRPCa-derived  cells
escape cell  death in  the  absence  of androgenic  stimulation.
© 2015 Elsevier Ltd.  All rights  reserved.
1. Introduction
Metastatic prostate cancer (PCa) is associated with a poor prog-
nosis with a  5-year relative survival of 27% [1].  Reference treatment
of metastatic PCa consists in pharmacological or surgical andro-
gen deprivation therapy. However, androgen deprivation is only
temporarily efficient. After a  few months or years, the tumor
inevitably relapses despite the absence of androgenic stimulation
and becomes hormone-refractory (HRPCa). Effective treatment at
this stage is  largely limited to docetaxel-based chemotherapies
conferring a median survival of only 17–19 months [2,3]. Among
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commercially available HRPCa cell lines, only LNCaP cells harbor
the androgen receptor (AR) [4].
The role of Ca2+ in  prostate involution induced by  androgen
deprivation (AD) has been recognized for more  than two  decades
[5].  Mitochondrial membrane permeabilization (MMP) constitutes
a key event in apoptotic cell  death [6].  At least, two mecha-
nisms can enhance the Ca2+ transfer between ER and  mitochondria.
On  the one hand, this could be related to an increase in Ca2+
conductance between ER and mitochondria after apoptosis induc-
tion. Indeed, it  has  been proposed that excessive transfer of
Ca2+ from the ER  to the mitochondria possibly through a  pro-
tein complex comprising the inositol trisphosphate receptor, the
glucose-regulated protein 75 and the voltage-dependent anion
channel (IP3R/grp75/VDAC) [7] via MMP  induction, release of
intermembrane proapoptotic factors, dissipation of mitochondrial
transmembrane potential (1	m), formation of apoptosomes and
subsequent cell death [8,9]. Thus, overactivation/overexpression
of one member of the IP3R/grp75/VDAC complex could enhance
http://dx.doi.org/10.1016/j.ceca.2015.02.004
0143-4160/© 2015 Elsevier Ltd. All rights reserved.
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Fig. 1. Intracellular Ca2+ homeostasis alterations after androgen deprivation. (A) LNCaP cells cultured for  48 h in  the presence of  0.2  nM R1881 (+R1881 condition) or in  its
absence  (−R1881 condition) were loaded with Fura-2/AM and  stimulated with 1 mM  thapsigargin in the absence of  extracellular Ca2+ .  After 5 min, Ca2+ was  reintroduced in
the  external medium to evaluate SOCE amplitude. Representative thapsigargin-evoked changes in [Ca2+]c are presented for both conditions. (B) Bar histogram showing in both
conditions the [Ca2+]c measured in Fura-2/AM stained LNCaP cells first in the absence of  extracellular Ca2+ ,  then after addition of 1 mM  thapsigargin (Thaps) and finally after
addition of 1.8 mM  extracellular Ca2+ (SOCE) (means ± S.D. of five independent experiments, **p <  0.01, ***p < 0.001). (C) By measurement of  Fura-2/AM emission intensity
(excitation at 360 nm), the progressive fluorescence quenching due to the influx  of  Mn2+ , taken as a surrogate of  Ca2+ ,  was monitored in LNCaP cells in both conditions. The
slope  of the Mn2+-induced fluorescence quenching was decreased more than twice in the  −R1881 condition, revealing that the calcium influx through the cell membrane
was  strongly decreased after AD (means ± S.D. of  three independent experiments).
the sensitivity to proapoptotic agents. On the other hand, the
ER-mitochondria Ca2+ flux might be enhanced by an  increase in
the electrochemical gradient, e.g.  subsequently to an  increase in
[Ca2+]ER.  Indeed, antiapoptotic proteins such as Bcl-2 or Bcl-XL
decrease [Ca2+]ER whereas proapoptotic proteins such as Bax  or
Bak have the opposite effect, at least in  some cell systems [10].
This suggests that [Ca2+]ER is closely related to the sensitivity to
cytotoxic stimuli [11].  Increase in [Ca2+]ER can be secondary to
an increase in the ER refilling, e.g. due to an increase in  SERCA
activity or expression, or to a  decrease in Ca2+ leak from  ER. In
mouse embryonic fibroblasts, the group of Korsmeyer showed sev-
eral years ago that IP3R1 constituted an ER Ca2+ leak channel, the
permeability of which was modulated by a protein kinase A (PKA)-
mediated phosphorylation, itself increased by Bcl-2 and decreased
by Bax or Bak  expression [12].  In T-lymphocytes however Bcl-2
can dock both DARPP-32 and calcineurin to  the IP3R, whereby the
PKA-mediated phosphorylation of the latter is antagonized, leading
to decreased IP3R-mediated Ca2+ release [13].  Very recently, in an
siRNA screen for the identification of  ER Ca2+-leak channels, IP3R1
channels emerged as one of the most prominent Ca2+-transport
systems implicated in ER Ca2+ leak [14].
In the present study, we show that AD decreases [Ca2+]ER in
LNCaP cells and suggest that this is  mediated by a  phosphorylation-
dependent increase in IP3R1 permeability. Inhibition of  IP3R1
phosphorylation restores LNCaP cells sensitivity to AD and could
be a  novel therapeutic target for the treatment of  HRPCa.
2. Results
2.1. Androgen deprivation alters intracellular Ca2+ homeostasis
In order to  study the effects of AD on [Ca2+]c and on [Ca2+]ER,
we measured [Ca2+]c in LNCaP cells cultured in the absence or in
the presence of synthetic androgen R1881 for 48 h. Fura-2 loaded
cells were treated with the SERCA inhibitor thapsigargin in the
absence of  external Ca2+ and then, Ca2+ was reintroduced in the
external medium to evaluate the amplitude of  store-operated Ca2+
entry (SOCE). We  observed that AD had no  effect on  [Ca2+]c but
reduced by about 40% the amount of thapsigargin-induced Ca2+
release, suggesting a decrease of the ER  Ca2+ store content. SOCE
was also decreased after AD (Fig. 1A and B). Interestingly, treatment
of the cells with the AR  specific inhibitor bicalutamide (50 mM)  for
48 h also decreased releasable Ca2+ from the ER  (data not shown).
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Fig. 2.  Bar histogram showing the relative mRNA expression of genes involved in
calcium  homeostasis after AD in LNCaP cells. Two days after AD treatment, total RNA
was extracted and  reverse-transcribed. qPCR was performed with specific primers.
The mRNA expression of  each gene was normalized to b2-microglobulin expression
(means ± S.D. of four independent experiments, **p <  0.01, ***p < 0.001).
We also observed that basal influx of Ca2+ through the plasma
membrane as measured by the Mn2+-induced Fura-2 quenching
technique was diminished after androgen removal (Fig. 1C).
We  therefore tried to  decipher the mechanisms underlying
these modifications and measured the expression of  a  series of pro-
teins possibly involved in Ca2+ homeostasis (Ca2+ pumps, channels
and buffers). AD  induced a strong decrease in TRPM8 expression
and a  more than twofold increase in IP3R1 expression at the mRNA
level (Fig. 2). Previous studies have shown that the expression of
the Ca2+ channel TRPM8 is  highly dependent on the presence of
androgens and is overexpressed in prostate cancer cells [15,16].
Its repression after androgen removal might therefore explain
alterations in  Ca2+ homeostasis. IP3R1 beside its  well-known role
in  agonist-induced Ca2+ signaling, might also function as an ER
Ca2+ leak  channel [12,17],  thereby controlling resting [Ca2+]ER.
Importantly, its activity has been reported to  be phosphorylation-
dependent [18].
2.2. Involvement of TRPM8 in Ca2+ homeostasis alterations
induced by AD
Given the importance of AD on  TRPM8 expression, we tried to
mimic  this effect by  depleting TRPM8 in LNCaP cells using specific
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Fig. 3. Role of  TRPM8 in LNCaP cells. (A, B)  LNCaP cells were transfected with a siRNA targeting TRPM8 mRNA (siTRPM8) or with a non-silencing control siRNAs (siUNR) pool
and  then cultured in the presence of  0.2 nM R1881. The  silencing of  TRPM8 was proved by RT-qPCR (A) and immunoblot (B). b-Actin was used as loading control. Four days
after  transfection, total RNA was extracted and  reverse-transcribed. qPCR was  performed with specific primers. The results are expressed as the level of  TRPM8 expression
normalized to b2-microglobulin expression (means ± S.D. of three independent experiments, ***p < 0.001). (B) Bar histogram showing in siUNR and siTRPM8 conditions the
intracellular Ca2+ concentrations measured in Fura-2/AM stained LNCaP cells first in the absence of extracellular Ca2+ (Rest), then after addition of 1 mM thapsigargin (Thaps)
and  finally after addition of  1.8 mM extracellular Ca2+ (SOCE) (means ± S.D. of  three independent experiments). (C) Mn2+-induced fluorescence quenching of Fura-2/AM in
LNCaP  cells four days after transfection with siUNR or  siTRPM8 (means ± S.D. of three independent experiments, *p  < 0.05).
Fig. 4. Phosphorylation of  IP3R1 on Ser-1716 after AD. (A)  Immunoblot analysis of
the expression of  IP3R1 and of  its phosphorylation on Ser-1716 in  LNCaP cells  cul-
tured for 48  h in the presence of 0.2 nM R1881 (+R1881 condition) or  in its absence
(−R1881 condition). b-Actin was used as a loading control. Data presented are
representative of  seventeen independent experiments. (B) Bar histogram showing
phosphorylation and total expression level of IP3R1 in both conditions (means ± S.D.
of  seventeen independent experiments, **p < 0.01, ***p < 0.001).
siRNA. The silencing of TRPM8 was proved by RT-qPCR (Fig. 3A)
and was correlated with a  significant decrease of basal influx of
Ca2+ (Fig. 3C). This indicates that the channel is expressed, at least
partially, at the plasma membrane and that the decrease of its
expression due to AD could  be responsible for basal Ca2+ influx
reduction. However, we did not observe any subsequent decrease
in [Ca2+]c,  in  thapsigargin-evoked Ca2+ release or in  SOCE (Fig. 3B).
2.3. Involvement of IP3R1 in Ca2+ homeostasis alterations
induced by AD
It has been suggested that  IP3R1 could control resting [Ca2+]ER
[12,14]. After AD treatment in LNCaP cells, we observed a mod-
est increase in the amount of  IP3R1 protein (Fig. 4A and B) and a
dramatic increase in IP3R1 phosphorylation on the PKA  consensus
site Ser-1716 (equivalent to Ser-1756 in the rat IP3R1 amino acid
sequence). Incidentally, IP3R2 was not expressed in LNCaP cells [19]
and expression of  IP3R3 mRNA was not modified by AD (Fig. 2).
In order to  evaluate the effects of IP3R1 phosphorylation and
expression on [Ca2+]ER,  we  first measured the Ca
2+ content in
the ER  after inhibition of PKA-mediated IP3R1 phosphorylation.
As also  performed in  Fig. 1, we  tried to evaluate [Ca2+]ER after
thapsigargin treatment. However, we observed that acute inhibi-
tion (5  min  pretreatement) of IP3R by xestospongin B decreased
by itself the amount of  releasable Ca2+ (Fig. 5A).  This  suggested
that IP3R is the Ca2+ leak channel in  thapsigargin-induced ER
depletion. Since we  were interested in the permeability of  IP3R, a
procedure using thapsigargin to evaluate [Ca2+]ER was obviously
inadequate. We  then decided to use ionomycin to permeabilize
the ER membrane and measure releasable Ca2+ independently of
the IP3R-mediated leak. We observed that the ionomycin-induced
Ca2+ release was  decreased by  AD (Fig. 5E and F), confirming the
results obtained with thapsigargin (Fig. 1B). We  then interfered
with IP3R1 phosphorylation by using a cell-permeable TAT-peptide
(TAT-IP3R1S1716) containing the Ser-1716 consensus phosphoryla-
tion sequence. AD-induced phosphorylation of IP3R1 was  abolished
after treatment with 80 mM TAT-IP3R1S1716 (Fig. 5B and C). As Ser-
1716 is  known to be phosphorylated by  PKA [20,21], we treated
LNCaP cells with H89, a  selective inhibitor of  this kinase. We
observed that 10 mM  H89 treatment strongly reduced IP3R1 phos-
phorylation (Fig. 5B  and 5D). This effect was  stronger than that
observed with TAT-IP3R1S1716 treatment and occurred even in the
presence of  androgen. In the presence of 80  mM TAT-IP3R1S1716,
the effect of AD on ionomycin-induced Ca2+ release was abolished
(Fig. 5E). Inhibition of PKA  by H89 strongly increased [Ca2+]ER and
also inhibited AD-induced decrease in  [Ca2+]ER (Fig. 5F).
2.4. Involvement of IP3R1 phosphorylation in the resistance to AD
The results presented above suggest that the decrease in [Ca2+]ER
is due to an  increase of the amount of IP3R1 phosphorylated on its
serine 1716 residue consecutively to AD. We therefore investigated
whether this process was involved in the resistance of  LNCaP cells
to AD. LNCaP cells were treated for 72 h with 80  mM TAT-IP3R1S1716
in the presence or in the absence of androgen. Simultaneous
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Fig. 5. Involvement of IP3R1 phosphorylation in  Ca2+ homeostasis alterations induced by  AD. (A) Bar histogram showing the  thapsigargin-induced Ca2+ release in the  absence
of  extracellular Ca2+ measured in  Fura-2/AM-loaded LNCaP cells cultured in  the presence or in  the  absence of  0.2  nM  R1881 and  pretreated or  not with 2 mM Xestospongin
B  (means ± S.D. of  three independent experiments, *p  <  0.05). (B) Immunoblot analysis of the expression of IP3R1 and of  its  phosphorylation on Ser-1716 in  LNCaP cells
cultured in the presence or in the  absence of 0.2 nM R1881 and treated for 48 h  with 80 mM cell-permeant TAT-peptide (TAT-IP3R1S1716) containing the  Ser-1716 consensus
phosphorylation sequence or  with 10  mM PKA inhibitor H89. b-Actin was used as a  loading control. Data presented are representative of three independent experiments.
(C,  D) Quantification of data presented in  A and  B (means ± S.D.  of  three to seven independent experiments, **p  <  0.01, ***p  <  0.001). (E) Bar histograms showing the effects
of  TAT-IP3R1S1716 on the [Ca2+]c measured in Fura-2/AM-loaded LNCaP cells cultured in  the presence or in the  absence of  0.2 nM R1881 after addition of  10 mM  ionomycin
in  the absence of  extracellular Ca2+ (means ±  S.D. from 6 to 7 independent experiments, *p  <  0.05). (F)  Bar histograms showing the effects of  H89 on  the [Ca2+]c measured in
Fura-2/AM-loaded LNCaP cells cultured in the presence or in  the  absence of  0.2 nM R1881 after addition of  10  mM  ionomycin in the  absence of  extracellular Ca2+ (means ±  S.D.
from  5 to  6  independent experiments, *p  <  0.05, ***p < 0.001).
fluorimetric detection of  mitochondrial membrane potential
(1	m)  dissipation and plasma membrane permeabilization, two
markers associated with cell death, showed that TAT-IP3R1S1716
strongly sensitized LNCaP cells to AD (Fig. 6A and B).  TAT-IP3R1S1716
did however not exert any effect on  cell death in  the presence of
androgen.
Additionally, we  observed that 10 mM H89 also restored AD-
dependent cell death but did not  affect cell viability in  the presence
of androgen (Fig. 6C and D).  Its effect on  AD-dependent cell death
was strongly diminished by adding 0.5 mM thapsigargin during
the last 24  h  of AD treatment. This suggests that  the inhibition
of PKA by H89 exerts its  effect on  cell death by modulating
[Ca2+]ER.
To confirm the role of Ca2+ store in the resistance to AD, we
partially prevented AD-induced Ca2+ store depletion by overex-
pressing SERCA2b, the isoform the most ubiquitously expressed
in non-muscle tissues (Fig. 7A) and measured the effects of such
[Ca2+]ER stabilization on cell survival. We observed that SERCA2b
overexpression increased the proportion of apoptotic cells after AD
treatment proving ER Ca2+ store control on LNCaP sensitivity to AD
(Fig. 7B).
2.5. Effects of IP3R1 phosphorylation on autophagy
We  previously showed that AD induces autophagy in
LNCaP cells and that genetic or pharmacological inhibition of
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Fig. 6. Inhibition of IP3R1 phosphorylation sensitizes LNCaP cells to AD. (A)  Cytofluorimetric assessment of the  effects of  AD in  the absence or  in the presence of 80 mM
TAT-IP3R1S1716 on apoptosis-associated mitochondrial transmembrane potential (1	m) dissipation and plasma membrane permeabilization. Cells were  treated for 72 h
and  then labeled with the  1	m-sensitive probe DiOC6(3)  and with propidium iodide (PI). Representative dot plots recorded upon AD treatment in  the  absence and in the
presence of TAT-IP3R1S1716 are shown. Numbers in each quadrant indicate the  percentage of cells. (B) Quantification of data illustrated in  A as well as  of cells cultured in
the  presence of R1881 and  similarly treated. White and black columns represent percentages of cells exhibiting 1	m loss alone  (DiOC6(3)
low) or in  association with plasma
membrane breakdown (PI+), respectively. Data are presented as means ±  S.D. of three independent experiments (*p < 0.05). (C, D)  Similar experiments were performed in  the
absence or in the presence of  10 mM H89 for 72 h. Effects of  thapsigargin (Thaps) were also  monitored. Data are presented as means ± S.D. of  three independent experiments
(*p  < 0.05, ***p <  0.001).
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Fig. 7. SERCA2b overexpression prevents Ca2+ store depletion and promotes cell  death after AD. (A)  LNCaP cells cultured in the presence or in  the absence of 0.2 nM R1881
were  transfected with a control plasmid or a  plasmid encoding SERCA2b and with a dsRed expressing plasmid allowing detection of transfected cells. Cells were loaded
with Fura-2/AM and stimulated with 10 mM ionomycin in  the absence of  extracellular Ca2+ .  Bar  histogram showing the effects of  SERCA2b overexpression on the [Ca2+]c in
dsRed-positive cells after addition of ionomycin (means ± S.D. from 4 to 6 independent experiments, ***p < 0.001). (B) Cytofluorimetric assessment of  the effects of  AD in
dsRed-positive cells on apoptosis-associated mitochondrial transmembrane potential (1	m) dissipation. Transfected LNCaP cells were cultured for 72 h in  the presence or
in  the absence of 0.2 nM R1881 and then labeled with the 1	m-sensitive probe DiOC6(3). Bar histogram shows percentages of dsRed-positive cells exhibiting 1	m loss for
each condition. Data are presented as  means ±  S.D.  of three independent experiments (*p <  0.05, **p  < 0.01).
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Fig. 8.  [Ca2+]ER and autophagy. (A) Immunoblot analysis assessing LC3-II protein levels after 48 h AD treatment in with the absence or presence of 10 mM H89. E64d (10 mg/ml)
and  pepstatin A (10 mg/ml) were added during the  treatment. b-Actin was used as a loading control. Immunoblots are representative of  three independent experiments.
(B)  Quantification of data illustrated in  A.  Data are presented as  means ±  S.D.  of  at least three independent experiments (*p <  0.05). (C) LNCaP cells were  transfected with a
plasmid encoding a GFP-LC3 fusion protein. Bar histogram showing the number of  cells exhibiting more than 10 fluorescent dots after treatment by  10  mM  H89 for 48 h in
the  presence or in the absence of  0.2 nM R1881 (means ± S.D. of three independent experiments, **p < 0.01, ***p  < 0.001). (D) LNCaP cells were transfected with  a pool of  4
siRNAs  targeting Atg5 mRNA (siATG5) or with a  non-silencing control siRNAs (siUNR) pool and then cultured in the presence or  in the absence of  0.2  nM R1881 for 48 h.
LNCaP  cells were loaded with Fura-2/AM and stimulated with 1 mM thapsigargin in  the absence of  extracellular Ca2+ . Bar histogram showing thapsigargin-evoked changes
in  [Ca2+]c for each condition (means ± S.D. of three independent experiments, *** p < 0.001).
autophagy also restores AD-dependent cell death [22].  Further-
more, IP3Rs and downstream Ca2+ signaling have been implicated
in mTOR-controlled autophagy [23,24].  We therefore studied
here whether AD-induced [Ca2+]ER modulation was involved in
autophagy.
Upon autophagy induction, the LC3-I protein is modified into
the lipidated form, LC3-II. This latter is associated with autophago-
somes and its detection is  routinely used to monitor autophagy
[25].  We observed that LC3-II levels declined after AD (Fig. 8A and
B). To distinguish whether this observation was  due to a decrease
in the on-rate of  autophagic LC3-II  formation or an increase in
the off-rate of, the lysosomal LC3-II degradation, we used a  com-
bination of  E64d and pepstatin A to inhibit lysosomal function
and block LC3-II degradation. The use of  inhibitors revealed that
LC3-II was increased, demonstrating that AD promotes autophagy
at the level of  the autophagosomal/lysosomal fusion and/or
degradation events. Together, these observations confirm our  pre-
vious study showing that AD increases autophagic rate in LNCaP
cells [22].
H89 treatment did not preclude AD-induced LC3-II degrada-
tion, suggesting that phosphorylation of  IP3R1 is  not responsible
for the AD-induced autophagy flux at the level of autophago-
somes/lysosomes (Fig. 8A and  B).  These results were corroborated
by detection of another biochemical sign of autophagy, namely
the redistribution of  GFP-LC3 fusion protein from a ubiquitous,
diffuse pattern toward autophagosomes, which became visible
as cytoplasmic puncta, independently of  the presence of H89
(Fig. 8C).
Consistent with these findings, genetic inhibition of  autophagy
by siRNA-mediated depletion of  the essential autophagy gene
product Atg5 did not modify AD-induced decrease of  the
thapsigargin-releasable pool of  Ca2+ (Fig. 8D). This suggests that the
effects of AD  on Ca2+ stores were not  due to an  autophagic degrada-
tion  of ER membranes or ER proteins involved in intracellular Ca2+
handling in addition to the control of IP3R1 permeability.
3. Discussion
Several reports have demonstrated the role of  [Ca2+]ER in  the
resistance to proapoptotic stimuli and increased proliferation, two
major hallmarks of cancer cells [26,27]. In LNCaP cells, AD  for 96 h
has been shown to induce neuroendocrine differentiation associ-
ated with a  reduction in  [Ca2+]ER.  This observation was attributed
to a decreased expression of SERCA2b and of  the luminal Ca2+-
binding/storage chaperone protein calreticulin and was correlated
with a decrease in sensitivity to  thapsigargin and TNF-a  [28].  In
our experiments, we  confirmed the decrease in [Ca2+]ER after AD
but expression levels of  SERCA2b and calreticulin were not modi-
fied. This apparent discrepancy could be attributed to the fact that
in our study, AD was  maintained for only 48  h.  The TRPM8 expres-
sion was however strongly decreased and we  also observed that
basal  Ca2+ influx through the plasma membrane was diminished
after  AD. This observation could explain the decrease in [Ca2+]ER.
Since expression of  TRPM8 is  known to be dependent of andro-
gen receptor activation [16], we  measured basal Ca2+ influx after
siRNA-mediated TRPM8 depletion. It was  decreased in TRPM8-
depleted cells suggesting that it was, at least partially, localized
in the plasma membrane. However, neither thapsigargin-induced
Ca2+ release nor SOCE were modified by  repression of  TRPM8. We
therefore conclude that TRPM8 repression and decrease in basal
Ca2+ influx after AD were not related to the decrease in [Ca2+]ER.  As
expected, AD  induced-TRPM8 decrease or siRNA-mediated TRPM8
depletion decreased Ca2+ entry. However, they  did not modify res-
ting cytosolic [Ca2+], suggesting that their  effects on Ca2+ entry  is
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compensated by the activity of transporters allowing fluxes of  Ca2+
out of the cells or into the ER.
As mentioned above, phosphorylated IP3R1 was reported as
an ER leak channel in mouse embryonic fibroblasts cells [12].  We
therefore measured the expression and the phosphorylation of
IP3R1 in AD conditions. Expression was  increased by  only 50% but
phosphorylation on Ser-1716 increased threefold after AD for 48  h.
Inhibiting PKA-dependent phosphorylation of  IP3R1S1716 by com-
petition with TAT-IP3R1S1716 abolished the effect of AD  on [Ca2+]ER.
This underpins the concept that beside its role in response to ago-
nists, IP3R1 also constitutes in LNCaP cells an ER Ca2+ leak channel
that is modulated by AD-dependent phosphorylation. In those cells,
IP3R1 could therefore regulate [Ca2+]ER at  rest. Inhibition of PKA
by H89 also abolished AD-dependent decrease in [Ca2+]ER but also
dramatically increased [Ca2+]ER in  the presence of androgen. This
could be due to the higher efficiency of  H89 to reduce IP3R1 phos-
phorylation in comparison with TAT-IP3R1S1716 (Fig. 5B and D).
However, we cannot exclude an alternative pathway connecting
PKA and [Ca2+]ER.
Our results also clearly show that AD-dependent phosphoryla-
tion of IP3R1 is an  important mediator of  androgen resistance in
PCa cells. Indeed, inhibition of IP3R1 phosphorylation with H89 or
TAT-IP3R1S1716 dramatically increased sensitivity to  AD in LNCaP
cells. Interestingly, this effect was seriously decreased after pre-
treatment with thapsigargin, indicating that the effect of PKA on
AD-induced cell death is  dependent on the Ca2+ content in the ER.
The role of [Ca2+]ER in  androgen resistance was also confirmed by
the fact that SERCA2b overexpression limited the effect of AD on
Ca2+ store content and increased AD-induced apoptosis. Therefore,
we show for the first time that survival of PCa cells in  response to
androgen removal is dependent on the (partial) depletion of their
Ca2+ stores.
It has been reported that PKA is overexpressed in  PCa and
constitutes a marker of  poor prognosis [7].  Moreover, PKA hyper-
activity could contribute to  resistance of  PCa  cells to AD [29]. Our
results suggest that IP3R1 phosphorylation by  PKA could explain
the decreased AD-induced cell death in  HRPCa. Targeting the PKA-
IP3R1 pathway could therefore constitute an  interesting strategy
to restore sensitivity to AD in HRPCa.
Since AD itself  induced phosphorylation on the PKA consensus
site IP3R1S1716,  we suggest that, beside its proapoptotic effect, AD
concomitantly triggers a prosurvival pathway. Bagchi et al. showed
that androgen stimulation induced PKA activation by increasing
cAMP production [30]. This result is apparently contradictory to our
data but  it is noteworthy that in contrast to our experimental design
(48 h AD), Bagchi et  al. investigated short-term (10 min) effect of
androgen on PKA-related pathways. Furthermore, prolonged AD
treatment has  been noticed to increase the expression of different
catalytic subunits of  PKA in LNCaP cells [31].
In a previous study, we  showed that AD induced autophagy in
LNCaP cells and that this process in  turn inhibited AD-triggered
cell death [22]. Therefore, we have investigated in the present
study whether IP3R1S1716 phosphorylation and Ca2+ store deple-
tion could be intermediates between AD and autophagy. Our data
showed that inhibition of IP3R1S1716 phosphorylation does  not
interfere with AD-induced autophagy. Moreover, siRNA-mediated
inhibition of autophagy has no effect on [Ca2+]ER.  This  suggests
that AD-induced autophagy and AD-induced IP3R1S1716 phosphor-
ylation constitute two independent mechanisms of  resistance to
AD.
In conclusion, we show that  phosphorylation of  IP3R1 on a PKA
consensus site modulates [Ca2+]ER and renders LNCaP cells more
resistant to  AD-induced apoptosis. This demonstrates that the com-
mon  anti-prostate cancer strategy consisting in androgen removal
could interfere with ER Ca2+ homeostasis, highlighting the role of
ER Ca2+ in  the mechanisms of cancer aggressiveness.
4. Materials and  methods
4.1. Cell culture and reagents
LNCaP cells (American Type Culture Collection, Manassas, VA,
USA, CRL-1740) were grown at 37 ◦C in  an humidified atmosphere
of 5% CO2–95% air in  RPMI 1640 (Gibco Invitrogen, Carlsbad, CA,
USA, 52400) supplemented with 10% fetal calf  serum, 100 IU/ml
penicillin (Gibco, 10270) and 100  mg/ml streptomycin (Gibco,
15140). Cells were cultured up to passage 30. Analysis of the effect
of androgen deprivation was  performed by culturing cells for 2
days in RPMI 1640 medium supplemented with charcoal-treated
FCS (Gibco, 12676) for serum steroid hormone removal (−R1881
condition). As control condition, the synthetic agonist of the andro-
gen receptor (AR), methyltrienolone (R1881), was added to the
medium at 0.2  nM (+R1881 condition). H89 (Sigma–Aldrich, Saint
Louis, MO,  B1427) was  used at 10 mM, thapsigargin (Sigma–Aldrich,
T9033) at 0.5 and 1 mM,  ionomycin (Invitrogen, Carlsbad, CA, USA,
I24222) at 10  mM.  Xestospongin B was purified from Xestospongia
exigua as  previously described [32].  The synthetic peptide TAT-
IP3R1S1716 (NH2-RKKRRQRRRGGRPSGRRESLTSFGNG-COOH) was
obtained from ThermoFisher Scientific (Waltham, MA,  USA) and
used at 80 mM.
4.2. siRNA transfection
The siRNA targeting TRPM8 mRNA (siTRPM8; 5′-
GCAAACUGGUUGCGAACUU-3′) as  well as  the non-silencing
control siRNAs (siUNR) pool were  purchased from Thermo Fisher
Scientific (Lafayette, CO, USA). LNCaP cells were transfected
using DharmaFECT reagent (Thermo Fisher Scientific, T-2002-03)
according to the manufacturer’s instructions. Twenty-four hours
later, cells were plated on six-well plates and after 48  additional
hours subjected to AD treatment. Four days after transfection,
efficiency of  siRNA-mediated depletion of  the TRPM8 mRNA was
assessed by RT-qPCR.
4.3. SERCA2b transfection
LNCaP cells, seeded in  six-well culture plates until ∼80% con-
fluence, were co-transfected with a  plasmid coding a DsRed
fluorescent protein and an empty plasmid or a plasmid coding
for SERCA2b using  Lipofectamine reagent (Invitrogen, 11668-019)
according to manufacturer’s instructions. After 24  h,  cells were
plated on six-well plates and 48 h later, were subjected to AD treat-
ment during 2 at 3 days.
4.4. Quantitative RT-PCR
LNCaP mRNAs were extracted with Trizol reagent (Invitrogen).
Gene-specific PCR primers were designed using Primer3 and pur-
chased from  Eurogentec (Seraing, Belgium). Primer sequences are
given Table 1. The b2-microglobulin was  used as housekeeping
gene. Quantitative RT-PCR was performed using 5 mL of cDNA,
12.5 mL of SYBRGreen Mix  (Bio-Rad, Hercules, CA, USA) and 300  nM
of each primer in a total reaction volume of 25 mL. The reaction
was initiated at 95 ◦C  for 3 min, followed by  40 cycles of  denatur-
ation at 95 ◦C for 10 s,  annealing at 60 ◦C for 1 min, and extension at
72 ◦C  for 10 s.  Data were  recorded on  a  MyiQ qPCR detection system
(Bio-Rad), and cycle threshold (Ct)  values for each reaction were
determined using analytical software from the same manufacturer.
Each cDNA was amplified in duplicate, and  Ct values  were aver-
aged for each duplicate. The average Ct  value for b2-microglobulin
was subtracted from the average Ct  value  for the gene of interest.
This 1Ct value obtained in–R1881 condition or in siRNA-TRPM8
silenced LNCaP was  then subtracted from the 1Ct  value obtained
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Table  1
Primers used in Real-Time PCR analyses.
Gene Forward primer  Reverse primer PCR Product (bp)
Serca2b ACCCACATTCGAGTTGGAAG CCAACGAAGGTCAGATTGGT 209
Calreticuline TCTCAGTTCCGGCAAGTTCT TCTGAGTCTCCGTGCATGTC 231
IP3R1 CTGATTCACCCACGAAGGTT TGCAAATCAGGTGCTTTCTG 200
IP3R3  AACTACCTGGCTGCTGAGGA CGAAAGAGTCGGTTTTCTGC 205
RyR1 TGTCGCTCTGCAGGTACATC CCCGTCGGTAGGCAGTAGTA 157
RyR2 CAACCGGACTCGTCGTATTT TTGGCTTTCTCTTTGGCTGT 249
Stim1 CCAGAGCCTCAGCCATAGTC CTTCCACATCCACATCACCA 200
Orai1 GACTGGATCGGCCAGAGTTA CACTGAAGGCGATGAGCAG 214
Homer1 AGCTGCTCGACTAGCAAAGG CCTCCCAATGTTTGCTGATT 230
Trpm8 ACTTAGCCAATGATGAGATTT CTTTATGAGAGCCGTAAACAT 86
in control conditions (+R1881 or  siUNR in  +R1881 condition) giving
a 11Ct value. As amplification efficiencies of the genes of inter-
est and b2-microglobulin were comparable, the amount of  mRNA,
normalized to b2-microglobulin, was given by  the relation 2−11Ct.
4.5. Immunoblotting
Cells were harvested by scraping in PBS and re-suspended
in lysis buffer containing 20 mM  Tris–HCl (pH 7.5), 150 mM
NaCl, 1  mM  Na2EDTA, 1 mM  EGTA, 1% Triton, 2.5 mM  sodium
pyrophosphate, 1 mM b-glycerophosphate, 1  mM  Na3VO4,  1 mM
phenylmethanesulfonylfluoride and 1 mg/mL leupeptin. Extracts
were diluted in a mix  of LDS Sample Buffer and Sample Reduc-
ing Agent (NuPAGE®, Invitrogen, NP0007 and NP0009) and heated
at 95 ◦C  for 3  min. Samples were electrophoresed on 4–12%
or 12% SDS-polyacrylamide gels (Invitrogen, NP0321BOX and
NP0341BOX) and transferred onto nitrocellulose membranes (Bio-
rad, 162-0097). The blots were saturated in  TBS-T buffer (20 mM
Tris, 137 mM NaCl, 0.05% Tween 20, pH 7.6) containing 5% skimmed
milk for 1  h at room temperature and incubated overnight at
4 ◦C with primary antibodies: anti-TRPM8 (Abcam, Cambridge,
UK, ab3243, dilution 1:10,000), and anti-phospho-IP3RS1756 (Cell
Signaling Technology, Beverly, MA,  USA, 3760; recognizing human
IP3R1 phosphorylated on  Ser-1716), anti-IP3R1 (Cell Signaling
Technology, 8568), anti-LC3 (Cell Signaling Technology, 3868) all
used at a dilution of  1:1000. Immunodetection of  b-actin with
monoclonal anti-actin antibody (Sigma–Aldrich, A5441) was used
as loading control (dilution 1:10,000). After incubation with appro-
priate secondary antibodies coupled to  peroxidase, peroxidase
activity was detected with ECL Prime (GE Healthcare, Uppsala,
Sweden, RPN2236) on  ECL hyperfilm. Immunoblots were quantified
using the ImageMaster densitometry program.
4.6. Calcium measurements
Cells were plated  on glass coverslips, subjected to various
treatments during 2  days and then incubated for 1  h at room tem-
perature with 1  mM  Fura-2/AM (Calbiochem, Camarillo, CA, USA)
in Krebs-HEPES buffer containing 11.5 mM  HEPES, 135.5 mM  NaCl,
5.9 mM KCl, 1.8 mM  CaCl2,  1.2 mM  MgCl2,  11.5 mM d-glucose, pH
7.4. After rinsing, measurements were then realized in Krebs-
HEPES buffer without CaCl2 and supplemented with 0.2 mM  EGTA.
Coverslips were mounted in a  heated (37 ◦C) microscope chamber.
Cells were alternately excited (0.5  Hz) at 340 and 380 nm using
a Lambda DG-4 Ultra High Speed Wavelength Switcher (Sutter
Instrument, Novato, CA,  USA)  coupled to a Zeiss Axiovert 200 M
inverted microscope (Zeiss Belgium, Zaventem, Belgium). Images
were acquired with a Zeiss Axiocam camera coupled to a  510-nm
emission filter and analyzed with Axiovision software. Cytosolic
free Ca2+ concentration ([Ca2+]c)  was  evaluated from the ratio of
fluorescence emission intensities excited at the two  wavelengths
using the Grynkiewicz equation [33].
The  progressive fluorescence quenching due to the influx of
100 mM Mn2+ (Sigma–Aldrich) was  monitored by  measurement of
Fura-2/AM emission intensity (excitation at 360 nm). The slope of
the Mn2+-induced fluorescence quenching was measured on  the
first 30 s after adding  Mn2+.
4.7. Flow cytometry
Simultaneous detection of  mitochondrial membrane potential
(1	m)  dissipation and plasma membrane permeabilization was
determined by staining with 40  nM 1	m-sensitive fluorochrome
DiOC6(3) (Molecular Probes-Invitrogen, Carlsbad, CA, USA, D273)
and 1 mg/ml vital dye propidium iodide, PI (Sigma–Aldrich,
P1304MP). All  PI+ events have been considered at DiOC low.
Cytofluorometric analyses were performed on a FACSCalibur
equipped with CellQuest Pro software (Becton Dickinson, Franklin
Lakes, NJ, USA).
4.8. GFP-LC3 transfection and imaging
LNCaP cells, seeded in six-well culture plates until ∼80% con-
fluence, were transfected with a  plasmid coding for GFP-LC3 using
Lipofectamine reagent. After 24 h,  cells were plated on glass cover-
slips and 48 h later, were subjected to various treatments during 2
days. GFP fluorescence was  analyzed on an inverted Axiovert 200
microscope (Zeiss) using FITC excitation and emission wavelengths
(100×, NA 1.4, oil  immersion). Images were acquired with a Zeiss
Axiocam and analyzed by the Zeiss Axiovision software.
4.9. Statistical analysis
Data are presented as means ± S.D. Student’s t-test and two-
way ANOVA were used to  determine statistical significance when
appropriate.
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Fig. S1: Effects of AD and bicalutamide treatment on AMPK activity.  
(A) Immunoblot analysis of phosphorylation of AMPK
Thr172
 in LNCaP cells either deprived in 
androgen (- R1881) or treated with 50 µM bicalutamide (+ Bic) for 48 hr. Data presented are 
representative of three independent experiments. (B) Quantification of data illustrated in A. 
Data are presented as means ± S.D. of at least three independent experiments (* p < 0.05). 
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Fig. S2: Effects of AMPK inhibition on AD-induced autophagy. 
Immunoblot analysis of LC3-I → LC3-II conversion in LNCaP cells either deprived in 
androgen (- R1881), or/and treated with the AMPK inhibitor 10 µM compound C (+ Cpd C) 
for 48 hr, in the absence or in the presence of 10 µg/ml E64d and 10 µg/ml pepstatin A. β-
actin immunodetection is used as a loading control. Data presented are representative of two 
independent experiments. 
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Fig. S3: Effects of AD on the UPR signaling pathway. 
Bar histogram showing the relative mRNA expression of genes involved in UPR pathway 
after AD in LNCaP cells. Two days after AD treatment, total RNA was extracted and reverse-
transcribed. A real-time PCR was performed with specific primers. The mRNA expression of 
each genes was reported to β2-microglobulin expression (means ± S.D. of three independent 
experiments, * p < 0.05). 
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Fig. S4: Effects of AD on the cellular energy homeostasis. 
Bar histogram showing the AMP/ATP ratios in LNCaP cells cultured in the presence or in the 
absence of androgen (- R1881) for 48 hr. These ratio were calculated from ATP and AMP 
concentrations determined by high-performance liquid chromatography (means ± S.D. of 
three independent experiments, *** p < 0.001). 
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General conclusions and future perspectives 
The results presented above allow us to clarify cell survival mechanisms of PCa subjected to 
AD. Indeed, we have highlighted the substantial roles of autophagy and Ca
2+
 signaling in 
apoptosis resistance of HRPCa. Five demonstrations are provided: 
 
a) Androgen deprivation or treatment with the anti-androgen bicalutamide 
promotes autophagy in the LNCaP model of HRPCa. 
By using several techniques, we observed that androgen withdrawal induced increased 
autophagy in LNCaP cells. The AR is a ligand-dependent transcriptional factor which keeps 
playing an important function in PCa [9]. 1,5% to 4,3% of the LNCaP transcriptome is 
directly or indirectly regulated by androgens [314]. Androgens have been observed to 
promote the expression of genes favoring nutrient availability which activates the energy 
sensor mTOR and stimulates the growth of LNCaP cells [45]. The downexpression of these 
genes after AD could explain the activation of autophagy. Besides, as explained in the 
introduction, AR also has non-genomic activities [9]. For instance, AR bound to its ligand, by 
interacting with p85, the regulatory subunit of class Ia PI3K, has been shown to directly 
stimulate the PI3-K/Akt/mTOR pathway in LNCaP cells [16]. We confirmed this interaction 
and observed an inhibition of PI3-K/Akt/mTOR pathway after AD and bicalutamide 
treatment. We suggest that the lower AR expression measured after AD for 48 hr could limit 
the formation of the AR/p85 complex, thereby inhibiting the PI3K activity. However, it would 
be better to evaluate more accurately the direct effects of AD on the complex using a time-
course experiment. Moreover, the nature of the AR involved in this interaction remains 
unknown. Non-genomic activities of AR have repeatedly been associated to AR tethered to 
the plasma membrane [12]. It would be interesting to assess the effects of non-internalizable 
testosterone-BSA conjugates on the p85/AR interaction and the PI3-K/Akt/mTOR pathway. 
Nevertheless, the modulation of Akt activity by direct binding of AR highlights that other 
regulation mechanisms of this signaling pathway should not be ignored [18]. 
It can be noticed that while we suggest a direct control of AD on autophagy through an 
inhibition of the PI3-K/Akt/mTOR pathway, another team has recently reported that the 
autophagic process observed after AD could be dependent on AMPK stimulation [315]. 
Furthermore, AD therapy promotes hypoxia in the tumor microenvironment, likely due to a 
concomitant rarefaction of tumor vessels [316]. Hypoxia, which has clearly been established 
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as being able to induce autophagy [317], could participate to the triggering of AD-induced 
autophagy. Chhipa et al. have shown that AD and hypoxia together stimulate an AMPK-
dependent autophagy in LNCaP cells although they did not find that androgen withdrawal 
alone was able to sufficiently activate AMPK so as to induce autophagy [318]. In our hands, 
the monitoring of the phosphorylation status of AMPK did not suggest involvement of this 
pathway. Although bicalutamide treatment for 48 hr seems to result in a small increase of 
AMPK phosphorylation, it was not the case after AD. In line with other studies [45, 46], 
AMPK is even stimulated by androgens rather than their withdrawal (Fig. S1). Furthermore, 
the AMPK inhibitor compound C was not able to suppress the enhancement of LC3-I → LC3-
II conversion after AD (Fig. S2). 
Interestingly, autophagy induced by AD has also been related to lipolysis. Lipid droplet 
degradation mediated by autophagy in PCa cells could contribute to their survival by 
providing energy [319]. It can also be noticed that, despite the fact that the unfolded protein 
response does not seem involved, the expression of GRP78 has been related to AD-induced 
autophagy, suggesting a role of androgens in the ER stability [320]. 
Arguably, culture of LNCaP cells in phenol red-free medium would have been preferable. 
Indeed, the pH indicator phenol red is a weak estrogen that can impact the growth of estrogen-
sensitive cells [321, 322]. It is likely to modulate AR activity, oestradiol receptor β interacting 
with AR in LNCaP cells [15]. The only use of charcoal stripped fetal calf serum would not be 
enough to remove any traces of hormone in the medium. Such a serum always contains itself 
very low concentrations of steroid hormones [56]. The presence of estrogens could reduce the 
impact of androgen withdrawal, oestradiol stimulating the growth of LNCaP cells [15]. 
However, such cell culture conditions are already far different from the physiological ones. 
Estrogens are always present in men undergoing an AD therapy. The use of a specific AR 
antagonist such as bicalutamide on cells cultured in regular medium thereby seems preferable 
to reproduce AD therapy in vitro. 
Although LNCaP cells are by far the most popular model of HRPCa expressing the AR, it 
may be objected that our results have been obtained in a single PCa cell line. 22Rv1 prostate 
carcinoma cells also seemed to be a good model for our purpose but they were no longer 
commercially available due to a viral contamination. Other PCa cell lines such as VCaP and 
MDA-PCa-2b were tested but they were very difficult to culture and presented very high 
basal level of apoptosis making them an unsuitable model for our study. However, it can be 
noticed that AR knockdown has been shown to promote autophagy in PCa cell lines [323]. 
Furthermore, Beclin-1 and LC3 expressions are increased in PCa and hyperplasia prostate 
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tissues from patients treated by 5-α reductase inhibitor finasteride which lowers the level of 
DHT, the form of testosterone with the greatest affinity for the AR [324, 325]. 
 
b) AD-induced autophagy seems to constitute a mechanism of resistance 
against anticancer therapy. 
Silencing of the two canonical autophagic products, Atg5 and Beclin-1, significantly increases 
the level of cell death induced by androgen depletion or bicalutamide. Moreover, 
concanamycin A and chloroquine, two autophagy inhibitors, reproduce these effects by 
dramatically increasing cell death after AD or bicalutamide treatment. These results are in line 
with other studies [319, 326-329]. Besides, the inhibition of autophagy has recently been 
shown to overcome anti-androgen resistance in a prostate xenograft mouse model, thereby 
confirming in vivo our observations [315]. These data lead us to support the idea that clinical 
trials using chloroquine or its derivates in combination with anti-androgen therapy should be 
considered in the management of HRPCa patients. Although some anti-tumor agents have 
been reported to promote an autophagic cell death in PCa cells [330-332], the interest of 
autophagy blockade combined with chemo- or radiotherapies to treat patients reached by 
advanced PCa has already been noticed [333, 334]. A phase II clinical trial has even been 
conducted to evaluate docetaxel and hydroxychloroquine association in treating patients with 
metastatic HRPCa. However, the fact that androgen withdrawal results by itself in autophagy 
leads us to believe that pharmacological inhibition of autophagy should be envisaged earlier, 
in parallel with AD therapy, in order to delay onset of metastasis and recourse to 
chemotherapy. The recent discovery of new anticancer properties of chloroquine supports this 
idea: independently of autophagy blockade, it tightens tumor vessels, impairs cancer cells 
invasion and metastasis and enhances chemotherapy delivery [335]. 
It can be noted that AD-induced autophagy in PCa cells parallels autophagy stimulation in 
breast cancer in response to anti-hormone therapies. As demonstrated in PCa, such autophagy 
also allows the survival of breast cancer cells and facilitates the progression to anti-estrogen 
resistance [336]. 
It does not seem so surprising to observe that the removal of an anabolic hormone promotes a 
catabolic pathway. However, a recent report indicated that, if low concentrations of androgen 
repress autophagy in LNCaP cells, higher androgen levels would also induce autophagy as 
well as result in senescence [66]. Interestingly, autophagy therefore seems associated with this 
form of cell cycle arrest, AD and likely high concentrations of androgen both promoting 
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autophagy and senescence. If autophagy protects from cell death triggered after AD, its 
relationship with the cell cycle remains to explore. Several pathways including mTOR and 
p53 regulate both cell growth and autophagy. The latter is known to be inhibited during the 
mitosis [337] whereas it is more active during the G1 and S phases of the cell cycle [338]. The 
disruption of Atg genes such as Beclin-1 seems to lead to an increased cell growth [120]. 
Autophagy could allow a rapid protein turnover required for the establishment of cellular 
senescence [339]. Nevertheless, autophagy impairment has also been reported to promote it 
[340]. Interestingly, overexpression of p27
Kip1
 could stimulate autophagy [341, 342]. Let us 
remember that the CDK inhibitor is upregulated after AD [40]. Its possible involvement in 
AD-induced autophagy thereby remains to be determined, as well as the consequences of an 
autophagy inhibition on the senescence arrest that AD causes. 
 
c) Overphosphorylation of IP3R1 and altered expression profile of TRP 
channels modify Ca
2+
 homeostasis after androgen deprivation. 
Prevarskaya and her team discovered that neuroendocrine differentiation associated to 
prolonged AD treatment (96 h) resulted in decreases in the [Ca
2+
]ER and store-operated Ca
2+
 
current in LNCaP cells [343]. They explained the reduction of Ca
2+
 store content by their 
observation of both SERCA2b pump and luminal Ca
2+
 binding chaperone calreticulin 
underexpression. After only 48 hr of AD treatment, we measured no change in the SERCA2b 
and calreticulin expression although we observed that ER Ca
2+
 store content was already 
reduced. Besides, we noted that SOCE amplitude and Ca
2+
 influx through cell membrane 
were also decreased after 2 days without androgen. 
In seeking to explain these changes, we found that the mRNA expression of IP3R1 was 
increased. The protein was only weakly overexpressed, but we observed that it was 
phosphorylated on Ser-1716, a PKA phosphorylation site known to regulate the sensitivity of 
the channel to IP3 [215, 216]. Actually, Ca
2+
 concentration in the ER is known to be 
controlled by the SERCA pumps activity and the Ca
2+
-binding proteins availability. However, 
steady state calcium level within the ER is also reported to be dependent on a Ca
2+
 leak 
through ER membrane which balances the influx created by the pumps [344]. The molecular 
nature of the leak mechanism is still debated and different proteins have been proposed such 
as Bcl-2 [247], BI-1 [345, 346], CALHM1 (calcium homeostasis modulator 1) [347], 
pannexin [348], presenillins [349], translocon [350] and SERCA splice variants [351]. 
Caspase-3 is able to cleave IP3R and the resulting truncated IP3R mediates an important Ca
2+
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flux through ER membrane [285]. However, native form of IP3R has long been considered 
uninvolved in the leak [344], despite the fact that basal IP3 levels in non-stimulated 
conditions have been noted to increase the leakiness of the stores [352]. Ten years ago, 
Korsmeyer and his collaborators were the first to establish that unaltered IP3R1 could also 
have a function of leak channel. As explained in the introduction, they observed that the 
channel became leakier after its phosphorylation on Ser-1756, the PKA phosphorylation site 
in mouse embryonic fibroblasts [259]. In human cells, the site primarily phosphorylated by 
PKA is Ser1716. Thus, we assume that phosphorylation on this site after AD leads to a Ca
2+
 
leak responsible for the [Ca
2+
]ER reduction. The fact that inhibition of IP3R1 phosphorylation 
by a permeant TAT-peptide containing the Ser-1716 consensus phosphorylation sequence 
prevented the AD-induced decrease in [Ca
2+
]ER is in line with our hypothesis. Moreover, IP3R 
inhibition by xestospongin B reduced Ca
2+
 release after thapsigargin-mediated SERCA 
inhibition, therefore reinforcing the idea that IP3R contributes to the leak of Ca
2+
 through the 
ER membrane. 
Furthermore, a screening of genes involved in the control of Ca
2+
 homeostasis revealed that 
TRPM8 expression was suppressed after AD for 48 hr. This observation was expected since 
expression of the TRPM8 gene is controlled by several AREs [200]. The downregulation of 
TRPM8 could explain the Ca
2+
 influx reduction observed after androgen withdrawal. Indeed, 
we showed that siRNA-mediated TRPM8 silencing reproduced at least in part the decrease in 
the Ca
2+
 influx resulting from AD. However, AD-induced TRPM8 depletion is not involved 
in the reduction of [Ca
2+
]ER since siRNA against TRPM8 did not modify releasable Ca
2+
 from 
the ER. Incidentally, our data also showed that TRPM8 is not involved in the SOCE. 
 
d) [Ca2+]ER reduction allows the resistance of HRPCa cells to androgen 
deprivation. 
We observed that inhibition of the [Ca
2+
]ER reduction by TAT-peptide containing the Ser-
1716 consensus phosphorylation sequence of IP3R1 or by PKA inhibitor H89 restored the 
sensitivity of LNCaP cells to AD. Upon this result, we cannot exclude that dephosphorylation 
of IP3R1 by itself promotes cell death in response to AD without any involvement of ER 
Ca
2+
. Phosphorylation profile of IP3R1 may affect numerous interactions of the protein 
including that with the anti-apoptotic members of the Bcl-2 protein family. However, 
SERCA2b overexpression, which increased [Ca
2+
]ER, made LNCaP cells sensitive to AD. This 
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observation prompted us to consider that it is rather the reconstitution of ER Ca
2+
 store which 
leads to the induction of cell death after AD treatment. 
A role for Ca
2+
 in the prostate involution in rats after castration has already been highlighted, 
Ca
2+
 channel antagonists delaying regression of the androgen-dependent tissues [184]. 
Furthermore, testosterone and its analogues do not only exert their effects through nuclear AR 
regulating transcription of various genes but also via membrane AR activating different 
signaling pathways. Stimulation of such AR has been reported to induce intracellular Ca
2+
 
increases in diverse cellular models [353]. Prevarskaya and her collaborators also showed that 
Ca
2+
 pool content could regulate apoptosis resistance and cell growth in PCa cells [185, 343, 
354, 355]. Fluctuation of [Ca
2+
]ER in a narrow range (≈30%) could cause massive changes in 
cell survival [356]. In this study, we suggest that AD, which triggers apoptosis in normal 
prostate cells, induces by itself a mechanism of resistance in HRPCa cells that suppresses AD-
induced cell death. In other words, in HRPCa cells, AD triggers both apoptotic pathways and 
resistance mechanisms against apoptosis. Reduction of [Ca
2+
]ER induced by AD allows the 
survival of PCa cells in response to AD. Moreover, we explained the main involved 
mechanism: the leak channel properties of IP3R1 and their regulation through 
phosphorylation of a PKA consensus site (Fig. 19). 
Thereby, inositol trisphosphate receptor could constitute another interesting therapeutic target 
in PCa treatment. As explained in the introduction, the channel seems to be involved in the 
mechanisms of cancerogenesis [210]. Furthermore, IP3R is involved in apoptosis regulation. 
Some pro-apoptotic stimuli such as Fas lead to PLC activation and IP3 synthesis [357, 358], 
although this has not been demonstrated for every pro-apoptotic stimuli causing Ca
2+
 release 
from the ER [356]. The importance of IP3R in cell death is also supported by the fact that 
antisense knockdown or genetic deletion of IP3R gene modify apoptosis sensitivity in 
numerous models [231]. However, the various IP3R isoforms could play distinct roles. IP3R3 
has been reported to be more significantly localized in the MAM where it would 
preferentially transmit apoptotic Ca
2+
 signals into mitochondria, whereas IP3R1 would 
preferentially allows Ca
2+
 release into cytosol [359]. This could explain why apoptosis 
induction is most effectively reduced by silencing IP3R3 than other isoforms [359-361]. 
Nevertheless, although the repression of IP3R1 expression can sensitize cells to apoptosis in 
some models [362], it has also been shown to inhibit cell death in others [284, 357, 363]. 
In addition to its role in the apoptosis triggering via the ER-mitochondria Ca
2+
 flux, IP3R can 
amplify apoptotic pathways by different ways [356]. Its cleavage by caspases (and calpains) 
which accelerates ER Ca
2+
 emptying through a constitutively open IP3R fragment could act as 
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a feed-forward mechanism [285, 364]. Similarly, its potential binding with released 
cytochrome c promotes IP3R opening, also facilitating Ca
2+
 release from the stores [365]. 
Phosphorylation of different sites on the IP3R protein also controls the induction of cell death. 
Indeed, Akt phosphorylates IP3Rs, in particular in LNCaP cells, thereby reducing cellular 
sensitivity to pro-apoptotic stimuli but without modifying the permeability of the channel, this 
last point being debated [224, 366]. As mentioned before, IP3R can play a role of scaffold 
protein and the multiplicity of its interactions, in particular with Bcl-2 family members, could 
explain its Ca
2+
-independent contribution in the regulation of cell death. It would be 
interesting to determine the effects of the inhibition of PI3K/Akt/mTOR pathway that we 
observed after AD on the IP3 receptors and the resistance to apoptosis of LNCaP cells. 
However, we can already assert that they probably would not be mediated by IP3R1, Akt 
primarily acting on IP3R3 [210]. 
Cross-talk between PKA and IP3R has already been explored. Korsmeyer’s team previously 
showed the importance of IP3R1 phosphorylation on its PKA consensus site in the control of 
the ER Ca
2+
 leak and apoptosis [259]. They observed that phosphorylation was dependent on 
the presence of Bcl-2 at the ER membrane. Although Bcl-2 protein was hardly detected in 
LNCaP cells, we measured a small increase in the Bcl-2 mRNA level after AD (only Bcl-2 
mRNA itself increased while the expression of other members of Bcl-2 family remained 
stable). It will be interesting to study its possible control on the phosphorylation and the 
activity of IP3R1. Indeed, in addition of the regulation of IP3R phosphorylation and its 
properties of leak channel, Bcl-2, as explained in the introduction, also regulates IP3-induced 
Ca
2+
 release through direct interaction with IP3R [217, 254-256]. Moreover, Bcl-2 has been 
noticed to compete with IP3R1 for the binding of protein phosphatase 1 (PP1), which 
preserves IP3R1 phosphorylation by PKA and protect cells from apoptosis [367]. 
Nonetheless, a negative feedback has recently been highlighted, allowing Bcl-2, through its 
interactions with DARPP-32 (a PP1 inhibitor) and calcineurin, to accurately control IP3R1 
phosphorylation on PKA consensus site and limit Ca
2+
 release [368]. It will also be interesting 
to monitor the RyRs permeability in our model, PKA being reported to phosphorylate these 
channels too, which results in an important Ca
2+
 leak from the stores [369]. Furthermore, it is 
also conceivable that PKA regulates other components of Ca
2+
 machinery. Thus, interestingly, 
TRPM8 channel opening has been noticed to be inhibited by the PKA pathway [370]. 
In this work, we did not investigate the mechanism of PKA-activation by AD. However, 
previous studies give us some insights about this phenomenon. As mentioned above, PKA 
and its activator cAMP play an important role in the mechanisms of carcinogenesis. PKA-1 
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isoform is often overexpressed in cancer cells including PCa cells and constitutes a marker of 
poor prognosis [371]. This pathway is known to regulate tumor cells proliferation. Otherwise, 
it controls the activity of androgen receptor [372]. It can also be noted that treatment of 
LNCaP cells with testosterone for 10 min increases cAMP level and PKA activity [373]. This 
was mediated via a Gsα-dependent pathway that was independent of nuclear AR. 
Interestingly, activation of PKA pathway in PCa cells (via cAMP analogs, adenylate cyclase 
stimulators or phosphodiesterase inhibitors) results in their NE differentiation [372]. In 
addition of PKA activation, other stimuli lead to NE differentiation including long-term AD 
and treatment with interleukin-1β and -6 or VIP (vasoactive intestinal peptide). For the latter, 
the induced NE differentiation is partially dependent on PKA [374]. Besides, NE 
differentiation associated to prolonged AD in LNCaP cells increases the expression of 
different catalytic subunits of PKA [375]. 
We still have to understand how the decrease in [Ca
2+
]ER favors cell survival. As explained 
above in the introduction, this is probably dependent on the Ca
2+
 transfer into the 
mitochondria. The increased leak of Ca
2+
 from the ER after AD could enhance spontaneous 
IP3R-dependent oscillations which promote cell survival and limit any possible massive 
arrival of Ca
2+
 to the mitochondria, thereby protecting cells from apoptosis. A measure of 
[Ca
2+
]m after androgen removal but also following a pro-apoptotic stimulus in the presence 
and the absence of androgen (with a cameleon probe targeted to mitochondria) would allow 
us to ensure the involvement of mitochondrial Ca
2+
 in the survival of LNCaP cells. 
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Fig. 19: The ER calcium store content and its effects on cell survival. 
AD treatment modifies the permeability of ER membrane through the PKA-mediated 
phosphorylation of IP3R1 in LNCaP cells. The generated Ca
2+
 leakage and the resulting 
[Ca
2+
]ER decrease would likely improve pro-survival moderated Ca
2+
 pulses but also avoid 
any deleterious Ca
2+
 overload into the mitochondria that could cause androgen withdrawal. 
(Abbreviations: ADP, adenosine diphosphate; ATP, adenosine triphosphate; ER, endoplasmic 
reticulum; GRP75, 75 kDa glucose regulation protein; IP3R1, inositol trisphosphate receptor 
isoform 1; IP3R3, inositol trisphosphate receptor isoform 3; MCU, mitochondrial Ca
2+
 
uniporter; P, phosphorylated residues; SERCA, sarco/endoplasmic reticulum Ca
2+
 ATPase; 
VDAC, voltage-dependent anion channel.) 
 
The decrease in the store-operated Ca
2+
 current after AD requires further clarification. Several 
store-operated currents have been described and can restore the Ca
2+
 content of the ER after 
its depletion. The best characterized is the Ca
2+
 release-activated Ca
2+
 current, I(CRAC) 
where ORAI1, the pore-forming subunit of the CRAC channel, is activated by STIM1 
(stromal interaction molecule 1) which is able to sense ER Ca
2+
 store emptying [376]. We can 
imagine that the SOCE decrease observed after AD is subsequent to the [Ca
2+
]ER reduction. 
Indeed, Ca
2+
 store being reduced after AD, a SOCE of large amplitude could not be necessary 
to fill them after their eventual emptying. Nevertheless, it must remembered that the 
overexpression of calreticulin allowing a Ca
2+
 storage increase has also been demonstrated to 
decrease SOCE amplitude [377]. Prevarskaya and her collaborators have already observed 
this decrease in the SOCE after AD. They have explained it by a downregulation of ORAI1 
and a cytoskeleton reorganization limiting the integration of store-operated channels in the 
 100 
plasma membrane [378, 379]. However, in our study, we did not note any variation in mRNA 
expression of ORAI1 and STIM1 after AD treatment for 48 hr. 
Various studies have shown a crucial role of SOCE in cell death. Only a Ca
2+
 store release 
paired with sustained store-operated Ca
2+
 entry seems to allow a massive triggering of 
apoptosis. Indeed, it has been shown that cell death induced by Ca
2+
 store depletion is 
improved by high concentrations of extracellular Ca
2+
 [250]. A SOCE decrease could reduce 
any detrimental Ca
2+
 overload into the mitochondria. Furthermore, Prevarskaya’s team 
showed that the downregulation of ORAI1, and consequently SOCE, participates to the 
apoptosis resistance acquisition of LNCaP cells [378]. Besides, they have recently highlighted 
an overexpression of ORAI3 isoform in human PCa which leads to an ORAI1 protein 
redistribution, a subsequent SOCE limitation and the cell survival promotion [380]. 
 
e) Autophagy and [Ca2+]ER reduction are independently induced in response 
to androgen deprivation. 
As explained before, Ca
2+
 signaling is known to participate in the regulation of autophagy. 
Although, in contrast with the effects of AD on PI3-K/Akt/mTOR pathway and [Ca
2+
]ER, 
rapamycin, the selective mTOR inhibitor and autophagy inducer, has been related to an 
increased [Ca
2+
]ER consecutive to a reduced Ca
2+
 leak from the ER [307], we then 
hypothesized that the decrease of [Ca
2+
]ER observed after AD treatment could lead to the 
induction of autophagy. 
Firstly, the unfolded protein response (UPR) could connect the two processes. Indeed, ER 
Ca
2+
 emptying can stimulate UPR while this one can lead to ER /Ca
2+
 store expansion but 
also cause autophagy [232, 381]. But a report from Bennett et al. [320] and a preliminary 
screening of UPR genes did not suggest a stimulation of the UPR pathway after AD (Fig. S3). 
Apart for a two-fold overexpression of the pro-apoptotic transcription factor CHOP, no 
variation in the splicing of XBP1 mRNA or in the expression of various genes related to ER 
stress was detected. However, a complete monitoring of the UPR pathway remains to be 
performed. 
The determination of ATP and AMP concentrations in LNCaP cells by high-performance 
liquid chromatography associated to the monitoring of the phosphorylation status of AMPK 
revealed no decrease in the cellular metabolism after AD. AMP/ATP ratio is even lowered 
after two days of treatment (Fig. S4), while AMPK is dephosphorylated (Fig. S1). This 
suggests that the [Ca
2+
]ER decrease does not result in the suppression of the ER-mitochondria 
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Ca
2+
 exchange which has been proved to inhibit ATP synthesis and promote autophagy [293]. 
Besides, we observed that inhibition of IP3R1 phosphorylation which restores the ER Ca
2+
 
store content could not inhibit AD-induced autophagy, demonstrating that the alterations of 
Ca
2+
 homeostasis are not responsible for the autophagy triggering in our model. However, a 
long-term control of autophagy by the Ca
2+
 leak can not be excluded. Since IP3R1 is known 
to regulate autophagy by allowing Bcl-2 interaction with Beclin-1, it would be interesting to 
evaluate the effects of the PKA-mediated phosphorylation of IP3R1 and its subsequent 
opening on its function of scaffold protein [294]. 
Several reports show that autophagosomes are partially formed from ER membranes [80] and 
a remodeling of Ca
2+
 signaling has already been observed during a starvation-induced 
autophagy [227]. We therefore sought to verify that autophagy did not participate to the ER 
Ca
2+
 store reduction. We found that autophagy inhibition by siRNA-mediated depletion of 
Atg5 did not modify the AD-induced decrease of releasable Ca
2+
 pool, suggesting that Ca
2+
 
store alterations are not subsequent to autophagic process. 
Therefore, the activation of autophagy and the decrease of [Ca
2+
]ER appears as two 
independent mechanisms allowing the survival of PCa cells in response to AD (Fig. 20). 
 
 
Androgen
deprivation
Cell death
Autophagy [Ca2+]ER
mTOR P-IP3R1
  
Fig. 20: Two mechanisms of adaptation for HRPCa-derived LNCaP cells in response to 
androgen deprivation. AD treatment leads to autophagy enhancement and a decrease of the 
ER Ca
2+
 store content. These two mechanisms that no link seems to connect allow the LNCaP 
cells to survive in the absence of androgenic stimulation. 
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Summary 
 
Prostate cancer (PCa) is the most frequent cancer in men above the age of 50 years. Despite 
radical prostatectomy or radiation therapy as primary treatment, 15-30% of patients will 
develop an advanced or metastatic cancer requiring systemic therapies. Reference treatment 
of advanced PCa relies on pharmacological or surgical androgen deprivation therapy. 
However, despite initial efficacy of androgen deprivation (AD), the tumor inevitably adapts to 
low testosterone environment and becomes hormone-refractory (HRPCa). A better 
understanding of the mechanisms of androgen independence is necessary to improve the 
management of HRPCa. 
Although autophagy confers chemoresistance in some cancers, its role in the development of 
HRPCa remained unknown. We found that AD or treatment with the anti-androgen 
bicalutamide promoted autophagy in HRPCa-derived LNCaP cells. This effect was associated 
with an inhibition of the PI3-K/Akt/mTOR pathway and with a disruption of the complex 
formed by androgen receptor and the regulatory subunit of PI3-K p85. Moreover, genetic or 
pharmacological inhibition of autophagy restored AD-dependent cell death indicating that 
autophagy is a protective mechanism against AD in HRPCa cells. 
Besides, in these same cells, we also observed different modifications of Ca
2+
 homeostasis 
after androgen withdrawal among which a reduction of the ER Ca
2+
 content. We discovered 
that the [Ca
2+
]ER decrease was due to the presence of IP3R1 made leakier by their 
phosphorylation on the PKA consensus site Ser-1716. Inhibition of the IP3R1 
phosphorylation by PKA inhibitor H89 or permeant TAT-peptide containing the Ser-1716 
consensus phosphorylation sequence sensitized LNCaP cells to AD, suggesting that [Ca
2+
]ER 
can control HRPCa cells resistance to AD. 
Therefore, we identified two distinct mechanisms by which HRPCa-derived cells manage to 
overcome cell death that they face in the absence of androgenic stimulation. We hope that 
these findings will help to device new therapeutic strategies to circumvent hormone 
independence of advanced PCa. 
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Résumé 
 
Le cancer de la prostate (CaP) est le cancer le plus fréquent chez l’homme de plus de 50 ans.  
Malgré l’efficacité de la prostatectomie radicale et de la radiothérapie comme traitement 
initial à un stade précoce, 15 à 30% des patients développeront un cancer métastatique 
nécessitant un traitement systémique. Le traitement de référence des CaP à un stade avancé 
est l’hormonothérapie, consistant à inhiber l'effet stimulant des androgènes sur les cellules 
cancéreuses. Cependant, malgré son efficacité initiale, le CaP finit inévitablement par 
s’adapter à l’absence de stimulation androgénique et devient hormono-résistant (HRCaP). 
Une meilleure compréhension des mécanismes d’échappement à l’hormonothérapie est 
nécessaire dans le but d’améliorer la prise en charge des patients malades. 
Bien que l’autophagie soit impliquée dans la chimiorésistance de certains cancers, son rôle 
dans le développement des HRCaP n’avait pas été exploré. Nous avons observé que le retrait 
des androgènes ainsi que l’utilisation de l’anti-androgène bicalutamide activaient l’autophagie 
dans la lignée cellulaire LNCaP dérivée d’un HRCaP. Cet effet était associé à l’inhibition de 
la voie de signalisation PI3-K/Akt/mTOR et à la diminution de l’interaction entre le récepteur 
aux androgènes et la sous-unité régulatrice p85 de la PI3-kinase. Par ailleurs, l’inhibition 
génétique ou pharmacologique de l’autophagie rétablissait la mort cellulaire induite par 
l’absence de stimulation androgénique, indiquant que l’autophagie est un mécanisme de 
résistance à l’hormonothérapie pour ces cellules prostatiques. 
En outre, dans ce même modèle cellulaire, nous avons observé différentes modifications de 
l’homéostasie calcique suite au retrait des androgènes, parmi lesquelles une réduction du 
contenu en calcium du réticulum endoplasmique (RE). Nous avons découvert que cette 
diminution de la [Ca
2+
]RE était due à une augmentation de la perméabilité du récepteur à l’IP3 
de type 1 du fait de sa phosphorylation sur le résidu sérine 1716 par la PKA.  L’inhibition de 
cette phosphorylation par le H89, un inhibiteur de la PKA, ou par un peptide TAT contenant 
le même site de phosphorylation entraînait la mort des cellules LNCaP en l’absence 
d’androgènes, suggérant que la réduction de la [Ca
2+
]RE participe à l’hormono-résistance des 
cellules cancéreuses prostatiques. 
Ainsi, nous avons identifié deux mécanismes distincts par lesquels les cellules d’un HRCaP 
parviennent à survivre dans un milieu hormonal qui leur est défavorable. Nous espérons que 
ces découvertes aideront à la mise au point de nouvelles stratégies thérapeutiques pour 
répondre à l’hormono-résistance des CaP à un stade avancé. 
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